0001493152-26-023197.txt : 20260514 0001493152-26-023197.hdr.sgml : 20260514 20260514172455 ACCESSION NUMBER: 0001493152-26-023197 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20260331 FILED AS OF DATE: 20260514 DATE AS OF CHANGE: 20260514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Streamex Corp. CENTRAL INDEX KEY: 0001530766 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 264333375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38659 FILM NUMBER: 26980575 BUSINESS ADDRESS: STREET 1: 2431 ALOMA AVENUE STREET 2: SUITE 243 CITY: WINTER PARK STATE: FL ZIP: 32792 BUSINESS PHONE: (203) 409-5444 MAIL ADDRESS: STREET 1: 2431 ALOMA AVENUE STREET 2: SUITE 243 CITY: WINTER PARK STATE: FL ZIP: 32792 FORMER COMPANY: FORMER CONFORMED NAME: BioSig Technologies, Inc. DATE OF NAME CHANGE: 20110921 10-Q 1 form10-q.htm 10-Q
false Q1 --12-31 0001530766 0001530766 2026-01-01 2026-03-31 0001530766 2026-05-13 0001530766 2026-03-31 0001530766 2025-12-31 0001530766 us-gaap:RelatedPartyMember 2026-03-31 0001530766 us-gaap:RelatedPartyMember 2025-12-31 0001530766 STEX:RestrictedGoldMember 2026-03-31 0001530766 STEX:RestrictedGoldMember 2025-12-31 0001530766 us-gaap:GoldMember 2026-03-31 0001530766 us-gaap:GoldMember 2025-12-31 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2026-03-31 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesFPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesFPreferredStockMember 2025-12-31 0001530766 2025-01-01 2025-12-31 0001530766 2025-01-01 2025-03-31 0001530766 us-gaap:CommonStockMember 2025-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001530766 us-gaap:RetainedEarningsMember 2025-12-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-12-31 0001530766 us-gaap:CommonStockMember 2024-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001530766 us-gaap:RetainedEarningsMember 2024-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-12-31 0001530766 2024-12-31 0001530766 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001530766 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001530766 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001530766 us-gaap:CommonStockMember 2026-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001530766 us-gaap:RetainedEarningsMember 2026-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2026-03-31 0001530766 us-gaap:CommonStockMember 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-03-31 0001530766 2025-03-31 0001530766 STEX:ViralClearMember 2026-03-31 0001530766 STEX:BioSigAIMember 2025-12-31 0001530766 STEX:GLDYServiceCoLLCMember 2026-03-31 0001530766 STEX:GLDYServiceCoLLCMember 2026-01-01 2026-03-31 0001530766 2026-01-01 2026-01-31 0001530766 country:US 2026-03-31 0001530766 country:CA 2026-03-31 0001530766 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001530766 STEX:PerformanceBasedRestrictedStockUnitMember 2026-01-01 2026-03-31 0001530766 STEX:PerformanceBasedRestrictedStockUnitMember 2025-01-01 2025-03-31 0001530766 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001530766 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001530766 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001530766 STEX:StreamexExchangeCorporationMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 0001530766 2025-11-04 2025-11-04 0001530766 2025-05-28 2025-05-28 0001530766 us-gaap:CommonStockMember STEX:ThirdpartyConsultantsMember 2026-01-01 2026-03-31 0001530766 us-gaap:CommonStockMember STEX:ThirdpartyConsultantsMember 2026-03-31 0001530766 STEX:ThirdpartyConsultantsMember 2026-01-01 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-05-28 0001530766 2025-05-28 0001530766 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-05-28 0001530766 STEX:SecuritizationPlatformMember 2025-05-28 0001530766 STEX:BlockchainIntegrationMember 2025-05-28 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 us-gaap:TradeNamesMember 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-12-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0001530766 STEX:LegalAndComplianceFrameWorkMember 2026-03-31 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-12-31 0001530766 us-gaap:PatentsMember 2026-03-31 0001530766 us-gaap:PatentsMember 2025-12-31 0001530766 us-gaap:TradeNamesMember 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-12-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0001530766 dei:LegalContactMember 2026-03-31 0001530766 dei:LegalContactMember 2025-12-31 0001530766 us-gaap:PatentsMember 2026-03-31 0001530766 us-gaap:PatentsMember 2025-12-31 0001530766 us-gaap:TradeNamesMember 2026-01-01 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-01-01 2026-03-31 0001530766 dei:LegalContactMember 2026-01-01 2026-03-31 0001530766 us-gaap:PatentsMember 2026-01-01 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-01-01 2025-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-01-01 2025-03-31 0001530766 dei:LegalContactMember 2025-01-01 2025-03-31 0001530766 us-gaap:PatentsMember 2025-01-01 2025-03-31 0001530766 STEX:ComplianceFrameworkMember 2026-03-31 0001530766 us-gaap:ComputerEquipmentMember 2026-03-31 0001530766 us-gaap:ComputerEquipmentMember 2025-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2026-03-31 0001530766 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001530766 STEX:TestingAndDemoEquipmentMember 2026-03-31 0001530766 STEX:TestingAndDemoEquipmentMember 2025-12-31 0001530766 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001530766 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001530766 2026-02-26 0001530766 STEX:SharePurchaseAgreementMember 2025-12-09 2025-12-09 0001530766 STEX:SharePurchaseAgreementMember 2025-12-09 0001530766 STEX:SharePurchaseAgreementMember 2025-12-31 0001530766 STEX:SharePurchaseAgreementMember 2025-01-01 2025-12-31 0001530766 STEX:EmpressRoyaltyCorpMember 2026-01-01 2026-01-31 0001530766 STEX:EmpressRoyaltyCorpMember 2026-01-01 2026-03-31 0001530766 STEX:RestrictedMember 2025-12-31 0001530766 STEX:UnrestrictedMember 2025-12-31 0001530766 srt:MaximumMember STEX:BrinksBaileeAgreementMember 2025-11-04 0001530766 STEX:UnrestrictedMember 2026-02-28 0001530766 STEX:RestrictedGoldMember 2026-02-05 0001530766 2026-02-05 2026-02-05 0001530766 STEX:UnrestrictedMember 2026-03-31 0001530766 STEX:TwoRelatedPartyMember 2026-03-31 0001530766 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001530766 STEX:StreamexLtdMember 2026-01-01 2026-03-31 0001530766 STEX:StreamexLtdMember STEX:ChiefInvestOfficerMember 2026-03-31 0001530766 STEX:StreamexLtdMember STEX:GeneralCounselOfficersMember 2026-03-31 0001530766 STEX:StreamexLtdMember 2026-03-31 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 2025-08-27 0001530766 2025-12-17 0001530766 2025-11-04 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2025-11-04 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2025-12-17 0001530766 us-gaap:SubsequentEventMember 2027-11-04 0001530766 us-gaap:SubsequentEventMember 2027-12-17 0001530766 us-gaap:SubsequentEventMember 2027-11-04 2027-11-04 0001530766 us-gaap:SubsequentEventMember 2027-12-17 2027-12-17 0001530766 srt:MaximumMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001530766 srt:MinimumMember 2026-03-31 0001530766 2026-02-06 0001530766 2026-02-06 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:TradeNamesMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:DevelopedTechnologyMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputCommonStockPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputCommonStockPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputIndicatedConversionPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputIndicatedConversionPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputFloorPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputFloorPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPrepaymentRateMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPrepaymentRateMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputPrepaymentPremiumMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputPrepaymentPremiumMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputRegistrationProbabilityMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputRegistrationProbabilityMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001530766 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001530766 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001530766 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001530766 us-gaap:PreferredStockMember 2026-03-31 0001530766 us-gaap:ConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:ConvertiblePreferredStockMember 2026-03-31 0001530766 us-gaap:InvestorMember 2024-01-12 2024-01-12 0001530766 2024-01-12 0001530766 us-gaap:OverAllotmentOptionMember 2026-01-22 2026-01-22 0001530766 2026-01-22 2026-01-22 0001530766 STEX:SalesAgreementMember 2026-01-01 2026-03-31 0001530766 us-gaap:InvestorMember 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-04 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-30 2025-12-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-29 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2026-03-31 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001530766 us-gaap:WarrantMember 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockOneMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockOneMember 2026-02-01 0001530766 STEX:CommonStockTwoMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockTwoMember 2026-02-01 0001530766 STEX:CommonStockThreeMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockThreeMember 2026-02-01 0001530766 STEX:CommonStockFourMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockFourMember 2026-02-01 0001530766 STEX:CommonStockFiveMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockFiveMember 2026-02-01 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFourMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFourMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFiveMember us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFiveMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001530766 STEX:RestrictedStockOneMember 2026-03-31 0001530766 STEX:RestrictedStockTwoMember 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember 2026-03-16 2026-03-16 0001530766 2026-03-16 2026-03-16 0001530766 us-gaap:CommonStockMember 2026-03-16 2026-03-16 0001530766 2026-03-16 0001530766 us-gaap:PerformanceSharesMember 2026-03-16 2026-03-16 0001530766 STEX:ShareBasedCompensationAwardTrancheMember 2026-03-16 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-03-16 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-03-16 0001530766 srt:MaximumMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearMember 2026-01-01 2026-03-31 0001530766 STEX:OptionsUnder999Member 2026-01-01 2026-03-31 0001530766 STEX:OptionsUnder999Member 2026-03-31 0001530766 STEX:Options1000To1999Member 2026-01-01 2026-03-31 0001530766 STEX:Options1000To1999Member 2026-03-31 0001530766 STEX:Options2000To4999Member 2026-01-01 2026-03-31 0001530766 STEX:Options2000To4999Member 2026-03-31 0001530766 STEX:Options5000To6999Member 2026-01-01 2026-03-31 0001530766 STEX:Options5000To6999Member 2026-03-31 0001530766 us-gaap:MeasurementInputSharePriceMember 2026-03-31 0001530766 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2026-03-31 0001530766 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001530766 us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001530766 us-gaap:MeasurementInputExpectedTermMember 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt03000Member 2026-03-31 0001530766 STEX:WarrantsAt03000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt09547Member 2026-03-31 0001530766 STEX:WarrantsAt09547Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt17800Member 2026-03-31 0001530766 STEX:WarrantsAt33640Member 2026-03-31 0001530766 STEX:WarrantsAt33640Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt40660Member 2026-03-31 0001530766 STEX:WarrantsAt40660Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt44550Member 2026-03-31 0001530766 STEX:WarrantsAt44550Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt44660Member 2026-03-31 0001530766 STEX:WarrantsAt44660Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt46626Member 2026-03-31 0001530766 STEX:WarrantsAt46626Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt49252Member 2026-03-31 0001530766 STEX:WarrantsAt49252Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt49290Member 2026-03-31 0001530766 STEX:WarrantsAt49290Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt51358Member 2026-03-31 0001530766 STEX:WarrantsAt51358Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt71810Member 2026-03-31 0001530766 STEX:WarrantsAt71810Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt75020Member 2026-03-31 0001530766 STEX:WarrantsAt75020Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt79630Member 2026-03-31 0001530766 STEX:WarrantsAt79630Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt90000Member 2026-03-31 0001530766 STEX:WarrantsAt90000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt95960Member 2026-03-31 0001530766 STEX:WarrantsAt95960Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt100992Member 2026-03-31 0001530766 STEX:WarrantsAt100992Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt102600Member 2026-03-31 0001530766 STEX:WarrantsAt102600Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt104678Member 2026-03-31 0001530766 STEX:WarrantsAt104678Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt113000Member 2026-03-31 0001530766 STEX:WarrantsAt113000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt132800Member 2026-03-31 0001530766 STEX:WarrantsAt132800Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt480000Member 2026-03-31 0001530766 STEX:WarrantsAt480000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt616000Member 2026-03-31 0001530766 STEX:WarrantsAt616000Member 2026-01-01 2026-03-31 0001530766 STEX:BioSigAIMember 2025-12-31 0001530766 STEX:BioSigAIMember 2025-01-01 2025-12-31 0001530766 STEX:BioSigAIMember 2024-12-31 0001530766 STEX:BioSigAIMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAIMember 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:OneOneTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember 2026-01-01 2026-03-31 0001530766 STEX:OneOneTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:OneEightTwoThousandTwentySixMember STEX:InterimExecutiveChairmanMember 2026-01-01 2026-03-31 0001530766 STEX:OneEightTwoThousandTwentySixMember STEX:InterimExecutiveChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:OneEightTwoThousandTwentySixMember STEX:ChiefExecutiveOfficierMember 2026-01-01 2026-03-31 0001530766 STEX:OneEightTwoThousandTwentySixMember STEX:ChiefExecutiveOfficierMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:OneTwentySevenTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember 2026-01-01 2026-03-31 0001530766 STEX:OneTwentySevenTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:TwoOneTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember 2026-01-01 2026-03-31 0001530766 STEX:TwoOneTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeThreeTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeThreeTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeSixteenTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeSixteenTwoThousandTwentySixMember STEX:ThirdPartyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeSixteenTwoThousandTwentySixMember srt:ChiefFinancialOfficerMember 2026-01-01 2026-03-31 0001530766 STEX:ThreeSixteenTwoThousandTwentySixMember srt:ChiefFinancialOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 srt:MaximumMember 2026-03-31 0001530766 srt:MinimumMember 2026-01-01 2026-03-31 0001530766 us-gaap:StockCompensationPlanMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2025-12-31 0001530766 STEX:PerformanceSharesAndAUMMember 2025-12-31 0001530766 STEX:PerformanceSharesAndAUMMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2026-03-31 0001530766 STEX:PerformanceSharesAndAUMMember 2026-03-31 0001530766 STEX:RangeOneMember STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 STEX:BioSigAIMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-03-31 0001530766 STEX:BioSigAISciencesIncMember 2025-01-01 2025-03-31 0001530766 STEX:StreamexLtdMember 2025-01-01 2025-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 STEX:BioSigAISciencesIncMember 2025-12-31 0001530766 STEX:StreamexLtdMember 2025-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 STEX:BioSigAISciencesIncMember 2024-12-31 0001530766 STEX:StreamexLtdMember 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-03-31 0001530766 STEX:BioSigAISciencesIncMember 2025-03-31 0001530766 STEX:StreamexLtdMember 2025-03-31 0001530766 us-gaap:CorporateMember 2026-01-01 2026-03-31 0001530766 us-gaap:CorporateMember 2025-01-01 2025-03-31 0001530766 us-gaap:SubsequentEventMember srt:BoardOfDirectorsChairmanMember 2026-04-17 2026-04-17 0001530766 us-gaap:SubsequentEventMember STEX:ChiefInvestmentOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2026-04-06 0001530766 us-gaap:SubsequentEventMember STEX:ChiefInvestmentOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2026-04-06 2026-04-06 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember STEX:PerformanceVestingRestrictedStockUnitsMember 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember STEX:ShareBasedCompensationAwardTrancheFourMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember STEX:ChiefInvestmentOfficerMember STEX:ShareBasedCompensationAwardTrancheFiveMember 2026-05-01 2026-05-01 0001530766 us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember us-gaap:CommonStockMember 2026-04-01 2026-05-14 0001530766 us-gaap:SubsequentEventMember us-gaap:CommonStockMember us-gaap:RelatedPartyMember STEX:EmploymentAgreementMember 2026-04-01 2026-05-14 0001530766 us-gaap:SubsequentEventMember STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember 2026-04-10 2026-04-10 0001530766 us-gaap:SubsequentEventMember STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember STEX:SixMonthAnniversariesMember 2026-04-10 2026-04-10 0001530766 us-gaap:SubsequentEventMember STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember STEX:TwelveMonthAnniversariesMember 2026-04-10 2026-04-10 0001530766 us-gaap:SubsequentEventMember STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember 2026-04-06 2026-04-06 0001530766 us-gaap:SubsequentEventMember STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember 2026-05-01 2026-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure STEX:Integer iso4217:CAD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2026

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission file number: 001-38659

 

STREAMEX CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   26-4333375

(State or other jurisdiction of incorporation

or organization)

 

(IRS Employer

Identification No.)

     

2431 Aloma Avenue, Suite 243

Winter Park, Florida

  32792
(Address of principal executive office)   (Zip Code)

 

(203) 409-5444

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   STEX   The NASDAQ Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of May 13, 2026, there were 104,274,817 shares of the registrants common stock, par value $0.001 per share, outstanding.

 

Exchangeable and Special Voting Shares:

 

As of May 13, 2026, there were outstanding 77,530,617 exchangeable shares of BST Sub ULC, a wholly owned subsidiary of the registrant. The exchangeable shares are exchangeable for an equal number of the registrants common stock, and carry rights substantially equivalent to the Company’s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee).

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION  
       
  ITEM 1. Financial Statements 3
       
    Condensed Consolidated Balance Sheets (Unaudited) 3
       
    Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 4
       
    Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) 5
       
    Condensed Consolidated Statements of Cash Flows (Unaudited) 6
       
    Notes to Condensed Consolidated Financial Statements (Unaudited) 7-38
       
  ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 39-42
  ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 43
  ITEM 4. Controls and Procedures 43
       
PART II. OTHER INFORMATION  
       
  ITEM 1. Legal Proceedings 44
  ITEM 1A. Risk Factors 44
  ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 44
  ITEM 3. Defaults Upon Senior Securities 44
  ITEM 4. Mine Safety Disclosures 44
  ITEM 5. Other Information 44
  ITEM 6. Exhibits 45
       
  SIGNATURES 46

 

2

 

 

PART IFINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

STREAMEX CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Par Value and Share Amounts)

 

   March 31,   December 31, 
   2026   2025 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $6,859   $20,316 
Sales tax receivable   59    51 
Due from related party   -    11 
Marketable securities   23,766    9,706 
Other assets held for sale – restricted gold   -    23,472 
Other assets held for sale – gold   -    1,000 
Prepaid expenses and other assets   15,220    17,339 
Total current assets   45,904    71,895 
Non-current assets:          
Other assets held at cost – gold   15,225    - 
Property and equipment, net   12    25 
Intangible assets, net   42,418    44,639 
Goodwill   69,758    70,984 
Total non-current assets   127,413    115,648 
Total assets  $173,317   $187,543 
           
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable and accrued expenses, including $907 and $66 to related parties as of March 31, 2026, and December 31, 2025, respectively.  $3,179   $2,952 
Dividends payable   123    121 
Convertible debentures, net   -    38,021 
Embedded derivative liability   -    1,700 
Total current liabilities   3,302    42,794 
Deferred tax liability   10,669    11,421 
Total liabilities   13,971    54,215 
           
Commitments and contingencies (Note 16)   -    - 
           
Mezzanine equity          
Redeemable Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $105; cumulative dividends payable of $123 and $121 as of March 31, 2026, and December 31, 2025, respectively).   105    105 
           
Stockholders’ equity:          
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock.   -    - 
Common stock, $0.001 par value, authorized 500,000,000 shares, 97,721,696 and 49,805,275 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively.   98    50 
Additional paid-in-capital   924,802    850,447 
Accumulated other comprehensive (loss) income   (1,102)   814 
Accumulated deficit   (764,813)   (718,120)
Total stockholders’ equity attributable to Streamex Corp.   158,985    133,191 
Non-controlling interest   256    32 
Total stockholders’ equity   159,241    133,223 
Total liabilities, mezzanine equity and stockholders’ equity  $173,317   $187,543 

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements

 

3

 

 

STREAMEX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In Thousands, Except Par Value and Share Amounts)

 

   2026   2025 
   For the Three Months Ended March 31, 
   2026   2025 
Revenue  $-   $- 
           
Operating expenses:          
Research and development   -    6 
General and administrative   34,254    2,957 
Depreciation and amortization   1,492    21 
Total operating expenses   35,746    2,984 
           
Loss from operations   (35,746)   (2,984)
           
Other income (expense):          
Interest expense, net   (12,195)   - 
Realized gain on sale of gold   2,938    - 
Realized gain on marketable securities   484    - 
Change in fair value of marketable securities   (134)   - 
Change in fair value of embedded derivative   497    - 
Realized loss on extinguishment of convertible debentures   (3,057)   - 
Realized loss on investment   (119)   - 
Gain on settlement and forgiveness of debt   -    199 
Other income (expense), net   73    (15)
Total other income (expense), net   (11,513)   184 
           
Loss before income taxes   (47,259)   (2,800)
           
Income taxes (benefit)   (565)   - 
           
Net loss   (46,694)   (2,800)
Non-controlling interest   1    (12)
Net loss attributable to Streamex Corp.   (46,693)   (2,812)
           
Preferred stock dividend   (2)   (2)
Preferred stock deemed dividend   -    - 
Net loss attributed to Streamex Corp. Common Shareholders   (46,695)   (2,814)
Net loss per common share, basic and diluted  $(0.27)  $(0.14)
Weighted average number of common shares outstanding, basic and diluted   174,590,397    20,787,808 
           
Comprehensive (Loss) Income:          
Net loss  $(46,694)  $(2,800)
Other comprehensive loss          
Change in foreign currency translation adjustments   (1,916)   - 
Total comprehensive loss   (48,610)   (2,800)
Comprehensive (loss) income attributable to non-controlling interest   1    (12)
Comprehensive loss attributable to Streamex Corp.  $(48,609)  $(2,812)

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements

 

4

 

 

STREAMEX CORP.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In Thousands, Except Par Value and Share Amounts)

 

  

Common

stock

Shares

   Amount  

Additional

Paid-in-

Capital

  

Accumulated

Deficit

  

Accumulated

Other

Comprehensive

Income

(Loss)

  

Non-

controlling

Interest

   Total 
Balance, December 31, 2025   49,805,275   $50   $850,447   $(718,120)  $814   $32   $133,223 
Stock based compensation   6,123,941    6    21,455    -    -    -    21,461 
Exercise of warrants   54,647    - *    -    -    -    -    - 
Net proceeds from issuance of common stock in underwritten public offering   13,416,667    13    37,171    -    -    -    37,184 
Conversion of exchangeable shares into common stock   24,571,166    25    (25)   -    -    -    - 
Conversion of convertible debentures into common stock   3,750,000    4    15,756    -    -    -    15,760 
Issuance of equity to noncontrolling interest holders   -    -    -    -    -    225    225 
Preferred stock dividend   -    -    (2)   -    -    -    (2)
Other comprehensive loss   -    -    -    -    (1,916)   -    (1,916)
Net loss   -    -    -    (46,693)   -    (1)   (46,694)
Balance, March 31, 2026   97,721,696   $98   $924,802   $(764,813)  $(1,102)  $256   $159,241 

 

  

Common

stock

Shares

   Amount  

Additional

Paid-in-

Capital

  

Accumulated

Deficit

  

Non-

controlling

Interest

   Total 
Balance, December 31, 2024   17,239,096   $17   $253,784   $(255,345)  $17   $(1,527)
Stock based compensation   1,663,543    2    2,072    -    -    2,074 
Exercise of warrants   48,996    - *    -    -    -    - 
Sale of common stock under at-the- market offering, net of transaction costs   4,403,166    4    3,878    -    -    3,882 
Sale of common stock and warrants   758,514    1    817    -    -    818 
Common stock issued to settle accounts payable   135,000    -*    189              189 
Preferred stock dividend   -    -    (2)   -    -    (2)
Net (loss) income   -    -    -    (2,812)   12    (2,800)
Balance, March 31, 2025   24,248,315   $24   $260,738   $(258,157)  $29   $2,634 

 

*- less than $1

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements

 

5

 

 

STREAMEX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In Thousands, Except Par Value and Share Amounts)

 

   2026   2025 
  

For the Three Months

Ended March 31,

 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(46,694)  $(2,800)
Adjustments to reconcile net loss to cash used in operating activities:          
Depreciation and amortization   1,492    21 
Amortization of debt discount and issuance costs   11,979    - 
Gain on settlement and extinguishment of accounts payable   -    199 
Non-cash lease expense   -    41 
Realized gain on sale of gold   (2,938)   - 
Realized gain on marketable securities   (484)   - 
Change in fair value of marketable securities   134    - 
Change in fair value of embedded derivative   (497)   - 
Realized loss on extinguishment of convertible debentures   3,057    - 
Realized loss on investment   119    - 
Stock-based compensation expense   25,370    2,074 
Deferred income taxes   (565)   - 
Changes in operating assets and liabilities:          
Accounts receivable   11    - 
Lease receivables   -    17 
Sales tax receivable   (9)   - 
Prepaid expenses and other assets   (1,934)   (70)
Accounts payable and accrued expenses   780    (555)
Operating lease liabilities   -    (42)
Net cash used in operating activities   (10,179)   (1,115)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of marketable securities   (23,900)   - 
Proceeds from the sale of marketable securities   10,190    - 
Proceeds from the sale of non-marketable equity investments   25    - 
Proceeds from sale of gold   26,410    - 
Purchase of gold assets   (14,225)   - 
Net cash used in investing activity   (1,500)   - 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from sale of common stock under at-the-market offerings, net of issuance costs   -    3,882 
Proceeds from sale of common stock and warrants, net of issuance costs   -    818 
Repayment of finance obligation   (546)   - 
Net proceeds from issuance of common stock in underwritten public offering   37,184    - 
Proceeds from issuance of equity in subsidiary to non-controlling interest holders   225    - 
Repayment of convertible debentures   (38,500)   - 
Net cash (used in) provided by financing activities   (1,637)   4,700 
           
Effect of exchange rate change on cash   (141)   - 
Net (decrease) increase in cash   (13,457)   3,585 
Cash, beginning of the period   20,316    142 
Cash, end of the period  $6,859   $3,727 
           
Supplemental disclosures of cash flow information:          
Cash paid during the period for interest  $403   $- 
Cash paid during the period for income taxes  $-   $- 
           
Noncash investing and financing activities:          
Common stock issued in settlement of accounts payable  $-   $189 
Dividend payable on preferred stock charged to additional paid-in-capital  $2   $2 
Conversion of convertible debentures into common stock  $15,760   $- 

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements

 

6

 

 

STREAMEX CORP.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 (Unaudited)

(in thousands, except par value and share amounts)

 

NOTE 1NATURE OF OPERATIONS

 

Business and organization

 

Streamex Corp. (the “Company”, “we”, “us” and “our”) is a technology company with two principal lines of business: (i) digital infrastructure focused on the tokenization and exchange of real-world assets and other commodity-linked financial products and (ii) biomedical technology focused on advanced signal acquisition and processing solutions in electrophysiology through our PURE EP™ platform. On May 28, 2025, the Company acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, British Columbia. In connection with this strategic expansion, on September 12, 2025, the Company changed its corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025, the Company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “STEX” (formerly “BSGM”).

 

On May 28, 2025, the Company completed the acquisition of Streamex Exchange pursuant to that certain Share Purchase Agreement dated as of May 23, 2025 (as amended on May 27, 2025, the “Share Purchase Agreement”) by and among the Company, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a British Columbia company and a wholly owned subsidiary of the Company (“Callco”), the shareholders of Streamex Exchange, and 1540873 B.C. Ltd., as trustee (the “Trustee”) under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”).

 

The Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). As of March 31, 2026 and December 31, 2025, the Company held a majority interest of approximately 70% in ViralClear. As of March 31, 2026, and December 31, 2025, the Company held a majority interest of approximately 84% in BioSig AI.

 

During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately 98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $225 of GLDY Tokens during March 2026. The Company also formed GLDY ServiceCo, LLC, a wholly owned subsidiary that acts as servicer to Streamex Ltd. under a servicing arrangement.

 

NOTE 2LIQUIDITY

 

As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026.

 

During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.1 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released.

 

We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.

 

7

 

 

Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

 

NOTE 3SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Basis of Consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity.

 

During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.

 

Foreign Currency Translation

 

The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.

 

8

 

 

Marketable Securities

 

The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).

 

Gold Assets

 

The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred.

 

Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026.

 

Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360.

 

Concentration of Assets

 

As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33).

 

As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions.

 

The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

 

Net Income (loss) Per Common Share

 

The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock.

 

9

 

 

The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss).

 

Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders.

 

In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share.

 

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 

   March 31,   March 31, 
   2026   2025 
Series C convertible preferred stock   434,845    564,234 
Options to purchase common stock   2,921,000    2,486,000 
Performance-based restricted stock units   1,500,000    - 
Warrants to purchase common stock   1,647,885    5,577,260 
Restricted stock units to acquire common stock   4,583,375    1,160,830 
Totals   11,087,105    9,788,324 

 

Recently adopted accounting pronouncements

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.

 

Recently issued accounting pronouncements not yet adopted

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements.

 

10

 

 

In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

 

NOTE 4 – BUSINESS ACQUISITION

 

Streamex Exchange Corporation

 

Transaction Overview

 

On May 28, 2025, the Company completed the acquisition of Streamex Exchange, a software development company based in Vancouver, British Columbia, specializing in digital tools for commodity trading and finance.

 

The acquisition was effected pursuant to the Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025, by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Streamex Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement.

 

Under the terms of the Share Purchase Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for 109,070,079 Exchangeable Shares of ExchangeCo, issued at a ratio of 2.046862 Exchangeable Shares per Purchased Share. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below.

 

The purpose of the Acquisition was to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition was undertaken to expand the Company’s technology platform into digital commodity trading and blockchain-based financial infrastructure and to obtain the assembled workforce, intellectual property, and regulatory capabilities of Streamex Exchange.

 

In connection with the transaction, the Company evaluated the accounting under ASC 805, Business Combinations, and ASC 810, Consolidation. The Company concluded the acquired set met the definition of a business. In making this determination, the Company considered the concentration test in ASC 805 and determined that substantially all of the fair value of the gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. The Company also evaluated whether the acquiree is a variable interest entity (“VIE”) and concluded Streamex Exchange is a VIE because, among other factors, it lacked sufficient equity at risk to finance its activities without additional subordinated financial support and the equity holders, as a group, did not have substantive power to direct the activities that most significantly impact economic performance at the acquisition date.

 

The Company concluded it is the primary beneficiary because it has both (i) the power to direct the activities that most significantly impact Streamex’s economic performance through governance rights in place at closing and (ii) the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, the transaction is accounted for as a business combination with the Company as the accounting acquirer, and Streamex Exchange has been consolidated in the Company’s financial statements from the acquisition date.

 

11

 

 

Shareholder Approval and Contingent Features

 

Initially, the Exchangeable Shares were not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company sought stockholder approval for certain matters related to the transaction, including the issuance of shares of common stock exchangeable for Exchangeable Shares, the issuance of shares underlying the Convertible Debentures, increases to the authorized share count and the 2023 Long-Term Incentive Plan, and amendments to the Company’s Amended and Restated Certificate of Incorporation. At the special meeting of stockholders held on September 5, 2025, all proposals except the issuance of shares exchangeable for Exchangeable Shares (Proposal A) were approved. Proposal A was subsequently approved on November 4, 2025.

 

Following stockholder approval of Proposal A on November 4, 2025, and subject to the terms of the Exchange Rights Agreement, the holders of Exchangeable Shares are entitled to exchange such shares for an aggregate of 109,070,079 shares of the Company’s common stock representing up to 75% of the Company’s fully diluted common stock as of the Share Purchase Agreement date.

 

Consideration Transferred

 

The fair value of the consideration transferred was $105,498, consisting entirely of Exchangeable Shares issued by ExchangeCo. Due to the lack of an active market for the Exchangeable Shares and the contingent nature of their conversion, a fundamentals-based valuation approach was used to estimate the fair value of the consideration. The contingent consideration related to the potential adjustment of the Exchange Ratio from 1.0 to 1.25—triggered if shareholder approval is not obtained within six months following the closing date—was not included in the purchase consideration as of May 28, 2025. As stockholder approval was obtained on November 4, 2025, within six months of the closing date, the exchange ratio adjustment was not triggered, and no additional consideration was required. For an overview of the Company’s derivative financial instruments and related disclosures required by ASC 815, see Note 11, Convertible Debentures and Related Derivative Instruments. See Note 12, Fair Value Measurements and Note 13, Stockholders’ Equity.

 

On November 4, 2025, the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Share Purchase Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. As a result of the reclassification, the Exchangeable Shares are classified as permanent equity and are presented within stockholders’ equity in the consolidated balance sheet. No derivative liability related to the Exchangeable Shares remained outstanding as of March 31, 2026 or December 31, 2025. Although the Exchangeable Shares were reclassified to permanent equity upon stockholder approval on November 4, 2025, the consideration transferred for purposes of the acquisition date purchase price allocation reflects the fair value of the Exchangeable Shares as of May 28, 2025.

 

In connection with the acquisition of Streamex Exchange, the Company incurred total acquisition-related costs of $5.9 million during the year ended December 31, 2025. These costs primarily consisted of legal, accounting, and consulting fees directly attributable to the transaction. Included in this amount was the issuance of 200,000 shares of the Company’s common stock to a third-party consultant, valued at $1,010 based on the grant-date fair value and the expected issuance of 824,052 shares of the Company’s common stock to third party consultants in connection with a finders fee, valued at $4,820. These costs were expensed as incurred and are reflected in general and administrative expenses in the Unaudited Condensed Consolidated Statements of Operations.

 

Purchase Price Allocation

 

The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their estimated fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. During the three months ended March 31, 2026, the Company completed its assessment of the fair values of the assets acquired and liabilities assumed in connection with the acquisition of Streamex Exchange. No measurement period adjustments were recorded during the three months ended March 31, 2026.

 

The Acquisition was recorded as a business combination based on a valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). Goodwill represents the excess of the purchase price consideration over the valuation of the net assets acquired. 

 

12

 

 

The final allocation of the purchase consideration is as follows:

 

Amount Recognized as of the Acquisition Date (In Thousands)    
Assets acquired     
Cash  $366 
Due from related party   11 
Sales tax receivable   14 
Prepaid expenses   22 
Trade name   5,100 
Developed technology   40,000 
Legal and compliance framework   2,400 
Goodwill   70,435 
Total assets acquired  $118,348 
Liabilities assumed     
Accounts payable and accrued expenses  $(262)
Deferred tax liability   (12,588)
Total liabilities assumed  $(12,850)
Net assets acquired   105,498 

 

Deferred tax liability

 

In connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets, resulting in a deferred tax liability of approximately $12,588, measured using the enacted combined Canadian federal and provincial rate of 26.5%. Because these deferred tax liabilities arise in a separate foreign jurisdiction, they cannot offset deferred tax assets of the U.S. parent. The corresponding increase in goodwill was recognized as part of purchase accounting.

 

Intangible Assets

 

The Company identified the following finite-lived intangible assets:

 

  Trade Name: Valued at $5,100 using the relief-from-royalty method, applying a 1.0% royalty rate and a 40.5% discount rate. The trade name is expected to be utilized over a 10-year period and is amortized accordingly.
     
  Developed Technology
     
    Comprised of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over 8 years:

 

  Securitization Platform: Valued at $31,100, representing proprietary protocols and infrastructure enabling the tokenization of real-world assets and integration with decentralized finance platforms.
     
  Blockchain Integration: Valued at $8,900, reflecting proprietary systems facilitating token creation and secondary market trading through blockchain-based platforms.

 

  Legal and Compliance Framework: Valued at $2,400 using the cost approach, based on the estimated cost to recreate the regulatory and legal infrastructure necessary for operations. The asset has a useful life of 7 years and is amortized accordingly. The legal and compliance framework supports the Company’s ability to operate in regulated jurisdictions and reduce legal and regulatory risk exposure.

 

13

 

 

Goodwill

 

Goodwill of $70,435 represents the excess of the purchase consideration over the fair value of net assets acquired and was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the consolidated reporting unit, as the Company operates as a single segment. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or noncontrolling interests.

 

NOTE 5GOODWILL AND INTANGIBLE ASSETS

 

Goodwill

 

The following table shows the changes in the carrying amount of goodwill for the period:

 

Goodwill as of December 31, 2025 (1)  $70,984 
Acquisition   - 
Impairment   - 
Foreign currency translation adjustment   (1,226)
Goodwill as of March 31, 2026  $69,758 

 

  1) Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.

 

During the three months ended March 31, 2026, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. Based on the qualitative assessment performed, management concluded that the combination of factors considered did not result in a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the three months ended March 31, 2026.

 

14

 

 

Intangible Assets

 

Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company evaluates its finite-lived intangible assets for impairment in accordance with ASC 360-10-35 whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. During the three months ended March 31, 2026, the Company evaluated whether any such triggering events existed, including consideration of changes in the business environment, market conditions, and asset utilization. Based on this assessment, management concluded that no triggering events occurred and that the carrying amounts of the Company’s finite-lived intangible assets were recoverable. Accordingly, no impairment charges were recorded for the three months ended March 31, 2026 or 2025.

 

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:

 

   March 31,   December 31, 
   2026   2025 
Trade name (1)  $5,100   $5,100 
Developed technology (1)   40,000    40,000 
Legal and compliance framework (1)   2,400    2,400 
Patents   380    380 
Total   47,880    47,880 
Foreign currency translation adjustment   (456)   371 
Accumulated amortization:          
Trade name   (425)   (303)
Developed technology   (4,162)   (2,975)
Legal and compliance framework   (285)   (204)
Patents   (134)   (130)
Total accumulated amortization   (5,006)   (3,612)
Intangible assets, net  $42,418   $44,639 

 

  1) Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.

 

Amortization expenses for total intangible assets were $1,479 and $3 for the three months ended March 31, 2026 and 2025, respectively. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $128, $1,260, $86 and $5, respectively, for the three months ended March 31, 2026. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $0, $0, $0 and $3, respectively, for the three months ended March 31, 2025. The weighted-average useful lives of total intangibles, trade name, developed technology, legal and compliance framework and patents were 7.4 years, 9.2 years, 7.2 years, 6.2 years and 13.5 years, respectively, as of March 31, 2026.

 

Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:

 

      
Remainder 2026  $4,362 
2027   5,816 
2028   5,816 
2029   5,816 
2030   5,816 
Thereafter   14,792 
Total  $42,418 

 

15

 

 

NOTE 6PROPERTY AND EQUIPMENT

 

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:

 

   March 31,   December 31, 
   2026   2025 
Computer equipment  $531   $531 
Furniture and fixtures   109    109 
Testing/Demo equipment   312    312 
Leasehold improvements   84    84 
Total   1,036    1,036 
Less accumulated depreciation   (1,024)   (1,011)
Property and equipment, net  $12   $25 

 

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amounts of its property and equipment may not be recoverable. Based on this assessment, no impairment indicators were identified and no impairment charges were recorded during the three months ended March 31, 2026 or 2025.

 

Depreciation expenses were $13 and $18 for the three months ended March 31, 2026 and 2025, respectively.

 

NOTE 7 – MARKETABLE SECURITIES

 

Exchange-Traded Funds

 

The Company’s marketable securities consist of exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments. As of March 31, 2026, the portfolio was composed of four ETFs: iShares 0-3 Month Treasury Bond ETF (SGOV), SPDR Portfolio Short-Term Treasury ETF (SPTS), Vanguard Short-Term Treasury Index ETF (VGSH), and Vanguard Short-Term Corporate Bond ETF (VCSH), each representing approximately 25% of the total portfolio. These securities are held in a brokerage account and are classified as equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities.

 

Fair value is determined using quoted market prices in active markets and, accordingly, all marketable securities are classified within Level 1 of the ASC 820 fair value hierarchy.

 

During the three months ended March 31, 2026, the Company purchased approximately $23,900 of marketable securities on February 26, 2026. No ETF securities were sold during the period; therefore, no realized gains or losses were recognized. As of March 31, 2026, the aggregate fair value of the ETF portfolio was approximately $23,766 against a cost basis of $23,900, resulting in a net unrealized loss of approximately $(134), which related entirely to equity securities still held as of March 31, 2026 and is included in “Change in fair value of marketable securities” in the unaudited condensed consolidated statements of operations. No impairment charges were recognized during the period. During the three months ended March 31, 2026, the Company earned dividend income and interest income on sweep balances totaling approximately $71, which is included in “Other income (expense), net” in the unaudited condensed consolidated statements of operations.

 

As of December 31, 2025, the Company held no ETF investments.

 

Empress Royalty Corp.

 

On December 9, 2025, the Company entered into a share purchase agreement with Terra Capital Natural Resources Fund Pty Ltd to acquire 12,671,297 common shares of Empress Royalty Corp. (“Empress”), representing approximately 9.9% of Empress’s outstanding common shares. Empress is listed on the TSX Venture Exchange and OTCQX.

 

As consideration, the Company issued 2,443,750 restricted shares of its common stock on December 12, 2025, the date ownership transferred. The investment was initially recognized at $10,533, based on the fair value of 2,443,750 Streamex shares issued at $4.31 per share on December 12, 2025. The Company does not have significant influence over Empress.

 

16

 

 

As of December 31, 2025, the fair value of the Empress investment was approximately $9,706, with the resulting unrealized loss of $(827) recognized in earnings during the year ended December 31, 2025. In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain of $484 measured from the December 31, 2025 fair value. The realized gain is included in “Realized gain on marketable securities” in other income (expense) in the unaudited condensed consolidated statements of operations. As the investment was disposed of prior to March 31, 2026, no unrealized gains or losses on the Empress investment were recognized during the three months ended March 31, 2026, and no impairment charges were recorded during any period in which the investment was held. As of March 31, 2026, the Company held no investment in Empress Royalty Corp.

 

NOTE 8 – GOLD ASSETS

 

Gold Bullion — Held for Sale (Sold February 2026)

 

As of December 31, 2025, the Company held LBMA Good Delivery gold bullion (the “Gold”) on an allocated, physically segregated basis in secure vaults operated by Brink’s Global Services USA, Inc. (“Brink’s”) and maintained the Gold in a securities account with Gold Bullion International, LLC (“GBI”). The aggregate carrying value of the Gold as of December 31, 2025 was approximately $24,472, of which approximately $23,472 was restricted and approximately $1,000 was unrestricted.

 

The restricted portion of the Gold and related account rights were pledged as collateral under the Company’s secured financing arrangements, including the Secured Convertible Debenture Purchase Agreement dated July 7, 2025 and the Guaranty and Security Agreement dated November 4, 2025.

 

Pursuant to the Securities Account Control Agreement dated November 4, 2025, GBI is required to comply with entitlement orders issued by YA II PN, LTD., acting as collateral agent (the “Collateral Agent”), and GBI will not follow Company instructions unless accompanied by the Collateral Agent’s express written consent. Upon receipt of a notice of sole control following an event of default, GBI would terminate the Company’s access to the securities account and take instructions solely from the Collateral Agent as the entitlement holder with respect to the account and property therein.

 

Pursuant to the Brink’s Bailee Agreement dated November 4, 2025, Brink’s acts solely as bailee of the Gold, acknowledges no property interest in the Gold, and any statutory or possessory liens are subordinated to the Collateral Agent’s first-priority security interest. Brink’s maximum liability amount under its arrangements with GBI is $125 million.

 

No entitlement orders or notices of sole control were issued during the three months ended March 31, 2026.

 

On December 29, 2025, management committed to a plan to sell the Gold in connection with the Company’s plan to resolve and repay its secured convertible debentures. The Company determined that all criteria for classification as held for sale under ASC 360-10-45-9 were met as of December 29, 2025. Accordingly, as of December 31, 2025, the Gold was classified as held for sale and measured at the lower of its carrying amount or fair value less cost to sell. Because fair value less cost to sell exceeded the carrying amount, no write-down was recorded prior to sale.

 

In February 2026, the Company transferred approximately $1,000 of unrestricted gold bullion at cost to Streamex Ltd. in connection with the establishment of the GLDY Token program. The transferred gold is included in “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet as of March 31, 2026 (see Note 9).

 

On February 5, 2026, the Company completed the sale of the remaining LBMA Good Delivery gold bullion previously classified as held for sale, with a carrying amount of approximately $23,472. The transaction was executed through the Company’s securities intermediary and resulted in cash proceeds of approximately $26,410. The Company recognized a gain of approximately $2,938 on the sale, which is included in “Realized gain on sale of gold” in other income (expense) in the unaudited condensed consolidated statements of operations. The proceeds were used to fund the repayment of the Yorkville Debentures (see Note 11).

 

As of March 31, 2026, no gold bullion classified as held for sale remained on the unaudited condensed consolidated balance sheet. Upon completion of the sale and settlement of the Convertible Debentures, all related security interests, liens, and custodial arrangements described above were terminated.

 

17

 

 

Gold Assets Held at Cost — Streamex Ltd. (VIE)

 

During the three months ended March 31, 2026, Streamex Ltd. (the Company’s consolidated VIE) acquired gold bullion consisting of (i) the approximately $1,000 of unrestricted gold transferred from the Company as described above, and (ii) approximately $14,225 of gold purchased directly by Streamex Ltd. with cash funded by the Company. As of March 31, 2026, the aggregate carrying amount of gold held by Streamex Ltd. was $15,225, classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The gold is held to support the long-term GLDY Token program and related leasing activities and is accounted for as a long-lived tangible asset within the scope of ASC 360 (see Note 3).

 

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amount of its gold assets held at cost may not be recoverable. Based on this assessment, including consideration of gold market prices as of the balance sheet date, management concluded that no triggering events existed and no impairment charges were recorded during the three months ended March 31, 2026. See Note 9 for additional information regarding Streamex Ltd.

 

NOTE 9 – STREAMEX LTD. (VIE)

 

Overview

 

Streamex Ltd. (“Streamex Ltd.” or the “VIE”) is a special-purpose entity organized in the Cayman Islands and formed to purchase and hold physical gold and to issue digital GLDY Tokens designed to provide tokenholders exposure to gold and gold-denominated leasing returns. Streamex Ltd. may also lease its gold holdings to generate gold-denominated yield. The Company is involved with Streamex Ltd. through its governance rights and through its economic interests in GLDY Tokens.

 

Streamex Ltd. began operations during the three months ended March 31, 2026.

 

Variable Interest Entity Consideration

 

The Company evaluated Streamex Ltd. under the variable interest entity (“VIE”) model in ASC 810, Consolidation. A legal entity is a VIE if, among other conditions, the holders of the equity investment at risk, as a group, lack the power, through voting rights or similar rights, to direct the activities that most significantly impact the entity’s economic performance. Streamex Ltd. is considered a VIE because the holders of GLDY Tokens (which represent non-voting participating equity interests) lack substantive voting rights and do not have the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance. Voting control resides with the single voting management share, which controls shareholder-level decisions including the appointment and removal of directors, and day-to-day operating authority has been delegated to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, pursuant to a services agreement. Because Streamex Ltd. is a VIE, the Company evaluated whether it is the primary beneficiary and therefore required to consolidate Streamex Ltd., as discussed below.

 

Primary Beneficiary Conclusion and Consolidation

 

The Company evaluated its involvement with Streamex Ltd. under ASC 810, Consolidation, and concluded it is the primary beneficiary and is required to consolidate Streamex Ltd. Under ASC 810-10-25-38, a reporting entity is the primary beneficiary of a VIE only if it has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company concluded both criteria are met as of March 31, 2026 because it has the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance through its control of the VIE’s governance structure (including the voting management share and related decision rights, as applicable) and the servicer arrangement, and has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE due to its economic interest in the GLDY Tokens.

 

18

 

 

As of March 31, 2026, the Company held approximately 98.5% of the outstanding GLDY Tokens issued by Streamex Ltd. (approximately $15,000 invested by the Company out of $15,225 total tokens issued). Two related party investors subscribed for an aggregate of approximately $225 in GLDY Tokens during March 2026, representing approximately 1.5% of total tokens outstanding. Accordingly, the Company has consolidated Streamex Ltd. from the date of its formation in the unaudited condensed consolidated financial statements.

 

Carrying Amounts of Assets and Liabilities of Consolidated VIE

 

The following table presents the carrying amounts and balance sheet classifications of the significant assets and liabilities of Streamex Ltd. included in the Company’s unaudited condensed consolidated balance sheet as of March 31, 2026. The assets of Streamex Ltd. are generally restricted and can be used only to settle obligations of Streamex Ltd.

 

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:

 

     
Assets    
Other assets held at cost – gold  $15,225 
Cash   60 
Total assets  $15,285 
      
Liabilities     
Accounts payable and accrued expenses  $33 
Total liabilities  $33 

 

During the three months ended March 31, 2026, Streamex Ltd. incurred a net loss of approximately $155, primarily consisting of operating expenses including bank fees, custody-related charges, and digital asset transaction costs. The net loss was funded by capital contributions from the Company and its affiliates (see Note 8 for additional information regarding the gold assets held by Streamex Ltd.).

 

During March 2026, two officers of the Company subscribed for GLDY Tokens directly with Streamex Ltd.: (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens on March 17, 2026, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens on March 27, 2026. These subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions and are related party transactions (see Note 18, Related Party Transactions).

 

Lack of Recourse / Restrictions

 

The assets of Streamex Ltd. are generally not available to satisfy the obligations of the Company or its other subsidiaries, and the creditors and tokenholders of Streamex Ltd. generally do not have recourse to the general credit of the Company beyond the assets of Streamex Ltd., except to the limited extent of intercompany balances eliminated in consolidation. The liabilities recognized as a result of consolidating Streamex Ltd. do not represent additional claims on the Company’s general assets.

 

Maximum Exposure to Loss / Financial Support

 

The Company’s maximum exposure to loss associated with its involvement with Streamex Ltd. as of March 31, 2026 is limited to the carrying amount of its approximately 98.5% economic interest in the GLDY Tokens and its net interest in Streamex Ltd.’s net assets, which totaled approximately $15,000 at the date of investment. The Company has no arrangements that legally obligate it to provide additional financial support to Streamex Ltd., such as guarantees or liquidity facilities, beyond its role as an investor and service provider. However, the Company funded approximately $158 of Streamex Ltd.’s operating expenses during Q1 2026 through capital contributions from the Company and its affiliates, which are eliminated in consolidation.

 

19

 

 

Related Party Considerations / Intercompany Eliminations

 

Streamex Ltd. pays servicing fees to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, under the applicable servicing arrangement. Because the servicer is a consolidated subsidiary, these servicing fees and related intercompany balances are eliminated in consolidation.

 

Noncontrolling Interest

 

As of March 31, 2026, noncontrolling interests in Streamex Ltd. consisted of (i) the single voting management share held by the VIE’s director, which carries governance rights but no material economic interest, and (ii) GLDY Tokens held by two officers of the Company who subscribed as related party investors during March 2026. In aggregate, related party tokenholders held approximately 1.5% of the outstanding GLDY Tokens as of March 31, 2026.

 

The noncontrolling interest attributable to Streamex Ltd. as of March 31, 2026 was approximately $224, consisting of related party token subscriptions described above, net of the noncontrolling interest’s proportionate share of the VIE’s net loss for the period. The noncontrolling interest is presented within noncontrolling interest on the unaudited condensed consolidated balance sheet and in the unaudited condensed consolidated statements of operations. See Note 15 for the noncontrolling interest rollforward and attribution tables.

 

Ongoing Assessment

 

The Company reassesses its primary beneficiary conclusion on an ongoing basis in accordance with ASC 810 whenever changes in facts and circumstances occur that could affect the determination of whether either criterion under ASC 810 continues to be met. Changes that could affect the primary beneficiary assessment include, but are not limited to, changes in GLDY Token ownership (including issuance, redemption, or transfer of GLDY Tokens to unrelated third parties that could affect the significance of the Company’s economic exposure to the VIE), modifications of governing documents or fee arrangements, changes in ownership of the management share, or replacement of the affiliated servicer by an unrelated party. As of March 31, 2026, no changes in facts or circumstances have occurred that would alter the Company’s conclusion.

 

NOTE 10ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:

 

   March 31,   December 31, 
   2026   2025 
Accrued accounting and legal  $725   $705 
Accrued consulting   564    406 
Accrued interest   -    200 
Accrued research and development expenses   167    169 
Accrued office and other   41    38 
Accrued insurance premium financing(1)   370    916 
Accrued payroll(2)   1,180    512 
Other accrued expenses   132    6 
Accounts payable and accrued expenses   $3,179   $2,952 

 

  (1) On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.
     
  (2) Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.

 

20

 

 

NOTE 11 – CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

 

On November 4, 2025 and December 17, 2025, the Company issued two tranches of senior secured convertible debentures to YA II PN, Ltd. (“Yorkville”) (collectively, the “Convertible Debentures”) with aggregate principal of $50,000 (each tranche with principal of $25,000). The Convertible Debentures were issued as part of the Company’s capital-raising strategy to fund operations and growth initiatives.

 

Each debenture was issued at a purchase price of 96% of principal, bore interest at 4.0% per annum (increasing to 18.0% upon an event of default), and had a contractual maturity date that was 24 months from issuance (November 4, 2027 and December 17, 2027, respectively).

 

The Convertible Debentures were secured by first-priority liens on substantially all assets of the Company and were guaranteed by certain subsidiaries. Upon settlement in February 2026, all related security interests and liens were released.

 

Conversion Features

 

Yorkville could convert all or any portion of the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price equal to the lower of:

 

(i) a fixed price of $6.016 per share, subject to a one-time downward-only reset following registration effectiveness, and

 

(ii) 97% of the lowest daily volume-weighted average price (“VWAP”) during the three trading days immediately preceding conversion, subject to a $4.00 per share floor price, in each case subject to customary anti-dilution adjustments.

 

Conversions were also subject to a beneficial ownership limitation (generally 4.99%) and an exchange cap tied to Nasdaq rules, unless stockholder approval was obtained or the limitation was otherwise waived pursuant to the debenture terms.

 

If fully converted at the $4.00 floor price, the $50,000 principal amount of the Convertible Debentures would have been convertible into a maximum of 12,500,000 shares of the Company’s common stock, exclusive of any shares issuable for accrued interest or premiums. The Company did not register any shares for issuance under the Convertible Debentures and elected to utilize its optional cash settlement provisions in February 2026.

 

Embedded Derivative Liability – Conversion Option

 

The Company determined that the holder’s optional conversion feature requires bifurcation as an embedded derivative under ASC 815, Derivatives and Hedging, because (i) the economic characteristics of the conversion feature were not clearly and closely related to the host debt instrument and (ii) the conversion feature did not qualify for equity classification due to its variable conversion pricing mechanics, including VWAP-based pricing, floor price provisions, and reset features.

 

21

 

 

Accordingly, the embedded conversion option was accounted for separately as a derivative liability measured at fair value, with changes in fair value recognized in earnings each reporting period. At issuance, the Company allocated proceeds between the host debt and the embedded derivative based on relative fair value, with the derivative recorded as a liability and a corresponding amount recorded as a debt discount on the host debenture. This debt discount was amortized to interest expense using the effective interest method over the estimated term of the debenture. As of March 31, 2026, the embedded derivative liability was fully settled and no balance remained outstanding. See Note 12, Fair Value Measurements, for information regarding the valuation methodology, significant unobservable inputs, sensitivity considerations, changes in fair value, the tabular presentation of gains and losses on derivative instruments recognized in earnings as required by ASC 815, and the Level 3 rollforward of the embedded derivative liability.

 

The Company does not designate any derivative instruments as hedging instruments for accounting purposes and does not apply hedge accounting.

 

Debt Carrying Amount and Interest Expense

 

As of March 31, 2026, the carrying value of the Convertible Debentures, net of unamortized original issue discount, debt issuance costs, and bifurcation-related discounts, was $0 on a combined basis.

 

Interest expense recognized for the three months ended March 31, 2026 includes stated coupon interest and amortization of debt discounts and issuance costs under the effective interest method. For the three months ended March 31, 2026, the Company recognized total interest expense of approximately $12,182 related to the Convertible Debentures, consisting of approximately $203 of contractual interest and approximately $11,979 of non-cash interest expense from the amortization of discounts and issuance costs. Interest expense is included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

 

The effective interest rate on the Convertible Debentures substantially exceeded the 4.0% stated coupon rate. On December 29, 2025, management committed to a plan to settle the Convertible Debentures in early 2026, which constituted a change in the estimated life of the instruments. The Company prospectively recalculated the effective interest rates based on the revised expected settlement date of February 6, 2026. The resulting effective interest rates for the November 4, 2025 tranche and the December 17, 2025 tranche were approximately 393.7% and 228.9%, respectively, reflecting the accelerated amortization of unamortized discounts and issuance costs over a significantly shortened expected term. These revised rates were applied from December 29, 2025 through the settlement date of February 6, 2026, and are the basis for the non-cash interest expense from the accelerated amortization of discounts and issuance costs described above. Upon settlement, all remaining unamortized discounts and issuance costs were fully amortized and the net carrying value of the Convertible Debentures was reduced to zero. Had the Convertible Debentures been held to their contractual maturity dates of November 4, 2027 and December 17, 2027, respectively, the effective interest rates would have been approximately 17.6% and 26.5%, respectively, still materially higher than the stated coupon due to the substantial original issue discount.

 

Outstanding Principal

 

As of March 31, 2026, and December 31, 2025, the outstanding principal balance of the Convertible Debentures was $0 and $50,000, respectively.

 

Settlement and Extinguishment

 

On January 22, 2026, the Company delivered an irrevocable optional prepayment notice with respect to the Convertible Debentures.

 

On February 6, 2026, the Company settled the Convertible Debentures, which had an aggregate outstanding principal of $50,000 and a net carrying value of $38,021 (after unamortized debt discounts of $11,979 as of December 31, 2025), through a combination of (i) a cash payoff of approximately $38,903, consisting of $35,000 of principal, a $3,500 prepayment premium, and approximately $403 of accrued interest, and (ii) conversion of $15,000 of principal, with no accrued interest, at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares of the Company’s common stock.

 

22

 

 

The remaining unamortized debt discounts of $11,979 were fully amortized to interest expense upon settlement during the three months ended March 31, 2026, and are included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

 

In connection with the settlement, the Company recognized the following:

 

      
Loss on extinguishment of convertible debentures — prepayment premium  $(3,500)
Gain on derecognition of embedded derivative at settlement   443 
Realized loss on extinguishment of convertible debentures  $(3,057)

 

Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.

 

We also entered into a SEPA with Yorkville that provided the Company with the right, but not the obligation, to sell shares of common stock during the commitment period. We terminated the SEPA effective January 29, 2026, and did not sell any shares under the SEPA.

 

Cross-references to related disclosures

 

Derivative-related qualitative, quantitative, and tabular disclosures are included in more than one note to the unaudited condensed consolidated financial statements. Accordingly, the Company provides the following cross-references:

 

  Note 4 — Business Acquisition (Exchangeable Shares issued as consideration and related acquisition disclosures)
     
  Note 12 — Fair Value Measurements (fair value hierarchy and valuation inputs for Level 3 instruments, as applicable)
     
  Note 13 — Stockholders’ Equity (Exchangeable Shares and Special Voting Preferred Stock; reclassification to equity)
     
  Note 14 — Options, Restricted Stock Units and Warrants (warrant terms and Fundamental Transaction cash settlement / repurchase activity)

 

NOTE 12 – FAIR VALUE MEASUREMENTS

 

The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations.

 

23

 

 

Nonrecurring Level 3 Fair Value Measurements

 

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:

 

Description  May 28, 2025 
Trade name  $5,100 
Developed technology  $40,000 
Legal and compliance framework  $2,400 
      
Goodwill  $70,435 

 

All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. See Note 4, Business Acquisition, for additional information regarding the purchase price allocation and valuation methodologies.

 

Derivative Liabilities – Recurring Fair Value Measurements (Embedded Conversion Options)

 

The embedded conversion options associated with the Company’s secured convertible debentures were bifurcated and accounted for as derivative liabilities under ASC 815. The derivative liabilities were measured at fair value upon issuance of each debenture tranche (November 4, 2025 and December 17, 2025) and subsequently remeasured at fair value on a recurring basis through settlement on February 6, 2026. See Note 11, Convertible Debentures and Related Derivative Instruments, for information regarding the terms of the Convertible Debentures, the bifurcation analysis, settlement mechanics, and extinguishment accounting.

 

The Company estimated the fair value of the embedded conversion options using a Monte Carlo simulation model within a “with-and-without” framework, which isolates the value of the holder’s conversion option by comparing the fair value of the debentures with and without the embedded conversion feature. The Monte Carlo model was designed to capture the path-dependent and non-linear features of the conversion option, including variable conversion pricing, contractual floor prices, amortization mechanics, optional prepayment features, and management’s expectations regarding conversion and repayment behavior. Because the valuation utilized significant unobservable inputs, the derivative liabilities were classified as Level 3 within the fair value hierarchy.

 

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):

 

SCHEDULE OF UNOBSERVABLE INPUT

   2/6/2026   12/31/2025 
Unobservable / key assumption  Remeasurement   Remeasurement 
Common stock price  $3.28   $3.03 
Indicated conversion price  $4.00   $4.00 
Floor price  $4.00   $4.00 
Prepayment probability   100%   70%
Prepayment premium   10%   10%
Registration probability   0%   0%

 

The February 6, 2026, valuation incorporated management’s assessment that optional prepayment was the most likely outcome and weighted prepayment and non-prepayment scenarios accordingly. Registration-dependent conversion scenarios were assigned a zero probability, as registration effectiveness was not expected.

 

The fair value of the derivative liabilities is most sensitive to changes in the Company’s stock price, expected volatility, and assumptions regarding the timing and likelihood of prepayment. An increase in expected volatility or stock price would generally increase the fair value of the derivative liability, while an increase in the probability of early prepayment would generally decrease the fair value. Due to the path-dependent nature of the valuation, quantitative sensitivity analyses are not presented.

 

During the three months ended March 31, 2026, the Company recognized a gain of $497 related to changes in the fair value of the embedded derivative liabilities prior to settlement on February 6, 2026. On settlement, the Company derecognized the remaining embedded derivative liability of $1,203, resulting in a gain on derecognition of $443 included in “Realized loss on extinguishment of convertible debentures” in the unaudited condensed consolidated statements of operations. See Note 11 for the complete extinguishment accounting.

 

24

 

 

The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:

 

   Amount 
Change in fair value of embedded derivative  $497 

 

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:

 SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY

   Amount 
Balance as of December 31, 2025  $1,700 
Change in fair value   (497)
Settlements   (1,203)
Balance as of March 31, 2026  $- 

 

Investment in Empress Royalty Corp.

 

The Company’s investment in Empress Royalty Corp. is measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. The fair value is based on quoted prices on the TSX Venture Exchange (principal market), translated into U.S. dollars using the spot exchange rate at the measurement date.

 

In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain on marketable securities of $484, which is included in other income (expense) in the unaudited condensed consolidated statements of operations. As of March 31, 2026, the Company held no investment in Empress Royalty Corp. See Note 7, Marketable Securities, for additional information.

 

Exchange-Traded Funds

 

The Company’s investments in exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments are measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy.

 

Recurring Fair Value Measurements

 

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):

 

Description  Level   March 31, 2026   December 31, 2025 
Embedded derivative liabilities – Yorkville Debentures   3   $-   $1,700 
Marketable securities   1   $23,766   $9,706 

 

NOTE 13STOCKHOLDERS’ EQUITY

 

Preferred stock

 

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2026 and December 31, 2025, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. As of March 31, 2026 and December 31, 2025, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.

 

25

 

 

Special Voting Preferred Stock

 

In connection with the issuance of Exchangeable Shares, the Company designated one share of Special Voting Preferred Stock, par value $0.001 per share. One share of Special Voting Preferred Stock was issued and outstanding as of March 31, 2026, and December 31, 2025.

 

The Special Voting Preferred Stock was issued to a trustee and does not have any economic rights, including rights to dividends or participation in liquidation, other than a nominal liquidation preference of $1.00. The Special Voting Preferred Stock is not convertible into common stock.

 

The sole purpose of the Special Voting Preferred Stock is to provide voting rights to holders of Exchangeable Shares on an equivalent basis with holders of the Company’s common stock. The holder of the Special Voting Preferred Stock is entitled to cast a number of votes equal to the aggregate number of votes that the holders of Exchangeable Shares would be entitled to cast if such Exchangeable Shares were exchanged for shares of the Company’s common stock, in accordance with the Exchange Rights Agreement.

 

The voting rights associated with the Special Voting Preferred Stock terminate automatically upon the exchange or cancellation of all outstanding Exchangeable Shares, at which time the Special Voting Preferred Stock is automatically cancelled for no consideration.

 

Series C Preferred Stock

 

Series C Preferred Stock (“Series C”) issued and outstanding totaled 105 shares as of March 31, 2026, and December 31, 2025. As of March 31, 2026, and December 31, 2025, the Company has accrued $123 and $121 dividends payable on the Series C, respectively. As of March 31, 2026, and December 31, 2025, the cumulative dividend per share payable on the Series C was approximately $1,175 and $1,153, respectively.

 

Each share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $0.3197 per share, based on the stated value of $1,000 per preferred share. As of March 31, 2026, the outstanding Series C shares were convertible into an aggregate of 434,845 shares of common stock, which includes 106,412 shares issuable for accrued dividends at a conversion rate of $1.1593 per share. The Series C is subject to full ratchet anti-dilution price protection upon issuance of equity or equity-linked securities at an effective price below $0.3197 per share, as well as customary anti-dilution adjustments for stock splits and similar events.

 

Common stock

 

The Company is authorized to issue 500,000,000 shares of $0.001 par value common stock. As of March 31, 2026, and December 31, 2025, the Company had 97,721,696 and 49,805,275 shares issued and outstanding, respectively.

 

Exchangeable Shares

 

During the three months ended March 31, 2026, holders of Exchangeable Shares converted a total of 24,571,166 Exchangeable Shares into an equal number of shares of the Company’s common stock. As of March 31, 2026 and December 31, 2025, the Company had 83,420,765 and 107,991,931 Exchangeable Shares outstanding, respectively, each of which is exchangeable on a one-for-one basis for a share of the Company’s common stock, subject to the terms of the exchange agreement.

 

Sale of Common Stock.

 

On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued 11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional 1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $40,250. The Company incurred transaction costs of approximately $3,066, including underwriting discounts, commissions, and other offering expenses, resulting in net proceeds of approximately $37,184.

 

26

 

 

ATM Sales Agreement 2024

 

As of March 31, 2026, the Company had approximately $4,500 of remaining capacity under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated December 18, 2024. No shares were sold under the ATM Offering during the three months ended March 31, 2026.

 

Equity Line of Credit

 

As of March 31, 2026, the Company had approximately $5,000 of remaining capacity under its Equity Subscription Agreement with Lind Global Fund III, LP, dated February 28, 2025, subject to the filing and effectiveness of a registration statement. No advances have been made under the Subscription Agreement as of March 31, 2026.

 

NOTE 14OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

 

Streamex Corp.

 

2023 Long-Term Incentive Plan

 

Stockholders approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September 5, 2025, increasing the total number of shares authorized for issuance under the plan by 10,359,211 shares, from 4,376,595 shares to 14,735,806 shares.

 

Stockholders approved the Fourth Amendment to the Company’s 2023 Long-Term Incentive Plan on December 30, 2025, increasing the total number of shares authorized for issuance under the plan by 22,494,324 shares, from 14,735,806 shares to 37,230,130 shares.

 

As of March 31, 2026, there were 18,109,340 shares available under the 2023 Long-Term Incentive Plan.

 

Options

 

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

 

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

 

The following table presents information related to stock options as of March 31, 2026:

 

Options Outstanding   Options Exercisable 
Exercise  Number of   Weighted Average Remaining Life  

Exercisable

Number of

 
Price  Options   In Years   Options 
$ Under 9.99   2,900,000    8.6    2,900,000 
$ 10.00-19.99   15,000    7.1    15,000 
$ 20.00-49.99   3,000    3.0    3,000 
$ 50.00-69.99   3,000    3.8    3,000 
    2,921,000    8.6    2,921,000 

 

27

 

 

A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows:

 

   Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term   Aggregate Intrinsic Value 
Outstanding at January 1, 2026   2,736,000   $0.78    8.7   $6,744,540 
Issued   250,000   $3.21    9.8      
Forfeited/expired   (65,000)  $5.01           
Outstanding at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 
Exercisable at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 

 

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $1.13 as of March 31, 2026, which would have been received by the option holders had those option holders exercised their options as of that date.

 

During the three months ended March 31, 2026, the Company granted an aggregate of 250,000 options to purchase the Company’s common stock at a weighted average exercise price of $3.21 per share for a term of ten years. The options vested immediately upon grant and the full grant-date fair value of approximately $770 was recognized as stock-based compensation expense during the three months ended March 31, 2026.

 

Stock based compensation expense related to stock options recognized during the three months ended March 31, 2026 and 2025, was $770 and $40, respectively, which is presented within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations. As of March 31, 2026, there was no unrecognized compensation expense related to stock options.

 

On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with the Company’s former Chief Executive Officer and Chairman of the Board. Pursuant to the amendment, all previously granted equity awards to the former Chief Executive Officer and Chairman of the Board including vested and unvested stock options were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing.

 

During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026:

 

Assumption  Value 
Weighted average grant date fair value  $3.08 
Expected volatility   124.17%
Risk-free interest rate   4.15%
Expected dividend yield   0.00%
Expected Term (in years)   5.0 

 

28

 

 

Warrants

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026:

 

Exercise Price     Number of Warrants     Expiration Date
$ 0.3000       11,982     Nov-28
  0.9547       577,916     Sep-28
  3.3640       117,828     Jul-29
  4.0660       25,000     Nov-32
  4.4550       107,483     Jun-28
  4.4660       5,580     Apr-29
  4.6626       49,550     Mar-29
  4.9252       71,593     Mar-29
  4.9290       99,243     Jul-28
  5.1358       83,270     Jul-28
  7.1810       9,846     Jul-28
  7.5020       21,369     Aug-28
  7.9630       21,709     Jun-27
  9.0000       84,390     Jan-29
  9.5960       19,118     Aug-28
  10.0992       51,705     Sep-28
  10.2600       84,296     Sep-28
  10.4678       40,417     Oct-28
  11.3000       96,198     Nov-28
  13.2800       12,500     Jul-26
  48.0000       56,892     Nov-27
  61.6000       11,982     Nov-28
          1,647,885      

 

During the three months ended March 31, 2026, the Company issued 54,647 shares of its common stock upon cashless exercise of 87,984 warrants to purchase shares of common stock, pursuant to the formula set forth in such warrants.

 

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

   Shares  

Weighted-Average

Exercise Price

  

Weighted-Average

Remaining

Contractual Term

  

Aggregate

Intrinsic Value

 
Outstanding at January 1, 2026   1,735,869   $6.94    2.8   $1,414,626 
Issued   -    -    -      
Forfeited/expired   -    -    -    - 
Exercised   (87,984)   0.95    -    - 
Outstanding at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
                     
Vested and expected to vest at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
Exercisable at March 31, 2026   1,647,885   $7.26    2.6   $111,231 

 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $1.13 as of March 31, 2026, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

 

Restricted Stock Units

 

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

   Number of Shares   Weighted-Average Grant Date Fair Value Per Share 
Restricted shares issued as of January 1, 2026   2,037,500   $5.36 
Granted   8,868,316   $2.91 
Vested and issued   (6,123,941)  $3.01 
Forfeited   (198,500)  $3.21 
Total   4,583,375   $3.86 
Comprised of:          
Vested restricted shares as of March 31, 2026   301,500   $3.21 
Unvested restricted shares as of March 31, 2026   4,281,875   $3.90 

 

29

 

 

Stock based compensation expense related to RSU grants was $24,545 and $2,236 for the three months ended March 31, 2026 and 2025, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, total unrecognized stock-based compensation cost related to unvested RSUs was approximately $24,545, which is expected to be recognized over a weighted-average period of approximately 1.33 years.

 

The following table summarizes the terms of individual RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date:

 

Grant Date  Recipient  RSUs Granted   Vesting Terms  GDFV1 
1/1/2026  Third-party consultant   250,000   25,000 immediately; remainder quarterly  $758 
1/8/2026  Interim Executive Chairman   100,000   4 equal quarterly installments over 1 year  $321 
1/8/2026  Chief Executive Officer   1,000,000   100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years  $3,210 
1/27/2026  Third-party consultant   125,000   16 quarterly installments over 4 years  $456 
2/1/2026  Third-party consultant   500,000   300,000 immediately; 200,000 in 4 quarterly installments over 12 months  $1,790 
3/3/2026  Third-party consultant   425,000   212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026  $876 
3/16/2026  Third-party consultant   65,000   5,000 immediately; remainder monthly  $119 
3/16/2026  Chief Financial Officer   500,000   16 quarterly installments over 4 years  $915 
       2,965,000      $8,445 

 

(1)Grant-date fair value (“GDFV”)

 

The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of 5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were 8,868,316, as reflected in the RSU activity table above.

 

Performance-Based Restricted Stock Units

 

During the three months ended March 31, 2026, the Company granted performance-vesting restricted stock units (“PSUs”) to certain consultants. The PSUs represent the right to receive shares of the Company’s common stock upon the achievement of specified performance conditions or market conditions, and satisfaction of service requirements, subject to certification by the Company’s Board of Directors or its Compensation Committee (the “Committee”). The PSUs are equity-classified awards and settle solely in shares of the Company’s common stock. No cash settlement alternative exists.

 

Stock Price-Based PSUs

 

On February 1, 2026, the Company granted 500,000 PSUs to a third-party consultant, under a consulting agreement effective February 1, 2026. The PSUs vest in five tranches upon the achievement of specified stock price milestones, measured by the closing price of the Company’s common stock on a U.S. national securities exchange, as follows: 100,000 shares at $5.00; 100,000 shares at $6.00; 100,000 shares at $8.00; 100,000 shares at $10.00; and 100,000 shares at $12.00. Each milestone is certified by the Committee in good faith, and the consultant must be providing continuous service through the certification date. All unvested PSUs are forfeited immediately upon cessation of service. The stock price milestones and shares issuable per tranche are subject to equitable adjustment for stock splits, reverse stock splits, and similar events under the Company’s 2023 Long-Term Incentive Plan.

 

30

 

 

The stock price targets represent market conditions because they relate to the achievement of specified stock prices of the Company’s equity instruments. In accordance with ASC 718, the effect of the market conditions is reflected in the estimate of the grant-date fair value of the awards. The Company estimated the grant-date fair value of each tranche using a Monte Carlo simulation model, which incorporated the following significant assumptions:

 

Assumption  Value 
Grant-date stock price  $3.58 
Stock price milestones   $5.00 – $12.00 
Expected volatility   152.9% 
Risk-free interest rate   3.72% 
Expected dividend yield   0.00% 
Derived service periods (range)   3.437.41 years 

 

The following table summarizes the grant-date fair value by tranche (in thousands, except per unit data and units):

 

Tranche  Milestone   GDFV1/Unit   Units   Agg FV2   DSP3 (yrs)   Q1 2026 Expense 
1  $5.00   $3.56    100,000   $356    3.43   $17 
2  $6.00   $3.55    100,000   $355    4.58   $12 
3  $8.00   $3.57    100,000   $357    5.99   $9 
4  $10.00   $3.56    100,000   $356    6.84   $8 
5  $12.00   $3.54    100,000   $354    7.41   $8 
              500,000   $1,778        $54 

 

(1)GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $3.56.
(2)Aggregate fair value (“Agg FV”)
(3)Derived service period (“DSP”)

 

The aggregate grant-date fair value of the 500,000 stock price-based PSUs was approximately $1,778. In accordance with ASC 718-10-25-8, compensation cost is recognized on a straight-line basis over the derived service period for each tranche, regardless of whether the stock price milestones are ultimately achieved. Previously recognized compensation cost is not reversed if a market condition is not satisfied, provided that all necessary service has been rendered.

 

During the three months ended March 31, 2026, the Company recognized stock-based compensation expense of approximately $54 related to the stock price-based PSUs, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, unrecognized compensation cost related to the stock price-based PSUs was approximately $1,724, however, following the consultant’s resignation in April 2026, the remaining unrecognized compensation cost associated with the unvested stock price-based PSUs will not be recognized in future periods because the requisite service condition will no longer be satisfied.

 

The consultant is also entitled to 500,000 time-based RSUs (300,000 vesting on the effective date and 200,000 vesting quarterly over 12 months), which are separately disclosed in the RSU section above.

 

31

 

 

AUM-Based PSUs

 

On March 16, 2026, the Company granted up to 1,000,000 PSUs to a third-party consultant, vesting upon the achievement of assets under management (“AUM”) milestones related to the Company’s rare earth elements (“REE”) Fund (a planned commodity-linked investment product): (i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000). The number of shares issuable under each tranche is the lesser of the fixed share amount or the dollar cap divided by the fair value per share at each vesting date. Although the number of shares is variable, the dollar caps function as a ceiling on value deliverable to the consultant and do not require delivery of a fixed monetary amount; the consultant bears downside stock price risk. The Company evaluated the award under ASC 480 and ASC 815 and concluded it does not meet the criteria for liability classification or derivative accounting. The award is equity-classified and indexed to the Company’s own stock.

 

These PSUs contain performance conditions under ASC 718. The grant-date fair value per unit was determined based on the closing price of the Company’s common stock of $1.83 on the grant date of March 16, 2026. At the grant-date stock price of $1.83, none of the dollar caps were binding (the lowest implied cap price is $3.00 for Tranche 1), and accordingly the grant-date fair value per unit equals $1.83 for all tranches. The aggregate grant-date fair value of the AUM-based PSUs is approximately $1,830 (based on the grant-date stock price of $1.83 applied to 1,000,000 units at the maximum fixed share amounts), subject to a maximum aggregate dollar cap of $3,500 (consisting of $150 for the first tranche, $350 for the second tranche, and $3,000 for the third tranche). The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period.

 

Summary of PSU Awards

 

As of March 31, 2026, total stock-based compensation expense recognized for PSU awards during the three months ended March 31, 2026 was approximately $54, consisting entirely of expense related to the stock price-based PSUs. For the AUM-based PSUs, management assessed the probability of achieving each performance condition on a tranche-by-tranche basis and concluded that no condition met the “probable” threshold under ASC 718; accordingly, no expense was recognized.

 

Total unrecognized compensation cost related to outstanding PSUs was approximately $1,724 as of March 31, 2026, consisting of $1,724 related to stock price-based PSUs (to be recognized over a weighted-average period of approximately 5.5 years) and $0 related to AUM-based PSUs (to be recognized when achievement becomes probable, with an aggregate grant-date fair value of approximately $1,830, subject to a maximum dollar cap of $3,500).

 

The Company accounts for forfeitures as they occur. No forfeitures of PSUs were recognized during the three months ended March 31, 2026.

 

The following table summarizes PSU activity for the three months ended March 31, 2026:

 

   PSUs – Stock Price   PSUs - AUM   Total PSUs 
Nonvested as of December 31, 2025   -    -    - 
Granted   500,000    1,000,000    1,500,000 
Vested and issued   -    -    - 
Forfeited   -    -    - 
Nonvested as of March 31, 2026   500,000    1,000,000    1,500,000 

 

32

 

 

The table above excludes (i) performance-based restricted stock units tied to Organic Gross Revenue Growth targets, under which certain consultants may earn additional units annually based on achievement of annual revenue growth targets established and certified by the Compensation Committee, as the number of units issuable is not determinable until the applicable targets are set, and (ii) PSU grants to four third-party consultants, involving an aggregate of up to approximately 910,000 units tied to cumulative gross revenue and token-related performance milestones, that have not been approved by the Board of Directors or the Compensation Committee as of March 31, 2026 and are therefore not considered granted under ASC 718.

 

ViralClear Pharmaceuticals, Inc.

 

2019 Long-Term Incentive Plan

 

There are 2,915,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.

 

Warrants (ViralClear)

 

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

           Weighted-Average 
           Remaining 
       Weighted-Average   Contractual 
   Shares   Exercise Price   Term 
Outstanding at January 1, 2026   473,772   $5.00    1.9 
Forfeited/expired   -    -    - 
Outstanding at March 31, 2026   473,772   $5.00    1.6 
Exercisable at March 31, 2026   473,772   $5.00    1.6 

 

The following table presents information related to warrants (ViralClear) at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$5.00    473,772    November 2027 

 

Restricted stock units (ViralClear)

 

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

 

Restricted shares outstanding at January 1, 2026:   678,679 
Forfeited   - 
Total restricted shares outstanding at March 31, 2026:   678,679 
      
Comprised of:     
Vested restricted shares as of March 31, 2026   678,679 
Unvested restricted shares as of March 31, 2026   - 
Total   678,679 

 

BioSig AI Sciences, Inc.

 

Warrants (BioSig AI)

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$1.00    130,500    June-July 2028 

 

33

 

 

NOTE 15 – NON-CONTROLLING INTEREST

 

As of March 31, 2026 and December 31, 2025, the Company had a majority interest in ViralClear of approximately 70% for both periods. As of March 31, 2026, and December 31, 2025, the Company had a majority interest in BioSig AI of approximately 84% for both periods. As of March 31, 2026, the Company consolidated Streamex Ltd. as a variable interest entity, with noncontrolling interest holders (consisting of two related party officers) holding approximately 1.5% of the outstanding GLDY Tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

 

A reconciliation of ViralClear Pharmaceuticals, Inc., BioSig AI Sciences, Inc. and Streamex Ltd. non-controlling loss attributable to the Company:

 

Net loss attributable to the non-controlling interest for the three months ended March 31, 2026:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Net Income (loss)  $-*   $-   $(155)  $(155)
Noncontrolling interest’s weighted-average ownership percentage   30.0%   16.0%   0.2%   0.01%
Net income (loss) attributable to non-controlling interest  $-*   $-   $(1)  $(1)

 

Net loss attributable to the non-controlling interest for the three months ended March 31, 2025:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Net loss  $-*    $75   $-   $75 
Noncontrolling interest’s weighted-average ownership percentage   32%   16%   -%   16%
Net loss attributable to non-controlling interest  $-   $12   $-   $12 

 

  * Less than $0.5 thousand

 

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Balance, January 1, 2026  $(171)  $203   $-   $32 
Issuance of equity to noncontrolling interest holders   -    -    225    225 
Net income (loss) attributable to non-controlling interest   -    -    (1)   (1)
Balance, March 31, 2026  $(171)  $203   $224   $256 

 

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Balance, January 1, 2025  $(171)  $188   $-   $17 
Net income (loss) attributable to non-controlling interest   -    12    -    12 
Balance, March 31, 2025  $(171)  $200   $-   $29 

 

34

 

 

NOTE 16 — COMMITMENTS AND CONTINGENCIES

 

Tokenized Yield Partnership Agreement

 

Overview

 

On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation, establishing an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms.

 

For additional information regarding the gold assets held by Streamex Ltd. and the related VIE disclosures, see Notes 8 and 9.

 

Exclusivity and Performance Conditions

 

For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation.

 

Consulting Services Agreement

 

On February 4, 2026, the Company entered into a consulting agreement with an independent third party to provide advisory and capital markets related services in connection with the Company’s GLDY Token program. The agreement has an initial term of six months and provides for a fixed consulting fee of $4,000, as well as potential transaction-based fees contingent upon the completion of certain activities during the term. The full $4,000 base fee was paid during the three months ended March 31, 2026. As of March 31, 2026, the unamortized portion of $2,785 is included in prepaid expenses and other assets on the unaudited condensed consolidated balance sheet and is being recognized ratably over the service period. No transaction-based fees were earned or payable during the period.

 

Litigation

 

We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of our business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

 

In November 2025, a former advisor filed a Notice of Civil Claim in the Supreme Court of British Columbia against the Company, its wholly owned subsidiary Streamex Exchange Corporation, and certain current officers and directors. The claim alleges, among other things, breach of contract, unjust enrichment, and civil conspiracy in connection with alleged agreements relating to equity interests in Streamex Exchange Corporation prior to the Company’s acquisition of that entity. The plaintiff seeks, among other relief, specific performance, equitable compensation, and damages.

 

The Company disputes the claims and intends to defend the matter vigorously. As of March 31, 2026, no liability has been recorded in the unaudited condensed consolidated financial statements related to this matter, as management, after consultation with legal counsel, believes that a loss is not probable. The matter is in a preliminary stage and, as a result, the Company is unable to reasonably estimate the possible loss or range of loss, if any, associated with this matter at this time.

 

35

 

 

NOTE 17 – SEGMENT REPORTING

 

Chief Operating Decision Maker (CODM) and Segment Evaluation

 

On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and a member of the Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director.

 

Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of March 31, 2026, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information.

 

Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of March 31, 2026. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level.

 

In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure.

 

Basis of Segmentation

 

The Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business, and the CODM does not receive or review separate financial information for Streamex Exchange or any other business unit. This approach reflects the manner in which the CODM:

 

  Assesses performance against budgeted targets;
  Forecasts future financial results;
  Makes strategic and operational decisions;
  Allocates resources across the organization.

 

Accordingly, the Company has determined that it operates as one reportable and operating segment as of March 31, 2026.

 

Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results.

 

Segment Performance Measures

 

The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives.

 

Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets.

 

The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve.

 

36

 

 

Revenue and Expense Information

 

Information concerning the operations of the Company’s reportable segments is as follows:

 

   2026   2025 
   For the Three Months Ended March 31, 
   2026   2025 
           
Revenues  $-   $- 
Less Segment expenses:          
Research and development   -    6 
General and administrative   8,884    883 
General and administrative - stock-based compensation expenses   25,370    2,074 
Depreciation and amortization   1,492    21 
Total operating and segment expense   (35,746)   (2,984)
Plus:          
Interest expense, net   (12,195)   - 
Realized gain on sale of gold   2,938    - 
Realized gain on marketable securities   484    - 
Change in fair value of marketable securities   (134)   - 
Change in fair value of embedded derivative   497    - 
Realized loss on extinguishment of convertible debenture   (3,057)   - 
Realized loss on investment   (119)   - 
Gain on settlement and forgiveness of debt   -    199 
Other income (expense), net   73    (15)
Total other income (expense)   (11,513)   184 
Income taxes (benefit)   (565)   - 
Segment Net Loss  $(46,694)  $(2,800)
Non-controlling interest   1    (12)
Net loss attributable to Streamex Corp.  $(46,693)  $(2,812)

 

NOTE 18RELATED PARTY TRANSACTIONS

 

Accounts payable and accrued expenses as of March 31, 2026 include $907 due to related parties, compared to $66 as of December 31, 2025. These amounts primarily relate to executives and board compensation, severance, and reimbursements.

 

During the three months ended March 31, 2026, two officers of the Company subscribed for GLDY Tokens issued by Streamex Ltd. (the Company’s consolidated VIE): (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens. Both subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions pursuant to the GLDY Subscription Agreement. As of March 31, 2026, the officers’ combined GLDY Token holdings represented approximately 1.5% of total outstanding tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

 

37

 

 

NOTE 19SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes below, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures.

 

GLDY Dividend

 

On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material.

 

Appointment of Director and Equity Awards

 

On April 28, 2026, the Board appointed the Company’s Chief Investment Officer (“CIO”), to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal.

 

In connection with the CIO’s amended employment agreement effective April 6, 2026, the Board granted the CIO 1,250,000 RSUs and a special incentive award of 1,000,000 RSUs. Both awards vest in sixteen equal quarterly installments commencing July 1, 2026, subject to continued service, and become fully vested upon a protected termination, a change in control, or the termination.

 

Amended Employment Agreements and Equity Awards

 

On May 1, 2026, the Company entered into amended and restated employment agreements with the Company’s Chief Executive Officer (“CEO”) and the Company’s Interim Executive Chairman (“Interim Chairman”).

 

In connection with the amended agreements, the Board granted each of the CEO and Interim Chairman 1,500,000 PSUs for shares of the Company’s common stock, divided into five equal tranches of 300,000 shares each. Each tranche vests upon the Company’s cumulative sales of GLDY reaching the following milestones: (i) $250,000,000; (ii) $500,000,000; (iii) $1,000,000,000; (iv) $2,000,000,000; and (v) $3,000,000,000. Cumulative GLDY sales are measured in good faith by the Company and certified by the Compensation Committee. Vesting is subject to continued employment, except that the awards become fully vested upon a protected termination or a change in control. Any tranche that has not vested on or before the tenth anniversary of the effective date shall be forfeited.

 

Equity Transactions

 

Between April 1, 2026 and May 14, 2026, an aggregate of 5,890,148 Exchangeable Shares were converted into the same number of common stock by holders of the Exchangeable Shares.

 

Between April 1, 2026 and May 14, 2026, the Company issued 1,157,973 shares of common stock for vested restricted stock units, of which 723,611 shares were issued to related parties, including certain executive officers and directors of the Company.

 

On April 10, 2026, the Company entered into an Advisory & Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 100,000 shares of the Company’s common stock, with 50,000 RSUs vesting and issued on the effective date and the remaining 50,000 RSUs vesting in two installments on the six-month and twelve-month anniversaries of the vesting commencement date, subject to continued service.

 

On April 6, 2026, the Company entered into a Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 155,000 shares of the Company’s common stock that were vested and issued on April 29, 2026.

 

In May 2026, the Company rescinded a previously approved equity compensation arrangement with the Company’s General Counsel covering 700,000 shares of common stock. As part of this rescission, the shares were cancelled and the arrangement was terminated with no further equity compensation obligations.

 

38

 

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Managements Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Managements current views with respect to future events and financial performance. You can identify these statements by forward-looking words such asmay,” “will,” “expect,” “anticipate,” “believe,” “estimateandcontinue,or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

 

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing for materials, and competition.

 

Business Overview

 

On May 28, 2025, the Company completed its acquisition of Streamex Exchange Corporation (“Streamex Exchange”). The unaudited condensed consolidated financial statements for the three months ended March 31, 2026 include the results of the Company and its consolidated subsidiaries, including Streamex Exchange, from the acquisition date, and VIE for which the Company is determined to be the primary beneficiary.

 

As a result of this acquisition, the Company expanded beyond its historical focus as a medical device technology company to a diversified technology platform centered on tokenized finance and the digitization of real-world assets (“RWAs”). Through Streamex Exchange, the Company has developed and operates an institutional grade technology platform that supports the tokenization of real-world assets, including gold, and other physical commodity asset interests. The Company operates as an infrastructure provider, enabling the issuance, trading, and backend infrastructure for digital tokens backed by tangible commodities, beginning with gold. The Company continues to operate its legacy medical device technology business, which focuses on healthcare technology innovation through the Company’s PURE EP™ Platform (“PURE EP™”).

 

The Company continues to evaluate strategic alternatives for its legacy majority-owned subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). ViralClear’s business is currently dormant and ViralClear’s business objectives are being evaluated. BioSig AI’s business operations have currently been placed on hold.

 

Historically, the Company developed and commercialized advanced digital signal processing solutions for electrophysiology. PURE EP™ is designed to deliver real-time, high-fidelity cardiac signal data to electrophysiologists during ablation procedures for the treatment of cardiovascular arrhythmias. In recent periods, the Company has shifted its biomedical strategy toward research and development of proprietary software algorithms intended to enhance clinical decision-making and procedural outcomes.

 

Streamex Exchange has developed and operates a blockchain-based platform designed to facilitate the compliant tokenization and exchange of RWAs. As of March 31, 2026, Streamex Exchange remained in the development stage and had not generated revenue. The Company launched GLDY and began actively accepting subscriptions during Q1 2026. Future revenue generation will depend on platform maturity, regulatory developments, market conditions, adoption and issuance volumes, and the Company’s ability to monetize GLDY and additional tokenized products through fee-based services.

 

During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately 98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $225 of GLDY Tokens during March 2026.

 

For the three months ended March 31, 2026, the Company operated as a single reportable segment.

 

Results of Operations (000s)

 

We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development and commercialization efforts, the timing and outcome of future regulatory submissions, and other macroeconomic and operational uncertainties. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.

 

39

 

 

Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025

 

Revenues and Cost of Goods Sold. Revenue for the three months ended March 31, 2026 and 2025 was $0 and $0, respectively, and comprised of recognized service revenue. Historically, the Company’s revenue has been generated from sales of the PURE EP™ Platform and related support services; however, commercial activity was not significant during the year ended December 31, 2024 and did not recur in subsequent periods.

 

Research and Development Expenses. Research and development expenses for the three months ended March 31, 2026 were $0, a decrease of $6, or 100%, from $6 for the three months ended March 31, 2025. The decrease primarily reflects reduced research and development activity associated with the Company’s legacy medical device business as the Company has prioritized resources toward its tokenized finance platform.

 

General and Administrative Expenses. General and administrative expenses for the three months ended March 31, 2026 were $34,254, an increase of $31,297 or 1059%, from $2,957 incurred in the three months ended March 31, 2025. Stock-based compensation and common stock issued for services totaled $25,370 in the current period, representing approximately 74% of total general and administrative expenses, compared to $2,074 in the prior period, reflecting equity awards issued under consulting, advisory, and service arrangements. Additional increases were driven by higher professional fees, payroll, and compliance-related costs associated with expanded corporate activities during the current period.

 

Depreciation and Amortization Expense. Depreciation and amortization expense for the three months ended March 31, 2026 totaled $1,492, an increase of $1,471, or 7005%, over the expense of $21 incurred in the three months ended March 31, 2025, as a direct result of the amortization of the intangible assets recognized from the acquisition of Streamex Exchange. The Company’s intangible assets primarily consist of trade name, developed technology, legal and compliance framework, and patents.

 

Other Income (Expense), net. Other income (expense), net for the three months ended March 31, 2026 totaled $(11,513), compared to other income of $184 for the three months ended March 31, 2025. The change of $(11,697) was driven primarily by the following items, none of which existed in the prior-year period due to the May 2025 acquisition of Streamex Exchange and the November/December 2025 convertible debenture financing:

 

Interest expense, net, of $(12,195) consisted primarily of non-cash accretion of the debt discount and issuance costs associated with the Company’s Yorkville secured convertible debentures, which were outstanding from January 1, 2026 through their settlement on February 6, 2026.

 

The Company recognized a realized loss on extinguishment of convertible debentures of $(3,057) in connection with the February 2026 settlement, which included a cash payoff of $38,903 (comprised of $35,000 principal, $3,500 prepayment premium, and approximately $403 of accrued interest) and a conversion of $15,000 of principal into 3,750,000 shares. The loss represents the difference between the carrying amount of the debentures (net of unamortized discount) and the total consideration transferred.

 

These charges were partially offset by a realized gain on sale of gold of $2,938 from the Company’s Streamex Ltd. (VIE) gold inventory transactions, a gain of $497 from the change in fair value of the embedded derivative liability prior to its derecognition upon the February 2026 debenture settlement, and a realized gain on marketable securities of $484. The Company also recognized a realized loss on investment of $(119) and a change in fair value of marketable securities of $(134).

In the prior-year period, other income of $184 consisted primarily of a gain on settlement and forgiveness of accounts payable and other liabilities of $199.

 

Income taxes (benefit). For the three months ended March 31, 2026, the Company recorded an income tax benefit of $565, compared to $0 in the prior-year period. The benefit resulted from the reversal of a portion of the deferred tax liability associated with the amortization of identifiable intangible assets recognized in the Company’s acquisition of Streamex Exchange Corporation, which is held through the Company’s Canadian subsidiary. Intangible amortization for book purposes creates a temporary difference because such amortization is not deductible for Canadian income tax purposes, resulting in a deferred tax liability that reverses as the book basis of the intangible assets declines. The deferred tax liability was initially recognized as part of the acquisition accounting in May 2025 and is remeasured each period for changes in enacted tax rates and foreign currency translation. No comparable benefit was recorded in the prior-year period as the acquisition had not yet occurred.

 

Preferred Stock Dividend. Preferred stock dividend for the three months ended March 31, 2026 and 2025 totaled $2 and $2, respectively. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015.

 

Net Loss Attributable to Streamex Corp. Common Stockholders. As a result of the foregoing, net loss attributable to common shareholders for the three months ended March 31, 2026 was $46,695 compared to a net loss of $2,814 for the three months ended March 31, 2025. The increase in net loss of $43,881 was primarily attributable to the changes in operating expenses, other income (expense), and income tax benefit described above.

 

40

 

 

Liquidity and Capital Resources and Going Concern

 

As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026.

 

During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.2 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released.

 

We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.

 

Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

 

Capital Strategy and Uses of Cash

 

Our capital strategy focuses on maintaining sufficient liquidity to support ongoing operations, product development, and strategic initiatives, while preserving balance sheet flexibility. We may evaluate additional capital sources from time to time, including:

 

  Public or private equity offerings
  Strategic partnerships or licensing arrangements
  Government grants or non-dilutive funding
  Debt financing, where feasible

 

While we previously implemented cost-saving measures to reduce cash burn, we have increased spending to accelerate the commercialization of the Streamex Exchange platform and related initiatives. These efforts are intended to support long-term growth but will increase near-term cash requirements. There can be no assurance that any future financing, if pursued, would be available on acceptable terms.

 

Future financing may include the issuance of equity or debt securities, credit facilities, or other arrangements. Any such financing could result in dilution to existing stockholders or the issuance of securities with rights senior to those of our common stock. Market volatility and macroeconomic conditions may also adversely affect our ability to raise capital on acceptable terms. These financing arrangements are part of management’s broader strategy to address liquidity needs and support commercialization, research and development, and infrastructure expansion. However, there can be no assurance that financing will be available on acceptable terms, or at all.

 

If additional capital were required and not obtained on acceptable terms, we may be required to delay or reduce certain research and development programs, scale back commercialization efforts, or enter into strategic arrangements that could require us to relinquish rights to certain technologies or products.

 

Our liquidity forecast includes assumptions regarding the timing of Streamex Exchange’s development and commercialization activities, planned expenditures, and cost containment measures.

 

41

 

 

Financing Activities

 

Conversion and Repayment of Convertible debentures

 

On February 6, 2026, Yorkville elected to convert $15,000 of principal into shares of the Company’s common stock at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares. No accrued interest was converted.

 

Following the expiration of the conversion election period, the Company prepaid the remaining amounts outstanding under the Convertible Debentures for an aggregate cash payoff of approximately $38,903, consisting of $35,000 of principal, $3,500 of prepayment premium, and approximately $403 of accrued interest. Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.

 

Sale of Common Stock.

 

On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued 11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional 1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $40,250, before underwriting discounts, commissions, and offering expenses.

 

Future Capital Requirements and Risks

 

We expect to continue incurring expenses related to:

 

  Expansion of business infrastructure and public company compliance
  Integration and scaling of Streamex Exchange’s tokenization platform and digital asset infrastructure
  Development of real-world asset (RWA) tokenization solutions, including commodities-on-chain initiatives

 

Our future capital requirements will depend on several factors, including:

 

  Progress and results of our R&D programs
  Timing and outcome of regulatory approvals
  Costs associated with intellectual property protection
  Market acceptance and commercialization success
  Availability of financing and strategic partnerships
  Execution of Streamex Exchange’s growth strategy within the global commodities and digital asset markets
  Infrastructure and personnel investments required to support Streamex Exchange’s platform scalability and compliance

 

Critical Accounting Estimates

 

We prepare our unaudited condensed consolidated financial statements in accordance with GAAP, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. These estimates are based on historical experience, current conditions, and other factors that management believes to be reasonable under the circumstances. Actual results may differ materially from these estimates, and such differences could have a significant impact on our financial condition or results of operations.

 

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our unaudited condensed consolidated financial statements that require estimation but are not deemed critical, as defined above.

 

Our significant accounting policies are more fully described in Note 3—Summary of Significant Accounting Policies to our unaudited condensed consolidated financial statements included in this report.

 

42

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required under Regulation S-K for “smaller reporting companies.”

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2026. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective due to the material weaknesses in our internal control over financial reporting described below and previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Material Weaknesses in Internal Control Over Financial Reporting

 

As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, management identified the following material weaknesses in the Company’s internal control over financial reporting as of December 31, 2025:

 

(i)inadequate identification, recording, and reporting of stock-based compensation;
(ii)ineffective review processes over period-end financial disclosure and reporting, including review of information produced by the entity (“IPE”);
(iii)inadequate segregation of duties for transaction posting and processing; and
(iv)ineffective review controls over business combinations and related financial instruments.

 

The material weaknesses did not result in any identified misstatements to the unaudited condensed consolidated financial statements and there were no changes to previously released financial results. These material weaknesses had not been remediated as of March 31, 2026, and accordingly, management concluded that our disclosure controls and procedures were not effective as of March 31, 2026.

 

Remediation Plan

 

Management has initiated and continues to execute remediation plans to address the material weaknesses described above. During the three months ended March 31, 2026, management undertook the following remediation actions:

 

Appointed a new Chief Financial Officer, effective March 16, 2026, to strengthen financial leadership and oversight of the accounting and reporting function;
Engaged external technical accounting and financial reporting advisors to assist with complex accounting matters, including stock-based compensation, business combination accounting, and derivative financial instruments;
Began enhancing supervisory review controls over period-end financial disclosures and reporting processes; and
Commenced evaluation of additional staffing and process improvements to strengthen segregation of duties within the finance and accounting function.

 

Management believes these actions, once fully implemented and operating effectively for a sufficient period of time, will remediate the underlying control deficiencies. The material weaknesses will not be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. There can be no assurance that our remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

 

Changes in Internal Control Over Financial Reporting

 

Except for the remediation actions described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

43

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

 

“Item 1 - Legal Proceedings” During the fiscal quarter ended March 31, 2026, there have been no material changes from the legal proceedings discussed in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

ITEM 1A. RISK FACTORS

 

In addition to other information contained elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K filed with the SEC on March 31, 2026, or the Annual Report, which could materially affect our business, financial condition, or future results. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

 

During the three months ended March 31, 2026, the Company issued the following shares of its common stock in transactions not registered under the Securities Act of 1933, as amended (the “Securities Act”):

 

  January 2, 2026: Issued 16,015 shares of common stock upon cashless exercise of warrants to purchase 23,154 shares at a weighted average exercise price of $0.9547 per share.
     
  February 26, 2026: Issued 38,632 shares of common stock upon cashless exercise of warrants to purchase 64,830 shares at a weighted average exercise price of $0.9547 per share.

 

All of the above issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D, as applicable. These transactions did not involve any public offering, and the recipients represented their intent to acquire the securities for investment purposes only and not with a view to distribution.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION

 

None.

 

44

 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
1.1   Underwriting Agreement, dated as of January 22, 2026, by and among the Company, and Needham & Company (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on January 27, 2026).
10.1   Offer Letter, dated February 3, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 9, 2026).
10.2   Offer Letter, dated March 3, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 6, 2026).
10.3   Separation and General Release Agreement, dated March 20, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 20, 2026).
10.4   Consulting Agreement, dated as of March 20, 2026, by and between the Company and Groenewald Enterprises LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 20, 2026).
10.5   Employment Agreement, dated March 16, 2026, by and between the Company and Christine Plummer (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March 20, 2026).
10.6   Form of Lock-Up Agreement, dated March 26, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 27, 2026).
31.1*   Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101 INS*   Inline XBRL Instance Document
101 SCH*   Inline XBRL Taxonomy Extension Schema Document
101 CAL*   Inline XBRL Taxonomy Calculation Linkbase Document
101 LAB*   Inline XBRL Taxonomy Labels Linkbase Document
101 PRE*   Inline XBRL Taxonomy Presentation Linkbase Document
101 DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

* Filed herewith.

 

** Furnished herewith.

 

45

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  STREAMEX CORP.
     
Date: May 14, 2026 By: /s/ Henry McPhie
    Henry McPhie
    Chief Executive Officer (Principal Executive Officer)
     
Date: May 14, 2026 By: /s/ Christine Plummer
    Christine Plummer
    Chief Financial Officer (Principal Financial and Accounting Officer)

 

46

 

EX-31.1 2 ex31-1.htm EX-31.1

 

EXHIBIT 31.1

 

CERTIFICATION

 

I, Henry McPhie, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Streamex Corp.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: May 14, 2026

 

/s/ Henry McPhie  
Henry McPhie  
Chief Executive Officer (Principal Executive Officer)  

 

 

 

EX-31.2 3 ex31-2.htm EX-31.2

 

EXHIBIT 31.2

 

CERTIFICATION

 

I, Christine Plummer, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Streamex Corp.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: May 14, 2026

 

/s/ Christine Plummer  
Christine Plummer  
Chief Financial Officer (Principal Financial and Accounting Officer)  

 

 

 

EX-32.1 4 ex32-1.htm EX-32.1

 

EXHIBIT 32.1

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Henry McPhie, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Streamex Corp. on Form 10-Q for the fiscal quarter ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Streamex Corp.

 

  By: /s/ Henry McPhie
Date: May 14, 2026 Name: Henry McPhie
  Title: Chief Executive Officer (Principal Executive Officer)

 

I, Christine Plummer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Streamex Corp. on Form 10-Q for the fiscal quarter ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Streamex Corp.

 

  By: /s/ Christine Plummer
Date: May 14, 2026 Name: Christine Plummer
  Title: Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 

EX-101.SCH 5 stex-20260331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 999007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 999008 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 999010 - Disclosure - BUSINESS ACQUISITION link:presentationLink link:calculationLink link:definitionLink 999011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 999012 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 999013 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 999014 - Disclosure - GOLD ASSETS link:presentationLink link:calculationLink link:definitionLink 999015 - Disclosure - STREAMEX LTD. (VIE) link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - NON-CONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - BUSINESS ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - STREAMEX LTD. (VIE) (Tables) link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - NON-CONTROLLING INTEREST (Tables) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 999038 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999039 - Disclosure - LIQUIDITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999041 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 999042 - Disclosure - SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) link:presentationLink link:calculationLink link:definitionLink 999043 - Disclosure - BUSINESS ACQUISITION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999044 - Disclosure - SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 999045 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 999046 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 999047 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999048 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 999049 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999050 - Disclosure - MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999051 - Disclosure - GOLD ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999052 - Disclosure - SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 999053 - Disclosure - STREAMEX LTD. (VIE) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999054 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 999055 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 999056 - Disclosure - SCHEDULE OF SETTLEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 999057 - Disclosure - CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999058 - Disclosure - SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 999059 - Disclosure - SCHEDULE OF UNOBSERVABLE INPUT (Details) link:presentationLink link:calculationLink link:definitionLink 999060 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS (Details) link:presentationLink link:calculationLink link:definitionLink 999061 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 999062 - Disclosure - SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999064 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999065 - Disclosure - SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 999066 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999067 - Disclosure - SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION (Details) link:presentationLink link:calculationLink link:definitionLink 999068 - Disclosure - SCHEDULE OF INFORMATION RELATED TO WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 999069 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999071 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS GRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 999072 - Disclosure - SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 999073 - Disclosure - SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 999074 - Disclosure - SCHEDULE OF NON VESTED RESTRICTED ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999075 - Disclosure - SUMMARY OF WARRANT ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999076 - Disclosure - SCHEDULE OF RELATED TO WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 999077 - Disclosure - SCHEDULE OF OUTSTANDING TO WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 999078 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999079 - Disclosure - NON-CONTROLLING INTEREST (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999080 - Disclosure - SCHEDULE OF NON-CONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 999081 - Disclosure - SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 999082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999083 - Disclosure - SCHEDULE OF SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 999084 - Disclosure - SEGMENT REPORTING (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999085 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999086 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 stex-20260331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 stex-20260331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 stex-20260331_lab.xml XBRL LABEL FILE Related and Nonrelated Parties [Axis] Related Party [Member] Product and Service [Axis] Restricted Gold [Member] Gold [Member] Class of Stock [Axis] Series C 9% Convertible Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Investment, Name [Axis] Viral Clear [Member] BioSig AI Sciences, Inc. [Member] Business Combination [Axis] GLDY ServiceCo, LLC [Member] Geographical [Axis] UNITED STATES CANADA Consolidated Entities [Axis] Consolidated Entity, Excluding Consolidated VIE [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Performance Based Restricted Stock Unit [Member] Warrant [Member] Restricted Stock [Member] Streamex Exchange Corporation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Share Purchase Agreement [Member] Third party Consultants [Member] Intangible Asset, Finite-Lived, Class [Axis] Trade Names [Member] Technology-Based Intangible Assets [Member] Securitization Platform [Member] Blockchain Integration [Member] Legal and Compliance Frame Work [Member] Developed Technology Rights [Member] Patents [Member] Intangible Asset, Indefinite-Lived, Class [Axis] Legal Contact [Member] Compliance Framework [Member] Long-Lived Asset, Class [Axis] Computer Equipment [Member] Furniture and Fixtures [Member] Testing and Demo Equipment [Member] Leasehold Improvements [Member] Legal Entity [Axis] Empress Royalty Corp [Member] Restricted [Member] Unrestricted [Member] Statistical Measurement [Axis] Maximum [Member] Brinks Bailee Agreement [Member] Two Related Party [Member] Streamex Ltd [Member] Title and Position [Axis] Chief Invest Officer [Member] General Counsel Officers [Member] Premium Finance Agreement [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Minimum [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Fair Value, Nonrecurring [Member] Developed Technology [Member] Measurement Input Type [Axis] Measurement Input Common Stock Price [Member] Measurement Input Indicated Conversion Price [Member] Measurement Input Floor Price [Member] Measurement Input, Prepayment Rate [Member] Measurement Input Prepayment Premium [Member] Measurement Input Registration Probability [Member] Fair Value, Inputs, Level 1 [Member] Preferred Stock [Member] Convertible Preferred Stock [Member] Investor [Member] Sale of Stock [Axis] Over-Allotment Option [Member] Sales Agreement [Member] Award Type [Axis] Plan Name [Axis] 2023 Long-Term Incentive Plan [Member] Restricted Stock Units (RSUs) [Member] Third Party Consultant [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Common Stock Four [Member] Common Stock Five [Member] Performance Shares [Member] Share-Based Payment Arrangement, Tranche Three [Member] Share Based Compensation Award Tranche Four [Member] Share Based Compensation Award Tranche Five [Member] Restricted Stock One [Member] Restricted Stock Two [Member] Share Based Compensation Award Tranche [Member] Viral Clear Pharmaceuticals Inc [Member] Equity Option [Member] Exercise Price Range [Axis] Options Under 9.99 [Member] Options 10.00 To 19.99 [Member] Options 20.00 To 49.99 [Member] Options 50.00 To 69.99 [Member] Measurement Input, Share Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Expected Term [Member] Warrants At 0.3000 [Member] Warrants At 0.9547 [Member] Warrants At 1.7800 [Member] Warrants At 3.3640 [Member] Warrants At 4.0660 [Member] Warrants At 4.4550 [Member] Warrants At 44660 [Member] Warrants At 4.6626 [Member] Warrants At 4.9252 [Member] Warrants At 4.9290 [Member] Warrants At 5.1358 [Member] Warrants At 7.1810 [Member] Warrants At 7.5020 [Member] Warrants At 7.9630 [Member] Warrants At 9.0000 [Member] Warrants At 9.5960 [Member] Warrants At 10.0992 [Member] Warrants At 10.2600 [Member] Warrants At 10.4678 [Member] Warrants At 11.3000 [Member] Warrants At 13.2800 [Member] Warrants At 48.0000 [Member] Warrants At 61.6000 [Member] Award Date [Axis] One One Two Thousand Twenty Six [Member] One Eight Two Thousand Twenty Six [Member] Interim Executive Chairman [Member] Chief Executive Officier [Member] One Twenty Seven Two Thousand Twenty Six [Member] Two One Two Thousand Twenty Six [Member] Three Three Two Thousand Twenty Six [Member] Three Sixteen Two Thousand Twenty Six [Member] Chief Financial Officer [Member] Share-Based Payment Arrangement [Member] Performance shares And AUM [Member] Range One [Member] Bio Sig AI Sciences Inc [Member] Segments [Axis] Corporate Segment [Member] Board of Directors Chairman [Member] Chief Investment Officer [Member] Employment Agreement [Member] Performance Vesting Restricted Stock Units [Member] Third Party [Member] Six Month Anniversaries [Member] Twelve Month Anniversaries [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets: Cash Sales tax receivable Due from related party Marketable securities Other assets held for sale – gold Prepaid expenses and other assets Total current assets Non-current assets: Other assets held at cost – gold Property and equipment, net Intangible assets, net Goodwill Total non-current assets Total assets LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and accrued expenses, including $907 and $66 to related parties as of March 31, 2026, and December 31, 2025, respectively. Dividends payable Convertible debentures, net Embedded derivative liability Total current liabilities Deferred tax liability Total liabilities Commitments and contingencies (Note 16) Mezzanine equity Redeemable Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $105; cumulative dividends payable of $123 and $121 as of March 31, 2026, and December 31, 2025, respectively). Stockholders’ equity: Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. Common stock, $0.001 par value, authorized 500,000,000 shares, 97,721,696 and 49,805,275 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively. Additional paid-in-capital Accumulated other comprehensive (loss) income Accumulated deficit Total stockholders’ equity attributable to Streamex Corp. Non-controlling interest Total stockholders’ equity Total liabilities, mezzanine equity and stockholders’ equity Statement [Table] Statement [Line Items] Accounts payable and accrued expenses, related parties Temporary equity, par value Temporary equity, stated value Temporary equity, shares authorized Temporary equity, shares issued Temporary equity, shares outstanding Liquidation preference Cumulative dividends Preferred stock, par value Preferred stock, shares authorized Preferred stock, voting rights Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development General and administrative Depreciation and amortization Total operating expenses Loss from operations Other income (expense): Interest expense, net Realized gain on sale of gold Realized gain on marketable securities Change in fair value of marketable securities Change in fair value of embedded derivative Realized loss on extinguishment of convertible debentures Realized loss on investment Gain on settlement and forgiveness of debt Other income (expense), net Total other income (expense), net Loss before income taxes Income taxes (benefit) Net loss Non-controlling interest Net loss attributable to Streamex Corp. Preferred stock dividend Preferred stock deemed dividend Net loss attributed to Streamex Corp. Common Shareholders Net loss per common share, basic Net loss per common share, diluted Weighted average number of common shares outstanding, diluted Weighted average number of common shares outstanding, diluted Comprehensive (Loss) Income: Change in foreign currency translation adjustments Total comprehensive loss Comprehensive (loss) income attributable to non-controlling interest Comprehensive loss attributable to Streamex Corp. Balance Balance, shares Stock based compensation Stock based compensation, shares Exercise of warrants Exercise of warrants, shares Net proceeds from issuance of common stock in underwritten public offering Net proceeds from issuance of common stock in underwritten public offering, shares Conversion of exchangeable shares into common stock Conversion of exchangeable shares into common stock, shares Conversion of convertible debentures into common stock Conversion of convertible debentures into common stock, shares Issuance of equity to noncontrolling interest holders Preferred stock dividend Other comprehensive loss Net (loss) income Sale of common stock under at-the- market offering, net of transaction costs Sale of common stock under-at-the market offering, net of transaction costs, shares Sale of common stock and warrants Sale of common stock and warrants, shares Common stock issued to settle accounts payable Common stock issued to settle accounts payable, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to cash used in operating activities: Amortization of debt discount and issuance costs Gain on settlement and extinguishment of accounts payable Non-cash lease expense Realized gain on sale of gold Realized gain on marketable securities Change in fair value of marketable securities Change in fair value of embedded derivative Realized loss on extinguishment of convertible debentures Realized loss on investment Stock-based compensation expense Deferred income taxes Changes in operating assets and liabilities: Accounts receivable Lease receivables Sales tax receivable Prepaid expenses and other assets Accounts payable and accrued expenses Operating lease liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of marketable securities Proceeds from the sale of marketable securities Proceeds from the sale of non-marketable equity investments Proceeds from sale of gold Purchase of gold assets Net cash used in investing activity CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock under at-the-market offerings, net of issuance costs Proceeds from sale of common stock and warrants, net of issuance costs Repayment of finance obligation Net proceeds from issuance of common stock in underwritten public offering Proceeds from issuance of equity in subsidiary to non-controlling interest holders Repayment of convertible debentures Net cash (used in) provided by financing activities Effect of exchange rate change on cash Net (decrease) increase in cash Cash, beginning of the period Cash, end of the period Supplemental disclosures of cash flow information: Cash paid during the period for interest Cash paid during the period for income taxes Noncash investing and financing activities: Common stock issued in settlement of accounts payable Dividend payable on preferred stock charged to additional paid-in-capital Conversion of convertible debentures into common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS LIQUIDITY Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] BUSINESS ACQUISITION Intangible Asset, Goodwill and Other [Abstract] GOODWILL AND INTANGIBLE ASSETS Property, Plant, and Equipment [Abstract] PROPERTY AND EQUIPMENT Investments, Debt and Equity Securities [Abstract] MARKETABLE SECURITIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] GOLD ASSETS STREAMEX LTD. (VIE) Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Equity [Abstract] STOCKHOLDERS’ EQUITY OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Noncontrolling Interest [Abstract] NON-CONTROLLING INTEREST Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] SEGMENT REPORTING Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Basis of Consolidation Use of estimates Foreign Currency Translation Marketable Securities Gold Assets Concentration of Assets Net Income (loss) Per Common Share Recently adopted accounting pronouncements Recently issued accounting pronouncements not yet adopted SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED SCHEDULE OF CARRYING AMOUNT OF GOODWILL SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE SCHEDULE OF SETTLEMENT SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS SCHEDULE OF UNOBSERVABLE INPUT SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION SCHEDULE OF INFORMATION RELATED TO WARRANTS SUMMARY OF WARRANT ACTIVITY SCHEDULE OF RESTRICTED STOCK ACTIVITY SCHEDULE OF RESTRICTED STOCK UNITS GRANTS SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE SCHEDULE OF NON VESTED RESTRICTED ACTIVITY SCHEDULE OF RELATED TO WARRANTS SCHEDULE OF OUTSTANDING TO WARRANTS SCHEDULE OF NON-CONTROLLING INTEREST SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST SCHEDULE OF SEGMENT REPORTING OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table] Equity method investment, ownership percentage Other assets non current Variable interest entity acquired, percentage Variable interest entity acquired Working capital deficit Cash Net cash operating activities Net cash investing activities Net cash financing activities Secured debt Net proceeds Marketable securities Sale of trust assets Cash payments AccountingPoliciesTable [Table] Assets Consolidated asset percentage Intangible assets and goodwill Cash Prepaid expenses and other assets ComputationOfEarningPerShareTable [Table] Totals Cash Due from related party Sales tax receivable Prepaid expenses Trade name Developed technology Legal and compliance framework Goodwill Total assets acquired Accounts payable and accrued expenses Deferred tax liability Total liabilities assumed Net assets acquired Business Combination [Table] Business Combination [Line Items] Business acquisition, date Number of shares issued Exchangeable shares per purchased share Exchangeable shares issued, value Acquisition-related costs Business acquisition issuance of shares Business acquisition issuance of shares, value Number of shares issuance for acquisitions Finders fee, value Deferred tax liability Federal and provincial rate Finite lived intangible assets Royalty rate Discount rate Estimated useful lives Goodwill acquired Goodwill, beginning Acquisition Impairment Foreign currency translation adjustment Goodwill, ending Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Line Items] Total Foreign currency translation adjustment Total accumulated amortization Intangible assets, net Remainder 2026 2027 2028 2029 2030 Thereafter Intangible Asset, Indefinite-Lived [Table] Intangible Asset, Indefinite-Lived [Line Items] Amortization expenses Finite lived intangible asset, useful life Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Total Less accumulated depreciation Property and equipment, net Depreciation Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Outstanding percentage Fair value of marketable securities Marketable securities cost Unrealized loss Dividend income Issuance of shares acquired Issuance of restricted shares Investments Issuance of shares Share price Fair value of investment Unrealized gain or loss Gross proceeds Realized gain Impairment charges DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTable [Table] Aggregate carrying value Other liabilities Inventory write-down Held for sale with carrying amount Cash proceeds Recognized gain sale of gold Purchase of gold assets Other assets held at cost - gold Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Assets Total assets Liabilities Accounts payable and accrued expenses Total liabilities Interest percentage Investement amount Variable interest percentage Net loss Variable interst entity Operating expense Minority interest Accrued accounting and legal Accrued consulting Accrued interest Accrued research and development expenses Accrued office and other Accrued insurance premium financing Accrued payroll Other accrued expenses Accounts payable and accrued expenses  Total Premium Paid as down payment Financed paid Finance charge Accounts Payable, Other Accounts payable, monthly installments Annual percentage rate Prepaid insurance Prepaid insurance premium financing Other separation-related obligations Loss on extinguishment of convertible debentures — prepayment premium Gain on derecognition of embedded derivative at settlement Realized loss on extinguishment of convertible debentures Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Face amount Stated interest rate Interest rate effective percentage Interest rate for basic Conversion price Share price Convertible debt Conversion of convertible shares Debt instrument fair value Interest expense Amortization of discounts and issuance costs Debt instrumental principal amount Debt principal amount Converitible debt Unamorization debt discount Cash payoff Debt instrument periodic payment Debt instrument accrued interest Principal conversion amount Number of shares issued Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Fair value of intangible assets Goodwill Derivative liability measurement input Change in fair value of embedded derivative Balance as of December 31, 2025 Change in fair value Settlements Balance as of March 31, 2026 Embedded derivative liabilities – Yorkville Debentures Embedded derivative gain Embedded derivative liability Embedded derivative loss Gross proceeds Other income Stock, Class of Stock [Table] Class of Stock [Line Items] Temporary equity, liquidation preference Preferred stock, shares issued Preferred stock, shares outstanding Dividends payable Dividends payable Common stock conversion price Issued price Conversion of stock, shares converted Shares issued for services Conversion price Effective price Common stock shares, authorized Common stock share par value Common stock shares, issued Common stock shares, outstanding Exchangeable of common shares outstanding Sold to investors Adjustments to addtional paid issuance costs Gross proceed for stock offering Other offering expenses Proceeds from issuance of common stock Issuance cost Subscription amount Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Options Outstanding, Exercise Price Number of Options Outstanding Number of Options Outstanding Weighted Average Remaining Life Number of Options Outstanding Options Exercisable Options Outstanding, Exercise Price Outstanding shares Weighted Average Exercise Price Outstanding Weighted-Average Remaining Contractual Term Outstanding Aggregate Intrinsic Value Grants Weighted Average Exercise Price Grants Weighted-Average Remaining Contractual Term Forfeited/expired Weighted Average Exercise Price Forfeited/expired Outstanding shares Weighted Average Exercise Price Outstanding Outstanding Aggregate Intrinsic Value Outstanding shares Exercisable Weighted Average Exercise Price Outstanding Weighted-Average Remaining Contractual Term Outstanding Exercisable Aggregate Intrinsic Value Derivative liability Derivative liability, measurement input, expected life Exercise price Number outstanding Expiration date Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Outstanding shares Weighted-Average Exercise Price ending Weighted-Average Remaining Contractual Term, Outstanding Issued Exercised Exercised Weighted-Average Exercise Price Exercised Outstanding shares Weighted-Average Exercise Price ending Warrants Vested and expected to vest, Shares Weighted-Average Exercise Price Vested and expected to vest Weighted-Average Remaining Contractual Term, Exercised Warrants Vested and expected to vest, Aggregate Intrinsic Value Warrants Exercisable, Shares Weighted-Average Exercise Price Exercisable Weighted-Average Remaining Contractual Term Exercisable Warrants Exercisable, Aggregate Intrinsic Value Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total restricted shares outstanding Weighted average grant date fair value Granted Granted Vested Vested Forfeited Forfeited Total restricted shares outstanding Total Vested restricted shares Vested restricted shares, Weighted-Average Grant Date Fair Value Per Share Unvested restricted shares Unvested restricted, Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted Share based compensation arrangement by share-based payment award, award vesting rights Stock issued during the period, value ScheduleOfEstimatedGrantDateFairValueTable [Table] Stock price Stock price Expected volatility Interest rate Dividend yield Derived service period Share based compensation, price per share Nonvested as of December 31, 2025 Granted Vested and issued Forfeited Nonvested as of March 31, 2026 Restricted shares outstanding beginning balance Forfeited Restricted shares outstanding ending balance Vested restricted shares Unvested restricted shares Vested and unvested restricted shares total Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, beginning Weighted-Average Exercise Price, Outstanding Forfeited Expired Weighted-Average Exercise Price, Forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Ending Weighted-Average Exercise Price, Outstanding Weighted-Average Remaining Contractual Term, Outstanding Exercisable warrants Weighted-Average Exercise Price, Exercisable Weighted-Average Remaining Contractual Term, Exercisable Warrants exercise price Warrants rights outstanding ScheduleOfOutstandingToWarrantsTable [Table] Shares authorized Exercise price Granted shares Weighted average exercise price Weighted average remaining contractual term Share based compensation Share based compensation expense Unrecognized compensation expense Shares of its common stock, warrants Warrants to purchase common stock Unrecognized stock-based compensation cost Weighted average period Other than options grants, GDFV Share based compensation, granted Other than options grants, milestone Weighted average grant date fair value Grant-date fair value Weighted average remaining contractual term Stock issued grant fair value Stock issued grant fair shares vesting Stock option description Stock issued during the period, conversion Stock issued during the period, conversion shares Stock issued during the period, other Share-based compensation, description Weighted average Years Employee share based compensation Shares available for future issuance ScheduleOfNonControllingInterestTable [Table] Majority interest Net loss Noncontrolling interest’s weighted-average ownership percentage Net loss attributable to non-controlling interest Balance, January 1, 2025 Net income (loss) attributable to non-controlling interest Balance, March 31, 2025 Consulting fees base fees Other prepaid expense Segment Reporting [Table] Segment Reporting [Line Items] Revenues General and administrative - stock-based compensation expenses Total operating and segment expense Realized gain on sale of gold Change in fair value of marketable securities Change in fair value of embedded derivative Realized loss on extinguishment of convertible debenture Gain on settlement and forgiveness of debt Income taxes (benefit) Number of reportable segment Related Party Transaction [Table] Related Party Transaction [Line Items] Other liabilities Subsequent Event [Table] Subsequent Event [Line Items] Dividend payment description Number of shares granted Shares issued Shares vested Shares converted Sales tax receivable. Series C 9% Convertible Preferred Stock [Member] GainLossOnSettlementAndForgivenessOfAccountsPayable Change in fair value of embedded derivative. Change in fair value of marketable securities. Stock issued during period value underwritten public offering. Stock issued during period shares underwritten public offering. Stock issued during period value conversion of convertible debentures into common stock. Stock issued during period shares conversion of convertible debenture into common stock. Issuance of equity to non controlling interest holders. Other comprehensive income. Increase decrease in sales tax receivable. Gain on settlement and extinguishment of accounts payable. Proceeds from sale of gold. Proceeds from sale of common stock under at the market offerings net of issuance costs. Repayment of finance obligation. Repayment of convertible debentures. Dividend payable on preferred stock charged to additional paid in capital. Conversion of convertible debentures into common stock. Working captal deficit Gold Assets [Policy Text Block] Common stock issued in settlement of accounts payable. Viral Clear [Member] BioSig AI Sciences, Inc. [Member] Streamex Ltd [Member] Concentration Of Assets [Policy Text Block] Consolidated asset percentage. Recently Adopted Accounting Pronouncements Policy [Policy Text Block] Streamex Exchange Corporation [Member] Share Purchase Agreement [Member] Business combination recognized identifiable assets acquired and liabilities assumed due from related party Business combination recognized identifiable assets acquired and liabilities assumed sales tax receivable. Business combination recognized identifiable assets acquired and liabilities assumed trade name. Business combination recognized identifiable assets acquired and liabilities assumed developed technology. Business combination recognized identifiable assets acquired and liabilities assumed legal and compliance framework. Business combination recognized identifiable assets acquired and liabilities assumed goodwill. Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued expenses. Federal and provincial rate. Royalty rate. Discount rate. Securitization Platform [Member] Blockchain Integration [Member] Legal and Compliance Frame Work [Member] Foreign currency translation adjustment Compliance Framework [Member] Outstanding percentage. Unrealized loss. Empress Royalty Corp [Member] Restricted [Member] Unrestricted [Member] Brinks Bailee Agreement [Member] Fair value of derivative liability. Settlements. Restricted Gold [Member] Variable interest percentage. Cumulative dividends payable, Preferred stock convertible effective price. Chief Invest Officer [Member] General Counsel Officers [Member] Operating expense. Accrued consulting current. Accrued interest current. Accrued research and development expenses. Accrued office expense and other expense. Accrued insurance premium financing. Premium Finance Agreement [Member] Sales Agreement [Member] Accounts payable monthly installments. Annual percentage rate. Other separation related obligations. 2023 Long-Term Incentive Plan [Member] Options Under 9.99 [Member] Options 10.00 To 19.99 [Member] Options 20.00 To 49.99 [Member] Options 50.00 To 69.99 [Member] Finite lived intangible assets amortization expense after year four. Sharebased compensation arrangement by sharebased payment award options issued weighted average remaining contractual term 2. Weighted average remaining contractual term options outstanding. GLDY ServiceCo, LLC [Member] Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term. Realized gain on marketable securities. Proceeds from issuance of sale of equity. Schedule of Warrants or Rights Shares Authorized Exercise Price Range [Table Text Block] Warrants At 0.3000 [Member] Warrants At 0.9547 [Member] Warrants At 17800 [Member] Warrants At 40660 [Member] Warrants At 44550 [Member] Warrants At 46626 [Member] Marketable securities realized gain. Warrants At 44660 [Member] Warrants At 49252 [Member] Warrants At 49290 [Member] Warrants At 51358 [Member] Warrants At 71810 [Member] Warrants At 75020 [Member] Warrants At 79630 [Member] Warrants At 90000 [Member] Warrants At 95960 [Member] Warrants At 100992 [Member] Warrants At 102600 [Member] Warrants At 104678 [Member] Warrants At 113000 [Member] Warrants At 132800 [Member] Warrants At 480000 [Member] Warrants At 616000 [Member] Warrants At 33640 [Member] Warrants expiration date description. Class of warrants or right issued. Class of warrantsr or right expried. Class of warrants or right exercised. Class of warrant or rights vested and expected to vest outstanding. Class of warrant or rights exercisable. Class of warrant or rights weighted average exercise price of warrants or rights outstanding. Class of warrant or right exercise price of warrants or rights exercised. Class of warrant or rights weighted average exercise price of warrants or rights vested and expected to vest outstanding. Class of warrant or rights weighted average exercise price of warrants or rights exercisable. Warrants outstanding weighted average remaining contractual term. Warrants weighted average remaining contractual term exercised. Warrants exercisable weighted average remaining contractual term. Shares issued for cashless exercise of warrants. Viral Clear Pharmaceuticals Inc [Member] Share based compensation arrangement by share based payment award equity instruments other than options vested number of shares. Share based compensation arrangement by share based payment award equity instruments other than options unvested number of shares. Schedule of NonControlling Interest [Table Text Block] Bio Sig AI Sciences Inc [Member] Net Income (Loss) Average noncontrolling interest percentage of profit losses. Consulting fees. Base fees. General and administrative stock based compensation expenses. Embedded derivative gain on embedded derivatives. One One Two Thousand Twenty Six [Member] Third Party Consultant [Member] One Eight Two Thousand Twenty Six [Member] Interim Executive Chairman [Member] Chief Executive Officier [Member] One Twenty Seven Two Thousand Twenty Six [Member] Two One Two Thousand Twenty Six [Member] Three Three Two Thousand Twenty Six [Member] Three Sixteen Two Thousand Twenty Six [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Common Stock Four [Member] Common Stock Five [Member] Granted share price. Performance shares And AUM [Member] Share based compensation arrangement by share based payment award options grants in period issued. Class of warrants or rights exercisable. Class of warrant or rights weighted average exercise price of warrant or rights exercisable. Warrants vested and expected to vest outstanding weighted average remaining contractual terms. Warrants exercisable weighted average remaining contractual terms. Share based compensation arrangement by share based payment award options grant in period gross. Schedule of warrants. Class of warrants or right outstanding. Share based compensation arrangement by share based payment award option non vested number of shares. Share based compensation arrangement by share based payment award option outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instrument outstanding number. Share based compensation arrangement by share based payment award equity instruments other than option unvested number of shares. Share based compensation arrangement by share based payment award equity instruments other than option unvested total number of shares. Schedule of outstanding warrants. Share Based Compensation Award Tranche Four [Member] Share Based Compensation Award Tranche Five [Member] Restricted Stock One [Member] Restricted Stock Two [Member] Stock option description. Share Based Compensation Award Tranche [Member] Chief Investment Officer [Member] Employment Agreement [Member] Performance Vesting Restricted Stock Units [Member] Third Party [Member] Six Month Anniversaries [Member] Twelve Month Anniversaries [Member] Common stock issued to settle accounts payable, shares. Common stock issued to settle accounts payable. Two Related Party [Member] Schedule of Effect of Significant Unobservable Inputs [Table Text Block] Measurement Input Common Stock Price [Member] Measurement Input Indicated Conversion Price [Member] Measurement Input Floor Price [Member] Measurement Input Prepayment Premium [Member] Measurement Input Registration Probability [Member] Third party Consultants [Member] Business combination acquisition finders fee. Share based compensation arrangement by share based payment award equity instruments other than options vested in period weighted average grant date. Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date. Range One [Member] Performance Based Restricted Stock Unit [Member] Testing and Demo Equipment [Member] Developed Technology [Member] Assets, Current Assets, Noncurrent Liabilities, Current Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Dividends, Preferred Stock Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Diluted Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings GainOnSettlementAndExtinguishmentOfAccountsPayable Increase (Decrease) in Accounts Receivable Increase (Decrease) in Leasing Receivables IncreaseDecreaseInSalesTaxReceivable Increase (Decrease) in Prepaid Expense Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Marketable Securities Payments to Acquire Mining Assets Cash Provided by (Used in) Investing Activity, Including Discontinued Operation RepaymentOfFinanceObligation RepaymentOfConvertibleDebentures Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation ConversionOfConvertibleDebenturesIntoCommonStock Cash and Cash Equivalent Cash Equivalents, at Carrying Value Long-Term Investments Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill Business Combination, Recognized Asset Acquired, Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Business Combination, Recognized Liability Assumed, Deferred Tax Liability Business Combination, Recognized Liability Assumed, Liability Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Deferred Tax Liabilities, Goodwill and Intangible Assets Foreign currency translation adjustment [Default Label] Intangible Asset, Finite-Lived, Accumulated Amortization Intangible Asset, Finite-Lived, after Accumulated Amortization Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Extinguishment of Debt, Amount Debt Securities, Realized Gain (Loss) Goodwill, Fair Value Disclosure Dividends Payable CumulativeDividendsPayable Preferred Stock, Convertible, Conversion Price Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedWeightedAverageRemainingContractualTerm2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of warrant or rights weighted average exercise price of warrants or rights outstanding Class of warrants or right exercised Class of warrant or rights vested and expected to vest outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding Class of warrant or rights exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDate Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedNumberOfShares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerms ClassOfWarrantsOrRightsExercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantOrRightsExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term Net Income (Loss) Debt Securities, Available-for-Sale, Realized Loss Equity Securities, FV-NI, Gain (Loss) Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Other Liabilities, Current EX-101.PRE 9 stex-20260331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover - $ / shares
3 Months Ended
Mar. 31, 2026
May 13, 2026
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2026  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2026  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38659  
Entity Registrant Name STREAMEX CORP.  
Entity Central Index Key 0001530766  
Entity Tax Identification Number 26-4333375  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 2431 Aloma Avenue  
Entity Address, Address Line Two Suite 243  
Entity Address, City or Town Winter Park  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 32792  
City Area Code (203)  
Local Phone Number 409-5444  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol STEX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   104,274,817
Entity Listing, Par Value Per Share $ 0.001  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash $ 6,859 $ 20,316
Sales tax receivable 59 51
Marketable securities 23,766 9,706
Prepaid expenses and other assets 15,220 17,339
Total current assets 45,904 71,895
Non-current assets:    
Other assets held at cost – gold 15,225
Property and equipment, net 12 25
Intangible assets, net 42,418 44,639
Goodwill 69,758 70,984 [1]
Total non-current assets 127,413 115,648
Total assets 173,317 187,543
Current liabilities:    
Accounts payable and accrued expenses, including $907 and $66 to related parties as of March 31, 2026, and December 31, 2025, respectively. 3,179 2,952
Dividends payable 123 121
Convertible debentures, net 38,021
Embedded derivative liability 1,700
Total current liabilities 3,302 42,794
Deferred tax liability 10,669 11,421
Total liabilities 13,971 54,215
Commitments and contingencies (Note 16)
Mezzanine equity    
Redeemable Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $105; cumulative dividends payable of $123 and $121 as of March 31, 2026, and December 31, 2025, respectively). 105 105
Stockholders’ equity:    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock.
Common stock, $0.001 par value, authorized 500,000,000 shares, 97,721,696 and 49,805,275 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively. 98 50
Additional paid-in-capital 924,802 850,447
Accumulated other comprehensive (loss) income (1,102) 814
Accumulated deficit (764,813) (718,120)
Total stockholders’ equity attributable to Streamex Corp. 158,985 133,191
Non-controlling interest 256 32
Total stockholders’ equity 159,241 133,223
Total liabilities, mezzanine equity and stockholders’ equity 173,317 187,543
Restricted Gold [Member]    
Current assets:    
Other assets held for sale – gold 23,472
Gold [Member]    
Current assets:    
Other assets held for sale – gold 1,000
Related Party [Member]    
Current assets:    
Due from related party $ 11
Stockholders’ equity:    
Non-controlling interest $ 224  
[1] Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, voting rights 1 1
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 97,721,696 49,805,275
Common stock, shares outstanding 97,721,696 49,805,275
Series C 9% Convertible Preferred Stock [Member]    
Temporary equity, par value $ 0.001 $ 0.001
Temporary equity, stated value $ 1,000 $ 1,000
Temporary equity, shares authorized 4,200 4,200
Temporary equity, shares issued 105 105
Temporary equity, shares outstanding 105 105
Liquidation preference $ 105 $ 105
Cumulative dividends $ 123 $ 121
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 200 200
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 600 600
Series C Preferred Stock [Member]    
Preferred stock, shares authorized 4,200 4,200
Series D Preferred Stock [Member]    
Preferred stock, shares authorized 1,400 1,400
Series E Preferred Stock [Member]    
Preferred stock, shares authorized 1,000 1,000
Series F Preferred Stock [Member]    
Preferred stock, shares authorized 200,000 200,000
Related Party [Member]    
Accounts payable and accrued expenses, related parties $ 907 $ 66
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenue
Operating expenses:    
Research and development 6
General and administrative 34,254 2,957
Depreciation and amortization 1,492 21
Total operating expenses 35,746 2,984
Loss from operations (35,746) (2,984)
Other income (expense):    
Interest expense, net (12,195)
Realized gain on sale of gold 2,938
Realized gain on marketable securities 484
Change in fair value of marketable securities (134)
Change in fair value of embedded derivative 497
Realized loss on extinguishment of convertible debentures (3,057)
Realized loss on investment (119)
Gain on settlement and forgiveness of debt 199
Other income (expense), net 73 (15)
Total other income (expense), net (11,513) 184
Loss before income taxes (47,259) (2,800)
Income taxes (benefit) (565)
Net loss (46,694) (2,800)
Non-controlling interest [1] 1 (12)
Net loss attributable to Streamex Corp. (46,693) (2,812)
Preferred stock dividend (2) (2)
Preferred stock deemed dividend
Net loss attributed to Streamex Corp. Common Shareholders $ (46,695) $ (2,814)
Net loss per common share, basic $ (0.27) $ (0.14)
Net loss per common share, diluted $ (0.27) $ (0.14)
Weighted average number of common shares outstanding, diluted 174,590,397 20,787,808
Weighted average number of common shares outstanding, diluted 174,590,397 20,787,808
Comprehensive (Loss) Income:    
Change in foreign currency translation adjustments $ (1,916)
Total comprehensive loss (48,610) (2,800)
Comprehensive (loss) income attributable to non-controlling interest 1 (12)
Comprehensive loss attributable to Streamex Corp. $ (48,609) $ (2,812)
[1] Less than $0.5 thousand
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2024 $ 17 $ 253,784 $ (255,345)   $ 17 $ (1,527)
Balance, shares at Dec. 31, 2024 17,239,096          
Stock based compensation $ 2 2,072   2,074
Stock based compensation, shares 1,663,543          
Exercise of warrants [1]  
Exercise of warrants, shares 48,996          
Preferred stock dividend (2)   (2)
Net (loss) income (2,812)   12 (2,800)
Sale of common stock under at-the- market offering, net of transaction costs $ 4 3,878   3,882
Sale of common stock under-at-the market offering, net of transaction costs, shares 4,403,166          
Sale of common stock and warrants $ 1 817   818
Sale of common stock and warrants, shares 758,514          
Common stock issued to settle accounts payable [1] 189       189
Common stock issued to settle accounts payable, shares 135,000          
Balance at Mar. 31, 2025 $ 24 260,738 (258,157)   29 2,634
Balance, shares at Mar. 31, 2025 24,248,315          
Balance at Dec. 31, 2025 $ 50 850,447 (718,120) $ 814 32 133,223
Balance, shares at Dec. 31, 2025 49,805,275          
Stock based compensation $ 6 21,455 21,461
Stock based compensation, shares 6,123,941          
Exercise of warrants [1]
Exercise of warrants, shares 54,647          
Net proceeds from issuance of common stock in underwritten public offering $ 13 37,171 37,184
Net proceeds from issuance of common stock in underwritten public offering, shares 13,416,667          
Conversion of exchangeable shares into common stock $ 25 (25)
Conversion of exchangeable shares into common stock, shares 24,571,166          
Conversion of convertible debentures into common stock $ 4 15,756 15,760
Conversion of convertible debentures into common stock, shares 3,750,000          
Issuance of equity to noncontrolling interest holders 225 225
Preferred stock dividend (2) (2)
Other comprehensive loss (1,916) (1,916)
Net (loss) income (46,693) (1) (46,694)
Sale of common stock under at-the- market offering, net of transaction costs           1,724
Balance at Mar. 31, 2026 $ 98 $ 924,802 $ (764,813) $ (1,102) $ 256 $ 159,241
Balance, shares at Mar. 31, 2026 97,721,696          
[1] - less than $1
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (46,694,000) $ (2,800,000)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 1,492,000 21,000
Amortization of debt discount and issuance costs 11,979,000
Gain on settlement and extinguishment of accounts payable 199,000
Non-cash lease expense 41,000
Realized gain on sale of gold (2,938,000)
Realized gain on marketable securities (484,000)
Change in fair value of marketable securities 134,000
Change in fair value of embedded derivative (497,000)
Realized loss on extinguishment of convertible debentures 3,057,000
Realized loss on investment 119,000
Stock-based compensation expense 25,370,000 2,074,000
Deferred income taxes (565,000)
Changes in operating assets and liabilities:    
Accounts receivable 11,000
Lease receivables 17,000
Sales tax receivable (9,000)
Prepaid expenses and other assets (1,934,000) (70,000)
Accounts payable and accrued expenses 780,000 (555,000)
Operating lease liabilities (42,000)
Net cash used in operating activities (10,179,000) (1,115,000)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of marketable securities (23,900,000)
Proceeds from the sale of marketable securities 10,190,000
Proceeds from the sale of non-marketable equity investments 25,000
Proceeds from sale of gold 26,410,000
Purchase of gold assets (14,225,000)
Net cash used in investing activity (1,500,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from sale of common stock under at-the-market offerings, net of issuance costs 3,882,000
Proceeds from sale of common stock and warrants, net of issuance costs 818,000
Repayment of finance obligation (546,000)
Net proceeds from issuance of common stock in underwritten public offering 37,184,000
Proceeds from issuance of equity in subsidiary to non-controlling interest holders 225,000
Repayment of convertible debentures (38,500,000)
Net cash (used in) provided by financing activities (1,637,000) 4,700,000
Effect of exchange rate change on cash (141,000)
Net (decrease) increase in cash (13,457,000) 3,585,000
Cash, beginning of the period 20,316,000 142,000
Cash, end of the period 6,859,000 3,727,000
Supplemental disclosures of cash flow information:    
Cash paid during the period for interest 403,000
Cash paid during the period for income taxes
Noncash investing and financing activities:    
Common stock issued in settlement of accounts payable 189,000
Dividend payable on preferred stock charged to additional paid-in-capital 2,000 2,000
Conversion of convertible debentures into common stock $ 15,760,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.26.1
NATURE OF OPERATIONS
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

NOTE 1NATURE OF OPERATIONS

 

Business and organization

 

Streamex Corp. (the “Company”, “we”, “us” and “our”) is a technology company with two principal lines of business: (i) digital infrastructure focused on the tokenization and exchange of real-world assets and other commodity-linked financial products and (ii) biomedical technology focused on advanced signal acquisition and processing solutions in electrophysiology through our PURE EP™ platform. On May 28, 2025, the Company acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, British Columbia. In connection with this strategic expansion, on September 12, 2025, the Company changed its corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025, the Company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “STEX” (formerly “BSGM”).

 

On May 28, 2025, the Company completed the acquisition of Streamex Exchange pursuant to that certain Share Purchase Agreement dated as of May 23, 2025 (as amended on May 27, 2025, the “Share Purchase Agreement”) by and among the Company, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a British Columbia company and a wholly owned subsidiary of the Company (“Callco”), the shareholders of Streamex Exchange, and 1540873 B.C. Ltd., as trustee (the “Trustee”) under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”).

 

The Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). As of March 31, 2026 and December 31, 2025, the Company held a majority interest of approximately 70% in ViralClear. As of March 31, 2026, and December 31, 2025, the Company held a majority interest of approximately 84% in BioSig AI.

 

During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately 98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $225 of GLDY Tokens during March 2026. The Company also formed GLDY ServiceCo, LLC, a wholly owned subsidiary that acts as servicer to Streamex Ltd. under a servicing arrangement.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.26.1
LIQUIDITY
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
LIQUIDITY

NOTE 2LIQUIDITY

 

As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026.

 

During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.1 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released.

 

We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.

 

 

Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Basis of Consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity.

 

During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.

 

Foreign Currency Translation

 

The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.

 

 

Marketable Securities

 

The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).

 

Gold Assets

 

The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred.

 

Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026.

 

Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360.

 

Concentration of Assets

 

As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33).

 

As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions.

 

The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

 

Net Income (loss) Per Common Share

 

The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock.

 

 

The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss).

 

Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders.

 

In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share.

 

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 

   March 31,   March 31, 
   2026   2025 
Series C convertible preferred stock   434,845    564,234 
Options to purchase common stock   2,921,000    2,486,000 
Performance-based restricted stock units   1,500,000    - 
Warrants to purchase common stock   1,647,885    5,577,260 
Restricted stock units to acquire common stock   4,583,375    1,160,830 
Totals   11,087,105    9,788,324 

 

Recently adopted accounting pronouncements

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.

 

Recently issued accounting pronouncements not yet adopted

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements.

 

 

In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.26.1
BUSINESS ACQUISITION
3 Months Ended
Mar. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
BUSINESS ACQUISITION

NOTE 4 – BUSINESS ACQUISITION

 

Streamex Exchange Corporation

 

Transaction Overview

 

On May 28, 2025, the Company completed the acquisition of Streamex Exchange, a software development company based in Vancouver, British Columbia, specializing in digital tools for commodity trading and finance.

 

The acquisition was effected pursuant to the Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025, by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Streamex Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement.

 

Under the terms of the Share Purchase Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for 109,070,079 Exchangeable Shares of ExchangeCo, issued at a ratio of 2.046862 Exchangeable Shares per Purchased Share. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below.

 

The purpose of the Acquisition was to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition was undertaken to expand the Company’s technology platform into digital commodity trading and blockchain-based financial infrastructure and to obtain the assembled workforce, intellectual property, and regulatory capabilities of Streamex Exchange.

 

In connection with the transaction, the Company evaluated the accounting under ASC 805, Business Combinations, and ASC 810, Consolidation. The Company concluded the acquired set met the definition of a business. In making this determination, the Company considered the concentration test in ASC 805 and determined that substantially all of the fair value of the gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. The Company also evaluated whether the acquiree is a variable interest entity (“VIE”) and concluded Streamex Exchange is a VIE because, among other factors, it lacked sufficient equity at risk to finance its activities without additional subordinated financial support and the equity holders, as a group, did not have substantive power to direct the activities that most significantly impact economic performance at the acquisition date.

 

The Company concluded it is the primary beneficiary because it has both (i) the power to direct the activities that most significantly impact Streamex’s economic performance through governance rights in place at closing and (ii) the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, the transaction is accounted for as a business combination with the Company as the accounting acquirer, and Streamex Exchange has been consolidated in the Company’s financial statements from the acquisition date.

 

 

Shareholder Approval and Contingent Features

 

Initially, the Exchangeable Shares were not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company sought stockholder approval for certain matters related to the transaction, including the issuance of shares of common stock exchangeable for Exchangeable Shares, the issuance of shares underlying the Convertible Debentures, increases to the authorized share count and the 2023 Long-Term Incentive Plan, and amendments to the Company’s Amended and Restated Certificate of Incorporation. At the special meeting of stockholders held on September 5, 2025, all proposals except the issuance of shares exchangeable for Exchangeable Shares (Proposal A) were approved. Proposal A was subsequently approved on November 4, 2025.

 

Following stockholder approval of Proposal A on November 4, 2025, and subject to the terms of the Exchange Rights Agreement, the holders of Exchangeable Shares are entitled to exchange such shares for an aggregate of 109,070,079 shares of the Company’s common stock representing up to 75% of the Company’s fully diluted common stock as of the Share Purchase Agreement date.

 

Consideration Transferred

 

The fair value of the consideration transferred was $105,498, consisting entirely of Exchangeable Shares issued by ExchangeCo. Due to the lack of an active market for the Exchangeable Shares and the contingent nature of their conversion, a fundamentals-based valuation approach was used to estimate the fair value of the consideration. The contingent consideration related to the potential adjustment of the Exchange Ratio from 1.0 to 1.25—triggered if shareholder approval is not obtained within six months following the closing date—was not included in the purchase consideration as of May 28, 2025. As stockholder approval was obtained on November 4, 2025, within six months of the closing date, the exchange ratio adjustment was not triggered, and no additional consideration was required. For an overview of the Company’s derivative financial instruments and related disclosures required by ASC 815, see Note 11, Convertible Debentures and Related Derivative Instruments. See Note 12, Fair Value Measurements and Note 13, Stockholders’ Equity.

 

On November 4, 2025, the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Share Purchase Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. As a result of the reclassification, the Exchangeable Shares are classified as permanent equity and are presented within stockholders’ equity in the consolidated balance sheet. No derivative liability related to the Exchangeable Shares remained outstanding as of March 31, 2026 or December 31, 2025. Although the Exchangeable Shares were reclassified to permanent equity upon stockholder approval on November 4, 2025, the consideration transferred for purposes of the acquisition date purchase price allocation reflects the fair value of the Exchangeable Shares as of May 28, 2025.

 

In connection with the acquisition of Streamex Exchange, the Company incurred total acquisition-related costs of $5.9 million during the year ended December 31, 2025. These costs primarily consisted of legal, accounting, and consulting fees directly attributable to the transaction. Included in this amount was the issuance of 200,000 shares of the Company’s common stock to a third-party consultant, valued at $1,010 based on the grant-date fair value and the expected issuance of 824,052 shares of the Company’s common stock to third party consultants in connection with a finders fee, valued at $4,820. These costs were expensed as incurred and are reflected in general and administrative expenses in the Unaudited Condensed Consolidated Statements of Operations.

 

Purchase Price Allocation

 

The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their estimated fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. During the three months ended March 31, 2026, the Company completed its assessment of the fair values of the assets acquired and liabilities assumed in connection with the acquisition of Streamex Exchange. No measurement period adjustments were recorded during the three months ended March 31, 2026.

 

The Acquisition was recorded as a business combination based on a valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). Goodwill represents the excess of the purchase price consideration over the valuation of the net assets acquired. 

 

 

The final allocation of the purchase consideration is as follows:

 

Amount Recognized as of the Acquisition Date (In Thousands)    
Assets acquired     
Cash  $366 
Due from related party   11 
Sales tax receivable   14 
Prepaid expenses   22 
Trade name   5,100 
Developed technology   40,000 
Legal and compliance framework   2,400 
Goodwill   70,435 
Total assets acquired  $118,348 
Liabilities assumed     
Accounts payable and accrued expenses  $(262)
Deferred tax liability   (12,588)
Total liabilities assumed  $(12,850)
Net assets acquired   105,498 

 

Deferred tax liability

 

In connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets, resulting in a deferred tax liability of approximately $12,588, measured using the enacted combined Canadian federal and provincial rate of 26.5%. Because these deferred tax liabilities arise in a separate foreign jurisdiction, they cannot offset deferred tax assets of the U.S. parent. The corresponding increase in goodwill was recognized as part of purchase accounting.

 

Intangible Assets

 

The Company identified the following finite-lived intangible assets:

 

  Trade Name: Valued at $5,100 using the relief-from-royalty method, applying a 1.0% royalty rate and a 40.5% discount rate. The trade name is expected to be utilized over a 10-year period and is amortized accordingly.
     
  Developed Technology
     
    Comprised of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over 8 years:

 

  Securitization Platform: Valued at $31,100, representing proprietary protocols and infrastructure enabling the tokenization of real-world assets and integration with decentralized finance platforms.
     
  Blockchain Integration: Valued at $8,900, reflecting proprietary systems facilitating token creation and secondary market trading through blockchain-based platforms.

 

  Legal and Compliance Framework: Valued at $2,400 using the cost approach, based on the estimated cost to recreate the regulatory and legal infrastructure necessary for operations. The asset has a useful life of 7 years and is amortized accordingly. The legal and compliance framework supports the Company’s ability to operate in regulated jurisdictions and reduce legal and regulatory risk exposure.

 

 

Goodwill

 

Goodwill of $70,435 represents the excess of the purchase consideration over the fair value of net assets acquired and was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the consolidated reporting unit, as the Company operates as a single segment. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or noncontrolling interests.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.26.1
GOODWILL AND INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2026
Intangible Asset, Goodwill and Other [Abstract]  
GOODWILL AND INTANGIBLE ASSETS

NOTE 5GOODWILL AND INTANGIBLE ASSETS

 

Goodwill

 

The following table shows the changes in the carrying amount of goodwill for the period:

 

Goodwill as of December 31, 2025 (1)  $70,984 
Acquisition   - 
Impairment   - 
Foreign currency translation adjustment   (1,226)
Goodwill as of March 31, 2026  $69,758 

 

  1) Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.

 

During the three months ended March 31, 2026, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. Based on the qualitative assessment performed, management concluded that the combination of factors considered did not result in a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the three months ended March 31, 2026.

 

 

Intangible Assets

 

Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company evaluates its finite-lived intangible assets for impairment in accordance with ASC 360-10-35 whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. During the three months ended March 31, 2026, the Company evaluated whether any such triggering events existed, including consideration of changes in the business environment, market conditions, and asset utilization. Based on this assessment, management concluded that no triggering events occurred and that the carrying amounts of the Company’s finite-lived intangible assets were recoverable. Accordingly, no impairment charges were recorded for the three months ended March 31, 2026 or 2025.

 

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:

 

   March 31,   December 31, 
   2026   2025 
Trade name (1)  $5,100   $5,100 
Developed technology (1)   40,000    40,000 
Legal and compliance framework (1)   2,400    2,400 
Patents   380    380 
Total   47,880    47,880 
Foreign currency translation adjustment   (456)   371 
Accumulated amortization:          
Trade name   (425)   (303)
Developed technology   (4,162)   (2,975)
Legal and compliance framework   (285)   (204)
Patents   (134)   (130)
Total accumulated amortization   (5,006)   (3,612)
Intangible assets, net  $42,418   $44,639 

 

  1) Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.

 

Amortization expenses for total intangible assets were $1,479 and $3 for the three months ended March 31, 2026 and 2025, respectively. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $128, $1,260, $86 and $5, respectively, for the three months ended March 31, 2026. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $0, $0, $0 and $3, respectively, for the three months ended March 31, 2025. The weighted-average useful lives of total intangibles, trade name, developed technology, legal and compliance framework and patents were 7.4 years, 9.2 years, 7.2 years, 6.2 years and 13.5 years, respectively, as of March 31, 2026.

 

Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:

 

      
Remainder 2026  $4,362 
2027   5,816 
2028   5,816 
2029   5,816 
2030   5,816 
Thereafter   14,792 
Total  $42,418 

 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.26.1
PROPERTY AND EQUIPMENT
3 Months Ended
Mar. 31, 2026
Property, Plant, and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 6PROPERTY AND EQUIPMENT

 

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:

 

   March 31,   December 31, 
   2026   2025 
Computer equipment  $531   $531 
Furniture and fixtures   109    109 
Testing/Demo equipment   312    312 
Leasehold improvements   84    84 
Total   1,036    1,036 
Less accumulated depreciation   (1,024)   (1,011)
Property and equipment, net  $12   $25 

 

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amounts of its property and equipment may not be recoverable. Based on this assessment, no impairment indicators were identified and no impairment charges were recorded during the three months ended March 31, 2026 or 2025.

 

Depreciation expenses were $13 and $18 for the three months ended March 31, 2026 and 2025, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.26.1
MARKETABLE SECURITIES
3 Months Ended
Mar. 31, 2026
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE SECURITIES

NOTE 7 – MARKETABLE SECURITIES

 

Exchange-Traded Funds

 

The Company’s marketable securities consist of exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments. As of March 31, 2026, the portfolio was composed of four ETFs: iShares 0-3 Month Treasury Bond ETF (SGOV), SPDR Portfolio Short-Term Treasury ETF (SPTS), Vanguard Short-Term Treasury Index ETF (VGSH), and Vanguard Short-Term Corporate Bond ETF (VCSH), each representing approximately 25% of the total portfolio. These securities are held in a brokerage account and are classified as equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities.

 

Fair value is determined using quoted market prices in active markets and, accordingly, all marketable securities are classified within Level 1 of the ASC 820 fair value hierarchy.

 

During the three months ended March 31, 2026, the Company purchased approximately $23,900 of marketable securities on February 26, 2026. No ETF securities were sold during the period; therefore, no realized gains or losses were recognized. As of March 31, 2026, the aggregate fair value of the ETF portfolio was approximately $23,766 against a cost basis of $23,900, resulting in a net unrealized loss of approximately $(134), which related entirely to equity securities still held as of March 31, 2026 and is included in “Change in fair value of marketable securities” in the unaudited condensed consolidated statements of operations. No impairment charges were recognized during the period. During the three months ended March 31, 2026, the Company earned dividend income and interest income on sweep balances totaling approximately $71, which is included in “Other income (expense), net” in the unaudited condensed consolidated statements of operations.

 

As of December 31, 2025, the Company held no ETF investments.

 

Empress Royalty Corp.

 

On December 9, 2025, the Company entered into a share purchase agreement with Terra Capital Natural Resources Fund Pty Ltd to acquire 12,671,297 common shares of Empress Royalty Corp. (“Empress”), representing approximately 9.9% of Empress’s outstanding common shares. Empress is listed on the TSX Venture Exchange and OTCQX.

 

As consideration, the Company issued 2,443,750 restricted shares of its common stock on December 12, 2025, the date ownership transferred. The investment was initially recognized at $10,533, based on the fair value of 2,443,750 Streamex shares issued at $4.31 per share on December 12, 2025. The Company does not have significant influence over Empress.

 

 

As of December 31, 2025, the fair value of the Empress investment was approximately $9,706, with the resulting unrealized loss of $(827) recognized in earnings during the year ended December 31, 2025. In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain of $484 measured from the December 31, 2025 fair value. The realized gain is included in “Realized gain on marketable securities” in other income (expense) in the unaudited condensed consolidated statements of operations. As the investment was disposed of prior to March 31, 2026, no unrealized gains or losses on the Empress investment were recognized during the three months ended March 31, 2026, and no impairment charges were recorded during any period in which the investment was held. As of March 31, 2026, the Company held no investment in Empress Royalty Corp.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.26.1
GOLD ASSETS
3 Months Ended
Mar. 31, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
GOLD ASSETS

NOTE 8 – GOLD ASSETS

 

Gold Bullion — Held for Sale (Sold February 2026)

 

As of December 31, 2025, the Company held LBMA Good Delivery gold bullion (the “Gold”) on an allocated, physically segregated basis in secure vaults operated by Brink’s Global Services USA, Inc. (“Brink’s”) and maintained the Gold in a securities account with Gold Bullion International, LLC (“GBI”). The aggregate carrying value of the Gold as of December 31, 2025 was approximately $24,472, of which approximately $23,472 was restricted and approximately $1,000 was unrestricted.

 

The restricted portion of the Gold and related account rights were pledged as collateral under the Company’s secured financing arrangements, including the Secured Convertible Debenture Purchase Agreement dated July 7, 2025 and the Guaranty and Security Agreement dated November 4, 2025.

 

Pursuant to the Securities Account Control Agreement dated November 4, 2025, GBI is required to comply with entitlement orders issued by YA II PN, LTD., acting as collateral agent (the “Collateral Agent”), and GBI will not follow Company instructions unless accompanied by the Collateral Agent’s express written consent. Upon receipt of a notice of sole control following an event of default, GBI would terminate the Company’s access to the securities account and take instructions solely from the Collateral Agent as the entitlement holder with respect to the account and property therein.

 

Pursuant to the Brink’s Bailee Agreement dated November 4, 2025, Brink’s acts solely as bailee of the Gold, acknowledges no property interest in the Gold, and any statutory or possessory liens are subordinated to the Collateral Agent’s first-priority security interest. Brink’s maximum liability amount under its arrangements with GBI is $125 million.

 

No entitlement orders or notices of sole control were issued during the three months ended March 31, 2026.

 

On December 29, 2025, management committed to a plan to sell the Gold in connection with the Company’s plan to resolve and repay its secured convertible debentures. The Company determined that all criteria for classification as held for sale under ASC 360-10-45-9 were met as of December 29, 2025. Accordingly, as of December 31, 2025, the Gold was classified as held for sale and measured at the lower of its carrying amount or fair value less cost to sell. Because fair value less cost to sell exceeded the carrying amount, no write-down was recorded prior to sale.

 

In February 2026, the Company transferred approximately $1,000 of unrestricted gold bullion at cost to Streamex Ltd. in connection with the establishment of the GLDY Token program. The transferred gold is included in “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet as of March 31, 2026 (see Note 9).

 

On February 5, 2026, the Company completed the sale of the remaining LBMA Good Delivery gold bullion previously classified as held for sale, with a carrying amount of approximately $23,472. The transaction was executed through the Company’s securities intermediary and resulted in cash proceeds of approximately $26,410. The Company recognized a gain of approximately $2,938 on the sale, which is included in “Realized gain on sale of gold” in other income (expense) in the unaudited condensed consolidated statements of operations. The proceeds were used to fund the repayment of the Yorkville Debentures (see Note 11).

 

As of March 31, 2026, no gold bullion classified as held for sale remained on the unaudited condensed consolidated balance sheet. Upon completion of the sale and settlement of the Convertible Debentures, all related security interests, liens, and custodial arrangements described above were terminated.

 

 

Gold Assets Held at Cost — Streamex Ltd. (VIE)

 

During the three months ended March 31, 2026, Streamex Ltd. (the Company’s consolidated VIE) acquired gold bullion consisting of (i) the approximately $1,000 of unrestricted gold transferred from the Company as described above, and (ii) approximately $14,225 of gold purchased directly by Streamex Ltd. with cash funded by the Company. As of March 31, 2026, the aggregate carrying amount of gold held by Streamex Ltd. was $15,225, classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The gold is held to support the long-term GLDY Token program and related leasing activities and is accounted for as a long-lived tangible asset within the scope of ASC 360 (see Note 3).

 

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amount of its gold assets held at cost may not be recoverable. Based on this assessment, including consideration of gold market prices as of the balance sheet date, management concluded that no triggering events existed and no impairment charges were recorded during the three months ended March 31, 2026. See Note 9 for additional information regarding Streamex Ltd.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.26.1
STREAMEX LTD. (VIE)
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
STREAMEX LTD. (VIE)

NOTE 9 – STREAMEX LTD. (VIE)

 

Overview

 

Streamex Ltd. (“Streamex Ltd.” or the “VIE”) is a special-purpose entity organized in the Cayman Islands and formed to purchase and hold physical gold and to issue digital GLDY Tokens designed to provide tokenholders exposure to gold and gold-denominated leasing returns. Streamex Ltd. may also lease its gold holdings to generate gold-denominated yield. The Company is involved with Streamex Ltd. through its governance rights and through its economic interests in GLDY Tokens.

 

Streamex Ltd. began operations during the three months ended March 31, 2026.

 

Variable Interest Entity Consideration

 

The Company evaluated Streamex Ltd. under the variable interest entity (“VIE”) model in ASC 810, Consolidation. A legal entity is a VIE if, among other conditions, the holders of the equity investment at risk, as a group, lack the power, through voting rights or similar rights, to direct the activities that most significantly impact the entity’s economic performance. Streamex Ltd. is considered a VIE because the holders of GLDY Tokens (which represent non-voting participating equity interests) lack substantive voting rights and do not have the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance. Voting control resides with the single voting management share, which controls shareholder-level decisions including the appointment and removal of directors, and day-to-day operating authority has been delegated to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, pursuant to a services agreement. Because Streamex Ltd. is a VIE, the Company evaluated whether it is the primary beneficiary and therefore required to consolidate Streamex Ltd., as discussed below.

 

Primary Beneficiary Conclusion and Consolidation

 

The Company evaluated its involvement with Streamex Ltd. under ASC 810, Consolidation, and concluded it is the primary beneficiary and is required to consolidate Streamex Ltd. Under ASC 810-10-25-38, a reporting entity is the primary beneficiary of a VIE only if it has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company concluded both criteria are met as of March 31, 2026 because it has the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance through its control of the VIE’s governance structure (including the voting management share and related decision rights, as applicable) and the servicer arrangement, and has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE due to its economic interest in the GLDY Tokens.

 

 

As of March 31, 2026, the Company held approximately 98.5% of the outstanding GLDY Tokens issued by Streamex Ltd. (approximately $15,000 invested by the Company out of $15,225 total tokens issued). Two related party investors subscribed for an aggregate of approximately $225 in GLDY Tokens during March 2026, representing approximately 1.5% of total tokens outstanding. Accordingly, the Company has consolidated Streamex Ltd. from the date of its formation in the unaudited condensed consolidated financial statements.

 

Carrying Amounts of Assets and Liabilities of Consolidated VIE

 

The following table presents the carrying amounts and balance sheet classifications of the significant assets and liabilities of Streamex Ltd. included in the Company’s unaudited condensed consolidated balance sheet as of March 31, 2026. The assets of Streamex Ltd. are generally restricted and can be used only to settle obligations of Streamex Ltd.

 

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:

 

     
Assets    
Other assets held at cost – gold  $15,225 
Cash   60 
Total assets  $15,285 
      
Liabilities     
Accounts payable and accrued expenses  $33 
Total liabilities  $33 

 

During the three months ended March 31, 2026, Streamex Ltd. incurred a net loss of approximately $155, primarily consisting of operating expenses including bank fees, custody-related charges, and digital asset transaction costs. The net loss was funded by capital contributions from the Company and its affiliates (see Note 8 for additional information regarding the gold assets held by Streamex Ltd.).

 

During March 2026, two officers of the Company subscribed for GLDY Tokens directly with Streamex Ltd.: (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens on March 17, 2026, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens on March 27, 2026. These subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions and are related party transactions (see Note 18, Related Party Transactions).

 

Lack of Recourse / Restrictions

 

The assets of Streamex Ltd. are generally not available to satisfy the obligations of the Company or its other subsidiaries, and the creditors and tokenholders of Streamex Ltd. generally do not have recourse to the general credit of the Company beyond the assets of Streamex Ltd., except to the limited extent of intercompany balances eliminated in consolidation. The liabilities recognized as a result of consolidating Streamex Ltd. do not represent additional claims on the Company’s general assets.

 

Maximum Exposure to Loss / Financial Support

 

The Company’s maximum exposure to loss associated with its involvement with Streamex Ltd. as of March 31, 2026 is limited to the carrying amount of its approximately 98.5% economic interest in the GLDY Tokens and its net interest in Streamex Ltd.’s net assets, which totaled approximately $15,000 at the date of investment. The Company has no arrangements that legally obligate it to provide additional financial support to Streamex Ltd., such as guarantees or liquidity facilities, beyond its role as an investor and service provider. However, the Company funded approximately $158 of Streamex Ltd.’s operating expenses during Q1 2026 through capital contributions from the Company and its affiliates, which are eliminated in consolidation.

 

 

Related Party Considerations / Intercompany Eliminations

 

Streamex Ltd. pays servicing fees to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, under the applicable servicing arrangement. Because the servicer is a consolidated subsidiary, these servicing fees and related intercompany balances are eliminated in consolidation.

 

Noncontrolling Interest

 

As of March 31, 2026, noncontrolling interests in Streamex Ltd. consisted of (i) the single voting management share held by the VIE’s director, which carries governance rights but no material economic interest, and (ii) GLDY Tokens held by two officers of the Company who subscribed as related party investors during March 2026. In aggregate, related party tokenholders held approximately 1.5% of the outstanding GLDY Tokens as of March 31, 2026.

 

The noncontrolling interest attributable to Streamex Ltd. as of March 31, 2026 was approximately $224, consisting of related party token subscriptions described above, net of the noncontrolling interest’s proportionate share of the VIE’s net loss for the period. The noncontrolling interest is presented within noncontrolling interest on the unaudited condensed consolidated balance sheet and in the unaudited condensed consolidated statements of operations. See Note 15 for the noncontrolling interest rollforward and attribution tables.

 

Ongoing Assessment

 

The Company reassesses its primary beneficiary conclusion on an ongoing basis in accordance with ASC 810 whenever changes in facts and circumstances occur that could affect the determination of whether either criterion under ASC 810 continues to be met. Changes that could affect the primary beneficiary assessment include, but are not limited to, changes in GLDY Token ownership (including issuance, redemption, or transfer of GLDY Tokens to unrelated third parties that could affect the significance of the Company’s economic exposure to the VIE), modifications of governing documents or fee arrangements, changes in ownership of the management share, or replacement of the affiliated servicer by an unrelated party. As of March 31, 2026, no changes in facts or circumstances have occurred that would alter the Company’s conclusion.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.26.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 10ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:

 

   March 31,   December 31, 
   2026   2025 
Accrued accounting and legal  $725   $705 
Accrued consulting   564    406 
Accrued interest   -    200 
Accrued research and development expenses   167    169 
Accrued office and other   41    38 
Accrued insurance premium financing(1)   370    916 
Accrued payroll(2)   1,180    512 
Other accrued expenses   132    6 
Accounts payable and accrued expenses   $3,179   $2,952 

 

  (1) On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.
     
  (2) Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.

 

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.26.1
CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS
3 Months Ended
Mar. 31, 2026
Debt Disclosure [Abstract]  
CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

NOTE 11 – CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

 

On November 4, 2025 and December 17, 2025, the Company issued two tranches of senior secured convertible debentures to YA II PN, Ltd. (“Yorkville”) (collectively, the “Convertible Debentures”) with aggregate principal of $50,000 (each tranche with principal of $25,000). The Convertible Debentures were issued as part of the Company’s capital-raising strategy to fund operations and growth initiatives.

 

Each debenture was issued at a purchase price of 96% of principal, bore interest at 4.0% per annum (increasing to 18.0% upon an event of default), and had a contractual maturity date that was 24 months from issuance (November 4, 2027 and December 17, 2027, respectively).

 

The Convertible Debentures were secured by first-priority liens on substantially all assets of the Company and were guaranteed by certain subsidiaries. Upon settlement in February 2026, all related security interests and liens were released.

 

Conversion Features

 

Yorkville could convert all or any portion of the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price equal to the lower of:

 

(i) a fixed price of $6.016 per share, subject to a one-time downward-only reset following registration effectiveness, and

 

(ii) 97% of the lowest daily volume-weighted average price (“VWAP”) during the three trading days immediately preceding conversion, subject to a $4.00 per share floor price, in each case subject to customary anti-dilution adjustments.

 

Conversions were also subject to a beneficial ownership limitation (generally 4.99%) and an exchange cap tied to Nasdaq rules, unless stockholder approval was obtained or the limitation was otherwise waived pursuant to the debenture terms.

 

If fully converted at the $4.00 floor price, the $50,000 principal amount of the Convertible Debentures would have been convertible into a maximum of 12,500,000 shares of the Company’s common stock, exclusive of any shares issuable for accrued interest or premiums. The Company did not register any shares for issuance under the Convertible Debentures and elected to utilize its optional cash settlement provisions in February 2026.

 

Embedded Derivative Liability – Conversion Option

 

The Company determined that the holder’s optional conversion feature requires bifurcation as an embedded derivative under ASC 815, Derivatives and Hedging, because (i) the economic characteristics of the conversion feature were not clearly and closely related to the host debt instrument and (ii) the conversion feature did not qualify for equity classification due to its variable conversion pricing mechanics, including VWAP-based pricing, floor price provisions, and reset features.

 

 

Accordingly, the embedded conversion option was accounted for separately as a derivative liability measured at fair value, with changes in fair value recognized in earnings each reporting period. At issuance, the Company allocated proceeds between the host debt and the embedded derivative based on relative fair value, with the derivative recorded as a liability and a corresponding amount recorded as a debt discount on the host debenture. This debt discount was amortized to interest expense using the effective interest method over the estimated term of the debenture. As of March 31, 2026, the embedded derivative liability was fully settled and no balance remained outstanding. See Note 12, Fair Value Measurements, for information regarding the valuation methodology, significant unobservable inputs, sensitivity considerations, changes in fair value, the tabular presentation of gains and losses on derivative instruments recognized in earnings as required by ASC 815, and the Level 3 rollforward of the embedded derivative liability.

 

The Company does not designate any derivative instruments as hedging instruments for accounting purposes and does not apply hedge accounting.

 

Debt Carrying Amount and Interest Expense

 

As of March 31, 2026, the carrying value of the Convertible Debentures, net of unamortized original issue discount, debt issuance costs, and bifurcation-related discounts, was $0 on a combined basis.

 

Interest expense recognized for the three months ended March 31, 2026 includes stated coupon interest and amortization of debt discounts and issuance costs under the effective interest method. For the three months ended March 31, 2026, the Company recognized total interest expense of approximately $12,182 related to the Convertible Debentures, consisting of approximately $203 of contractual interest and approximately $11,979 of non-cash interest expense from the amortization of discounts and issuance costs. Interest expense is included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

 

The effective interest rate on the Convertible Debentures substantially exceeded the 4.0% stated coupon rate. On December 29, 2025, management committed to a plan to settle the Convertible Debentures in early 2026, which constituted a change in the estimated life of the instruments. The Company prospectively recalculated the effective interest rates based on the revised expected settlement date of February 6, 2026. The resulting effective interest rates for the November 4, 2025 tranche and the December 17, 2025 tranche were approximately 393.7% and 228.9%, respectively, reflecting the accelerated amortization of unamortized discounts and issuance costs over a significantly shortened expected term. These revised rates were applied from December 29, 2025 through the settlement date of February 6, 2026, and are the basis for the non-cash interest expense from the accelerated amortization of discounts and issuance costs described above. Upon settlement, all remaining unamortized discounts and issuance costs were fully amortized and the net carrying value of the Convertible Debentures was reduced to zero. Had the Convertible Debentures been held to their contractual maturity dates of November 4, 2027 and December 17, 2027, respectively, the effective interest rates would have been approximately 17.6% and 26.5%, respectively, still materially higher than the stated coupon due to the substantial original issue discount.

 

Outstanding Principal

 

As of March 31, 2026, and December 31, 2025, the outstanding principal balance of the Convertible Debentures was $0 and $50,000, respectively.

 

Settlement and Extinguishment

 

On January 22, 2026, the Company delivered an irrevocable optional prepayment notice with respect to the Convertible Debentures.

 

On February 6, 2026, the Company settled the Convertible Debentures, which had an aggregate outstanding principal of $50,000 and a net carrying value of $38,021 (after unamortized debt discounts of $11,979 as of December 31, 2025), through a combination of (i) a cash payoff of approximately $38,903, consisting of $35,000 of principal, a $3,500 prepayment premium, and approximately $403 of accrued interest, and (ii) conversion of $15,000 of principal, with no accrued interest, at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares of the Company’s common stock.

 

 

The remaining unamortized debt discounts of $11,979 were fully amortized to interest expense upon settlement during the three months ended March 31, 2026, and are included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

 

In connection with the settlement, the Company recognized the following:

 

      
Loss on extinguishment of convertible debentures — prepayment premium  $(3,500)
Gain on derecognition of embedded derivative at settlement   443 
Realized loss on extinguishment of convertible debentures  $(3,057)

 

Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.

 

We also entered into a SEPA with Yorkville that provided the Company with the right, but not the obligation, to sell shares of common stock during the commitment period. We terminated the SEPA effective January 29, 2026, and did not sell any shares under the SEPA.

 

Cross-references to related disclosures

 

Derivative-related qualitative, quantitative, and tabular disclosures are included in more than one note to the unaudited condensed consolidated financial statements. Accordingly, the Company provides the following cross-references:

 

  Note 4 — Business Acquisition (Exchangeable Shares issued as consideration and related acquisition disclosures)
     
  Note 12 — Fair Value Measurements (fair value hierarchy and valuation inputs for Level 3 instruments, as applicable)
     
  Note 13 — Stockholders’ Equity (Exchangeable Shares and Special Voting Preferred Stock; reclassification to equity)
     
  Note 14 — Options, Restricted Stock Units and Warrants (warrant terms and Fundamental Transaction cash settlement / repurchase activity)

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.26.1
FAIR VALUE MEASUREMENTS
3 Months Ended
Mar. 31, 2026
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

NOTE 12 – FAIR VALUE MEASUREMENTS

 

The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations.

 

 

Nonrecurring Level 3 Fair Value Measurements

 

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:

 

Description  May 28, 2025 
Trade name  $5,100 
Developed technology  $40,000 
Legal and compliance framework  $2,400 
      
Goodwill  $70,435 

 

All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. See Note 4, Business Acquisition, for additional information regarding the purchase price allocation and valuation methodologies.

 

Derivative Liabilities – Recurring Fair Value Measurements (Embedded Conversion Options)

 

The embedded conversion options associated with the Company’s secured convertible debentures were bifurcated and accounted for as derivative liabilities under ASC 815. The derivative liabilities were measured at fair value upon issuance of each debenture tranche (November 4, 2025 and December 17, 2025) and subsequently remeasured at fair value on a recurring basis through settlement on February 6, 2026. See Note 11, Convertible Debentures and Related Derivative Instruments, for information regarding the terms of the Convertible Debentures, the bifurcation analysis, settlement mechanics, and extinguishment accounting.

 

The Company estimated the fair value of the embedded conversion options using a Monte Carlo simulation model within a “with-and-without” framework, which isolates the value of the holder’s conversion option by comparing the fair value of the debentures with and without the embedded conversion feature. The Monte Carlo model was designed to capture the path-dependent and non-linear features of the conversion option, including variable conversion pricing, contractual floor prices, amortization mechanics, optional prepayment features, and management’s expectations regarding conversion and repayment behavior. Because the valuation utilized significant unobservable inputs, the derivative liabilities were classified as Level 3 within the fair value hierarchy.

 

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):

 

SCHEDULE OF UNOBSERVABLE INPUT

   2/6/2026   12/31/2025 
Unobservable / key assumption  Remeasurement   Remeasurement 
Common stock price  $3.28   $3.03 
Indicated conversion price  $4.00   $4.00 
Floor price  $4.00   $4.00 
Prepayment probability   100%   70%
Prepayment premium   10%   10%
Registration probability   0%   0%

 

The February 6, 2026, valuation incorporated management’s assessment that optional prepayment was the most likely outcome and weighted prepayment and non-prepayment scenarios accordingly. Registration-dependent conversion scenarios were assigned a zero probability, as registration effectiveness was not expected.

 

The fair value of the derivative liabilities is most sensitive to changes in the Company’s stock price, expected volatility, and assumptions regarding the timing and likelihood of prepayment. An increase in expected volatility or stock price would generally increase the fair value of the derivative liability, while an increase in the probability of early prepayment would generally decrease the fair value. Due to the path-dependent nature of the valuation, quantitative sensitivity analyses are not presented.

 

During the three months ended March 31, 2026, the Company recognized a gain of $497 related to changes in the fair value of the embedded derivative liabilities prior to settlement on February 6, 2026. On settlement, the Company derecognized the remaining embedded derivative liability of $1,203, resulting in a gain on derecognition of $443 included in “Realized loss on extinguishment of convertible debentures” in the unaudited condensed consolidated statements of operations. See Note 11 for the complete extinguishment accounting.

 

 

The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:

 

   Amount 
Change in fair value of embedded derivative  $497 

 

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:

 SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY

   Amount 
Balance as of December 31, 2025  $1,700 
Change in fair value   (497)
Settlements   (1,203)
Balance as of March 31, 2026  $- 

 

Investment in Empress Royalty Corp.

 

The Company’s investment in Empress Royalty Corp. is measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. The fair value is based on quoted prices on the TSX Venture Exchange (principal market), translated into U.S. dollars using the spot exchange rate at the measurement date.

 

In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain on marketable securities of $484, which is included in other income (expense) in the unaudited condensed consolidated statements of operations. As of March 31, 2026, the Company held no investment in Empress Royalty Corp. See Note 7, Marketable Securities, for additional information.

 

Exchange-Traded Funds

 

The Company’s investments in exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments are measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy.

 

Recurring Fair Value Measurements

 

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):

 

Description  Level   March 31, 2026   December 31, 2025 
Embedded derivative liabilities – Yorkville Debentures   3   $-   $1,700 
Marketable securities   1   $23,766   $9,706 

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.26.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 13STOCKHOLDERS’ EQUITY

 

Preferred stock

 

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2026 and December 31, 2025, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. As of March 31, 2026 and December 31, 2025, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.

 

 

Special Voting Preferred Stock

 

In connection with the issuance of Exchangeable Shares, the Company designated one share of Special Voting Preferred Stock, par value $0.001 per share. One share of Special Voting Preferred Stock was issued and outstanding as of March 31, 2026, and December 31, 2025.

 

The Special Voting Preferred Stock was issued to a trustee and does not have any economic rights, including rights to dividends or participation in liquidation, other than a nominal liquidation preference of $1.00. The Special Voting Preferred Stock is not convertible into common stock.

 

The sole purpose of the Special Voting Preferred Stock is to provide voting rights to holders of Exchangeable Shares on an equivalent basis with holders of the Company’s common stock. The holder of the Special Voting Preferred Stock is entitled to cast a number of votes equal to the aggregate number of votes that the holders of Exchangeable Shares would be entitled to cast if such Exchangeable Shares were exchanged for shares of the Company’s common stock, in accordance with the Exchange Rights Agreement.

 

The voting rights associated with the Special Voting Preferred Stock terminate automatically upon the exchange or cancellation of all outstanding Exchangeable Shares, at which time the Special Voting Preferred Stock is automatically cancelled for no consideration.

 

Series C Preferred Stock

 

Series C Preferred Stock (“Series C”) issued and outstanding totaled 105 shares as of March 31, 2026, and December 31, 2025. As of March 31, 2026, and December 31, 2025, the Company has accrued $123 and $121 dividends payable on the Series C, respectively. As of March 31, 2026, and December 31, 2025, the cumulative dividend per share payable on the Series C was approximately $1,175 and $1,153, respectively.

 

Each share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $0.3197 per share, based on the stated value of $1,000 per preferred share. As of March 31, 2026, the outstanding Series C shares were convertible into an aggregate of 434,845 shares of common stock, which includes 106,412 shares issuable for accrued dividends at a conversion rate of $1.1593 per share. The Series C is subject to full ratchet anti-dilution price protection upon issuance of equity or equity-linked securities at an effective price below $0.3197 per share, as well as customary anti-dilution adjustments for stock splits and similar events.

 

Common stock

 

The Company is authorized to issue 500,000,000 shares of $0.001 par value common stock. As of March 31, 2026, and December 31, 2025, the Company had 97,721,696 and 49,805,275 shares issued and outstanding, respectively.

 

Exchangeable Shares

 

During the three months ended March 31, 2026, holders of Exchangeable Shares converted a total of 24,571,166 Exchangeable Shares into an equal number of shares of the Company’s common stock. As of March 31, 2026 and December 31, 2025, the Company had 83,420,765 and 107,991,931 Exchangeable Shares outstanding, respectively, each of which is exchangeable on a one-for-one basis for a share of the Company’s common stock, subject to the terms of the exchange agreement.

 

Sale of Common Stock.

 

On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued 11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional 1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $40,250. The Company incurred transaction costs of approximately $3,066, including underwriting discounts, commissions, and other offering expenses, resulting in net proceeds of approximately $37,184.

 

 

ATM Sales Agreement 2024

 

As of March 31, 2026, the Company had approximately $4,500 of remaining capacity under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated December 18, 2024. No shares were sold under the ATM Offering during the three months ended March 31, 2026.

 

Equity Line of Credit

 

As of March 31, 2026, the Company had approximately $5,000 of remaining capacity under its Equity Subscription Agreement with Lind Global Fund III, LP, dated February 28, 2025, subject to the filing and effectiveness of a registration statement. No advances have been made under the Subscription Agreement as of March 31, 2026.

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.26.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

NOTE 14OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

 

Streamex Corp.

 

2023 Long-Term Incentive Plan

 

Stockholders approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September 5, 2025, increasing the total number of shares authorized for issuance under the plan by 10,359,211 shares, from 4,376,595 shares to 14,735,806 shares.

 

Stockholders approved the Fourth Amendment to the Company’s 2023 Long-Term Incentive Plan on December 30, 2025, increasing the total number of shares authorized for issuance under the plan by 22,494,324 shares, from 14,735,806 shares to 37,230,130 shares.

 

As of March 31, 2026, there were 18,109,340 shares available under the 2023 Long-Term Incentive Plan.

 

Options

 

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

 

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

 

The following table presents information related to stock options as of March 31, 2026:

 

Options Outstanding   Options Exercisable 
Exercise  Number of   Weighted Average Remaining Life  

Exercisable

Number of

 
Price  Options   In Years   Options 
$ Under 9.99   2,900,000    8.6    2,900,000 
$ 10.00-19.99   15,000    7.1    15,000 
$ 20.00-49.99   3,000    3.0    3,000 
$ 50.00-69.99   3,000    3.8    3,000 
    2,921,000    8.6    2,921,000 

 

 

A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows:

 

   Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term   Aggregate Intrinsic Value 
Outstanding at January 1, 2026   2,736,000   $0.78    8.7   $6,744,540 
Issued   250,000   $3.21    9.8      
Forfeited/expired   (65,000)  $5.01           
Outstanding at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 
Exercisable at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 

 

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $1.13 as of March 31, 2026, which would have been received by the option holders had those option holders exercised their options as of that date.

 

During the three months ended March 31, 2026, the Company granted an aggregate of 250,000 options to purchase the Company’s common stock at a weighted average exercise price of $3.21 per share for a term of ten years. The options vested immediately upon grant and the full grant-date fair value of approximately $770 was recognized as stock-based compensation expense during the three months ended March 31, 2026.

 

Stock based compensation expense related to stock options recognized during the three months ended March 31, 2026 and 2025, was $770 and $40, respectively, which is presented within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations. As of March 31, 2026, there was no unrecognized compensation expense related to stock options.

 

On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with the Company’s former Chief Executive Officer and Chairman of the Board. Pursuant to the amendment, all previously granted equity awards to the former Chief Executive Officer and Chairman of the Board including vested and unvested stock options were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing.

 

During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026:

 

Assumption  Value 
Weighted average grant date fair value  $3.08 
Expected volatility   124.17%
Risk-free interest rate   4.15%
Expected dividend yield   0.00%
Expected Term (in years)   5.0 

 

 

Warrants

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026:

 

Exercise Price     Number of Warrants     Expiration Date
$ 0.3000       11,982     Nov-28
  0.9547       577,916     Sep-28
  3.3640       117,828     Jul-29
  4.0660       25,000     Nov-32
  4.4550       107,483     Jun-28
  4.4660       5,580     Apr-29
  4.6626       49,550     Mar-29
  4.9252       71,593     Mar-29
  4.9290       99,243     Jul-28
  5.1358       83,270     Jul-28
  7.1810       9,846     Jul-28
  7.5020       21,369     Aug-28
  7.9630       21,709     Jun-27
  9.0000       84,390     Jan-29
  9.5960       19,118     Aug-28
  10.0992       51,705     Sep-28
  10.2600       84,296     Sep-28
  10.4678       40,417     Oct-28
  11.3000       96,198     Nov-28
  13.2800       12,500     Jul-26
  48.0000       56,892     Nov-27
  61.6000       11,982     Nov-28
          1,647,885      

 

During the three months ended March 31, 2026, the Company issued 54,647 shares of its common stock upon cashless exercise of 87,984 warrants to purchase shares of common stock, pursuant to the formula set forth in such warrants.

 

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

   Shares  

Weighted-Average

Exercise Price

  

Weighted-Average

Remaining

Contractual Term

  

Aggregate

Intrinsic Value

 
Outstanding at January 1, 2026   1,735,869   $6.94    2.8   $1,414,626 
Issued   -    -    -      
Forfeited/expired   -    -    -    - 
Exercised   (87,984)   0.95    -    - 
Outstanding at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
                     
Vested and expected to vest at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
Exercisable at March 31, 2026   1,647,885   $7.26    2.6   $111,231 

 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $1.13 as of March 31, 2026, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

 

Restricted Stock Units

 

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

   Number of Shares   Weighted-Average Grant Date Fair Value Per Share 
Restricted shares issued as of January 1, 2026   2,037,500   $5.36 
Granted   8,868,316   $2.91 
Vested and issued   (6,123,941)  $3.01 
Forfeited   (198,500)  $3.21 
Total   4,583,375   $3.86 
Comprised of:          
Vested restricted shares as of March 31, 2026   301,500   $3.21 
Unvested restricted shares as of March 31, 2026   4,281,875   $3.90 

 

 

Stock based compensation expense related to RSU grants was $24,545 and $2,236 for the three months ended March 31, 2026 and 2025, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, total unrecognized stock-based compensation cost related to unvested RSUs was approximately $24,545, which is expected to be recognized over a weighted-average period of approximately 1.33 years.

 

The following table summarizes the terms of individual RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date:

 

Grant Date  Recipient  RSUs Granted   Vesting Terms  GDFV1 
1/1/2026  Third-party consultant   250,000   25,000 immediately; remainder quarterly  $758 
1/8/2026  Interim Executive Chairman   100,000   4 equal quarterly installments over 1 year  $321 
1/8/2026  Chief Executive Officer   1,000,000   100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years  $3,210 
1/27/2026  Third-party consultant   125,000   16 quarterly installments over 4 years  $456 
2/1/2026  Third-party consultant   500,000   300,000 immediately; 200,000 in 4 quarterly installments over 12 months  $1,790 
3/3/2026  Third-party consultant   425,000   212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026  $876 
3/16/2026  Third-party consultant   65,000   5,000 immediately; remainder monthly  $119 
3/16/2026  Chief Financial Officer   500,000   16 quarterly installments over 4 years  $915 
       2,965,000      $8,445 

 

(1)Grant-date fair value (“GDFV”)

 

The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of 5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were 8,868,316, as reflected in the RSU activity table above.

 

Performance-Based Restricted Stock Units

 

During the three months ended March 31, 2026, the Company granted performance-vesting restricted stock units (“PSUs”) to certain consultants. The PSUs represent the right to receive shares of the Company’s common stock upon the achievement of specified performance conditions or market conditions, and satisfaction of service requirements, subject to certification by the Company’s Board of Directors or its Compensation Committee (the “Committee”). The PSUs are equity-classified awards and settle solely in shares of the Company’s common stock. No cash settlement alternative exists.

 

Stock Price-Based PSUs

 

On February 1, 2026, the Company granted 500,000 PSUs to a third-party consultant, under a consulting agreement effective February 1, 2026. The PSUs vest in five tranches upon the achievement of specified stock price milestones, measured by the closing price of the Company’s common stock on a U.S. national securities exchange, as follows: 100,000 shares at $5.00; 100,000 shares at $6.00; 100,000 shares at $8.00; 100,000 shares at $10.00; and 100,000 shares at $12.00. Each milestone is certified by the Committee in good faith, and the consultant must be providing continuous service through the certification date. All unvested PSUs are forfeited immediately upon cessation of service. The stock price milestones and shares issuable per tranche are subject to equitable adjustment for stock splits, reverse stock splits, and similar events under the Company’s 2023 Long-Term Incentive Plan.

 

 

The stock price targets represent market conditions because they relate to the achievement of specified stock prices of the Company’s equity instruments. In accordance with ASC 718, the effect of the market conditions is reflected in the estimate of the grant-date fair value of the awards. The Company estimated the grant-date fair value of each tranche using a Monte Carlo simulation model, which incorporated the following significant assumptions:

 

Assumption  Value 
Grant-date stock price  $3.58 
Stock price milestones   $5.00 – $12.00 
Expected volatility   152.9% 
Risk-free interest rate   3.72% 
Expected dividend yield   0.00% 
Derived service periods (range)   3.437.41 years 

 

The following table summarizes the grant-date fair value by tranche (in thousands, except per unit data and units):

 

Tranche  Milestone   GDFV1/Unit   Units   Agg FV2   DSP3 (yrs)   Q1 2026 Expense 
1  $5.00   $3.56    100,000   $356    3.43   $17 
2  $6.00   $3.55    100,000   $355    4.58   $12 
3  $8.00   $3.57    100,000   $357    5.99   $9 
4  $10.00   $3.56    100,000   $356    6.84   $8 
5  $12.00   $3.54    100,000   $354    7.41   $8 
              500,000   $1,778        $54 

 

(1)GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $3.56.
(2)Aggregate fair value (“Agg FV”)
(3)Derived service period (“DSP”)

 

The aggregate grant-date fair value of the 500,000 stock price-based PSUs was approximately $1,778. In accordance with ASC 718-10-25-8, compensation cost is recognized on a straight-line basis over the derived service period for each tranche, regardless of whether the stock price milestones are ultimately achieved. Previously recognized compensation cost is not reversed if a market condition is not satisfied, provided that all necessary service has been rendered.

 

During the three months ended March 31, 2026, the Company recognized stock-based compensation expense of approximately $54 related to the stock price-based PSUs, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, unrecognized compensation cost related to the stock price-based PSUs was approximately $1,724, however, following the consultant’s resignation in April 2026, the remaining unrecognized compensation cost associated with the unvested stock price-based PSUs will not be recognized in future periods because the requisite service condition will no longer be satisfied.

 

The consultant is also entitled to 500,000 time-based RSUs (300,000 vesting on the effective date and 200,000 vesting quarterly over 12 months), which are separately disclosed in the RSU section above.

 

 

AUM-Based PSUs

 

On March 16, 2026, the Company granted up to 1,000,000 PSUs to a third-party consultant, vesting upon the achievement of assets under management (“AUM”) milestones related to the Company’s rare earth elements (“REE”) Fund (a planned commodity-linked investment product): (i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000). The number of shares issuable under each tranche is the lesser of the fixed share amount or the dollar cap divided by the fair value per share at each vesting date. Although the number of shares is variable, the dollar caps function as a ceiling on value deliverable to the consultant and do not require delivery of a fixed monetary amount; the consultant bears downside stock price risk. The Company evaluated the award under ASC 480 and ASC 815 and concluded it does not meet the criteria for liability classification or derivative accounting. The award is equity-classified and indexed to the Company’s own stock.

 

These PSUs contain performance conditions under ASC 718. The grant-date fair value per unit was determined based on the closing price of the Company’s common stock of $1.83 on the grant date of March 16, 2026. At the grant-date stock price of $1.83, none of the dollar caps were binding (the lowest implied cap price is $3.00 for Tranche 1), and accordingly the grant-date fair value per unit equals $1.83 for all tranches. The aggregate grant-date fair value of the AUM-based PSUs is approximately $1,830 (based on the grant-date stock price of $1.83 applied to 1,000,000 units at the maximum fixed share amounts), subject to a maximum aggregate dollar cap of $3,500 (consisting of $150 for the first tranche, $350 for the second tranche, and $3,000 for the third tranche). The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period.

 

Summary of PSU Awards

 

As of March 31, 2026, total stock-based compensation expense recognized for PSU awards during the three months ended March 31, 2026 was approximately $54, consisting entirely of expense related to the stock price-based PSUs. For the AUM-based PSUs, management assessed the probability of achieving each performance condition on a tranche-by-tranche basis and concluded that no condition met the “probable” threshold under ASC 718; accordingly, no expense was recognized.

 

Total unrecognized compensation cost related to outstanding PSUs was approximately $1,724 as of March 31, 2026, consisting of $1,724 related to stock price-based PSUs (to be recognized over a weighted-average period of approximately 5.5 years) and $0 related to AUM-based PSUs (to be recognized when achievement becomes probable, with an aggregate grant-date fair value of approximately $1,830, subject to a maximum dollar cap of $3,500).

 

The Company accounts for forfeitures as they occur. No forfeitures of PSUs were recognized during the three months ended March 31, 2026.

 

The following table summarizes PSU activity for the three months ended March 31, 2026:

 

   PSUs – Stock Price   PSUs - AUM   Total PSUs 
Nonvested as of December 31, 2025   -    -    - 
Granted   500,000    1,000,000    1,500,000 
Vested and issued   -    -    - 
Forfeited   -    -    - 
Nonvested as of March 31, 2026   500,000    1,000,000    1,500,000 

 

 

The table above excludes (i) performance-based restricted stock units tied to Organic Gross Revenue Growth targets, under which certain consultants may earn additional units annually based on achievement of annual revenue growth targets established and certified by the Compensation Committee, as the number of units issuable is not determinable until the applicable targets are set, and (ii) PSU grants to four third-party consultants, involving an aggregate of up to approximately 910,000 units tied to cumulative gross revenue and token-related performance milestones, that have not been approved by the Board of Directors or the Compensation Committee as of March 31, 2026 and are therefore not considered granted under ASC 718.

 

ViralClear Pharmaceuticals, Inc.

 

2019 Long-Term Incentive Plan

 

There are 2,915,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.

 

Warrants (ViralClear)

 

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

           Weighted-Average 
           Remaining 
       Weighted-Average   Contractual 
   Shares   Exercise Price   Term 
Outstanding at January 1, 2026   473,772   $5.00    1.9 
Forfeited/expired   -    -    - 
Outstanding at March 31, 2026   473,772   $5.00    1.6 
Exercisable at March 31, 2026   473,772   $5.00    1.6 

 

The following table presents information related to warrants (ViralClear) at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$5.00    473,772    November 2027 

 

Restricted stock units (ViralClear)

 

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

 

Restricted shares outstanding at January 1, 2026:   678,679 
Forfeited   - 
Total restricted shares outstanding at March 31, 2026:   678,679 
      
Comprised of:     
Vested restricted shares as of March 31, 2026   678,679 
Unvested restricted shares as of March 31, 2026   - 
Total   678,679 

 

BioSig AI Sciences, Inc.

 

Warrants (BioSig AI)

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$1.00    130,500    June-July 2028 

 

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.26.1
NON-CONTROLLING INTEREST
3 Months Ended
Mar. 31, 2026
Noncontrolling Interest [Abstract]  
NON-CONTROLLING INTEREST

NOTE 15 – NON-CONTROLLING INTEREST

 

As of March 31, 2026 and December 31, 2025, the Company had a majority interest in ViralClear of approximately 70% for both periods. As of March 31, 2026, and December 31, 2025, the Company had a majority interest in BioSig AI of approximately 84% for both periods. As of March 31, 2026, the Company consolidated Streamex Ltd. as a variable interest entity, with noncontrolling interest holders (consisting of two related party officers) holding approximately 1.5% of the outstanding GLDY Tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

 

A reconciliation of ViralClear Pharmaceuticals, Inc., BioSig AI Sciences, Inc. and Streamex Ltd. non-controlling loss attributable to the Company:

 

Net loss attributable to the non-controlling interest for the three months ended March 31, 2026:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Net Income (loss)  $-*   $-   $(155)  $(155)
Noncontrolling interest’s weighted-average ownership percentage   30.0%   16.0%   0.2%   0.01%
Net income (loss) attributable to non-controlling interest  $-*   $-   $(1)  $(1)

 

Net loss attributable to the non-controlling interest for the three months ended March 31, 2025:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Net loss  $-*    $75   $-   $75 
Noncontrolling interest’s weighted-average ownership percentage   32%   16%   -%   16%
Net loss attributable to non-controlling interest  $-   $12   $-   $12 

 

  * Less than $0.5 thousand

 

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Balance, January 1, 2026  $(171)  $203   $-   $32 
Issuance of equity to noncontrolling interest holders   -    -    225    225 
Net income (loss) attributable to non-controlling interest   -    -    (1)   (1)
Balance, March 31, 2026  $(171)  $203   $224   $256 

 

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025:

 

   ViralClear Pharmaceuticals, Inc.   BioSig AI Sciences, Inc.   Streamex Ltd   Total 
Balance, January 1, 2025  $(171)  $188   $-   $17 
Net income (loss) attributable to non-controlling interest   -    12    -    12 
Balance, March 31, 2025  $(171)  $200   $-   $29 

 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.26.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 16 — COMMITMENTS AND CONTINGENCIES

 

Tokenized Yield Partnership Agreement

 

Overview

 

On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation, establishing an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms.

 

For additional information regarding the gold assets held by Streamex Ltd. and the related VIE disclosures, see Notes 8 and 9.

 

Exclusivity and Performance Conditions

 

For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation.

 

Consulting Services Agreement

 

On February 4, 2026, the Company entered into a consulting agreement with an independent third party to provide advisory and capital markets related services in connection with the Company’s GLDY Token program. The agreement has an initial term of six months and provides for a fixed consulting fee of $4,000, as well as potential transaction-based fees contingent upon the completion of certain activities during the term. The full $4,000 base fee was paid during the three months ended March 31, 2026. As of March 31, 2026, the unamortized portion of $2,785 is included in prepaid expenses and other assets on the unaudited condensed consolidated balance sheet and is being recognized ratably over the service period. No transaction-based fees were earned or payable during the period.

 

Litigation

 

We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of our business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

 

In November 2025, a former advisor filed a Notice of Civil Claim in the Supreme Court of British Columbia against the Company, its wholly owned subsidiary Streamex Exchange Corporation, and certain current officers and directors. The claim alleges, among other things, breach of contract, unjust enrichment, and civil conspiracy in connection with alleged agreements relating to equity interests in Streamex Exchange Corporation prior to the Company’s acquisition of that entity. The plaintiff seeks, among other relief, specific performance, equitable compensation, and damages.

 

The Company disputes the claims and intends to defend the matter vigorously. As of March 31, 2026, no liability has been recorded in the unaudited condensed consolidated financial statements related to this matter, as management, after consultation with legal counsel, believes that a loss is not probable. The matter is in a preliminary stage and, as a result, the Company is unable to reasonably estimate the possible loss or range of loss, if any, associated with this matter at this time.

 

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT REPORTING
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 17 – SEGMENT REPORTING

 

Chief Operating Decision Maker (CODM) and Segment Evaluation

 

On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and a member of the Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director.

 

Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of March 31, 2026, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information.

 

Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of March 31, 2026. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level.

 

In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure.

 

Basis of Segmentation

 

The Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business, and the CODM does not receive or review separate financial information for Streamex Exchange or any other business unit. This approach reflects the manner in which the CODM:

 

  Assesses performance against budgeted targets;
  Forecasts future financial results;
  Makes strategic and operational decisions;
  Allocates resources across the organization.

 

Accordingly, the Company has determined that it operates as one reportable and operating segment as of March 31, 2026.

 

Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results.

 

Segment Performance Measures

 

The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives.

 

Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets.

 

The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve.

 

 

Revenue and Expense Information

 

Information concerning the operations of the Company’s reportable segments is as follows:

 

   2026   2025 
   For the Three Months Ended March 31, 
   2026   2025 
           
Revenues  $-   $- 
Less Segment expenses:          
Research and development   -    6 
General and administrative   8,884    883 
General and administrative - stock-based compensation expenses   25,370    2,074 
Depreciation and amortization   1,492    21 
Total operating and segment expense   (35,746)   (2,984)
Plus:          
Interest expense, net   (12,195)   - 
Realized gain on sale of gold   2,938    - 
Realized gain on marketable securities   484    - 
Change in fair value of marketable securities   (134)   - 
Change in fair value of embedded derivative   497    - 
Realized loss on extinguishment of convertible debenture   (3,057)   - 
Realized loss on investment   (119)   - 
Gain on settlement and forgiveness of debt   -    199 
Other income (expense), net   73    (15)
Total other income (expense)   (11,513)   184 
Income taxes (benefit)   (565)   - 
Segment Net Loss  $(46,694)  $(2,800)
Non-controlling interest   1    (12)
Net loss attributable to Streamex Corp.  $(46,693)  $(2,812)

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.26.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2026
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 18RELATED PARTY TRANSACTIONS

 

Accounts payable and accrued expenses as of March 31, 2026 include $907 due to related parties, compared to $66 as of December 31, 2025. These amounts primarily relate to executives and board compensation, severance, and reimbursements.

 

During the three months ended March 31, 2026, two officers of the Company subscribed for GLDY Tokens issued by Streamex Ltd. (the Company’s consolidated VIE): (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens. Both subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions pursuant to the GLDY Subscription Agreement. As of March 31, 2026, the officers’ combined GLDY Token holdings represented approximately 1.5% of total outstanding tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

 

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.26.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 19SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes below, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures.

 

GLDY Dividend

 

On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material.

 

Appointment of Director and Equity Awards

 

On April 28, 2026, the Board appointed the Company’s Chief Investment Officer (“CIO”), to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal.

 

In connection with the CIO’s amended employment agreement effective April 6, 2026, the Board granted the CIO 1,250,000 RSUs and a special incentive award of 1,000,000 RSUs. Both awards vest in sixteen equal quarterly installments commencing July 1, 2026, subject to continued service, and become fully vested upon a protected termination, a change in control, or the termination.

 

Amended Employment Agreements and Equity Awards

 

On May 1, 2026, the Company entered into amended and restated employment agreements with the Company’s Chief Executive Officer (“CEO”) and the Company’s Interim Executive Chairman (“Interim Chairman”).

 

In connection with the amended agreements, the Board granted each of the CEO and Interim Chairman 1,500,000 PSUs for shares of the Company’s common stock, divided into five equal tranches of 300,000 shares each. Each tranche vests upon the Company’s cumulative sales of GLDY reaching the following milestones: (i) $250,000,000; (ii) $500,000,000; (iii) $1,000,000,000; (iv) $2,000,000,000; and (v) $3,000,000,000. Cumulative GLDY sales are measured in good faith by the Company and certified by the Compensation Committee. Vesting is subject to continued employment, except that the awards become fully vested upon a protected termination or a change in control. Any tranche that has not vested on or before the tenth anniversary of the effective date shall be forfeited.

 

Equity Transactions

 

Between April 1, 2026 and May 14, 2026, an aggregate of 5,890,148 Exchangeable Shares were converted into the same number of common stock by holders of the Exchangeable Shares.

 

Between April 1, 2026 and May 14, 2026, the Company issued 1,157,973 shares of common stock for vested restricted stock units, of which 723,611 shares were issued to related parties, including certain executive officers and directors of the Company.

 

On April 10, 2026, the Company entered into an Advisory & Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 100,000 shares of the Company’s common stock, with 50,000 RSUs vesting and issued on the effective date and the remaining 50,000 RSUs vesting in two installments on the six-month and twelve-month anniversaries of the vesting commencement date, subject to continued service.

 

On April 6, 2026, the Company entered into a Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 155,000 shares of the Company’s common stock that were vested and issued on April 29, 2026.

 

In May 2026, the Company rescinded a previously approved equity compensation arrangement with the Company’s General Counsel covering 700,000 shares of common stock. As part of this rescission, the shares were cancelled and the arrangement was terminated with no further equity compensation obligations.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Basis of Consolidation

Basis of Consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity.

 

During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.

 

Use of estimates

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.

 

Foreign Currency Translation

Foreign Currency Translation

 

The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.

 

 

Marketable Securities

Marketable Securities

 

The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).

 

Gold Assets

Gold Assets

 

The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred.

 

Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026.

 

Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360.

 

Concentration of Assets

Concentration of Assets

 

As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33).

 

As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions.

 

The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

 

Net Income (loss) Per Common Share

Net Income (loss) Per Common Share

 

The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock.

 

 

The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss).

 

Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders.

 

In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share.

 

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 

   March 31,   March 31, 
   2026   2025 
Series C convertible preferred stock   434,845    564,234 
Options to purchase common stock   2,921,000    2,486,000 
Performance-based restricted stock units   1,500,000    - 
Warrants to purchase common stock   1,647,885    5,577,260 
Restricted stock units to acquire common stock   4,583,375    1,160,830 
Totals   11,087,105    9,788,324 

 

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.

 

Recently issued accounting pronouncements not yet adopted

Recently issued accounting pronouncements not yet adopted

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements.

 

 

In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 

   March 31,   March 31, 
   2026   2025 
Series C convertible preferred stock   434,845    564,234 
Options to purchase common stock   2,921,000    2,486,000 
Performance-based restricted stock units   1,500,000    - 
Warrants to purchase common stock   1,647,885    5,577,260 
Restricted stock units to acquire common stock   4,583,375    1,160,830 
Totals   11,087,105    9,788,324 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.26.1
BUSINESS ACQUISITION (Tables)
3 Months Ended
Mar. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED

The final allocation of the purchase consideration is as follows:

 

Amount Recognized as of the Acquisition Date (In Thousands)    
Assets acquired     
Cash  $366 
Due from related party   11 
Sales tax receivable   14 
Prepaid expenses   22 
Trade name   5,100 
Developed technology   40,000 
Legal and compliance framework   2,400 
Goodwill   70,435 
Total assets acquired  $118,348 
Liabilities assumed     
Accounts payable and accrued expenses  $(262)
Deferred tax liability   (12,588)
Total liabilities assumed  $(12,850)
Net assets acquired   105,498 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.26.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
3 Months Ended
Mar. 31, 2026
Intangible Asset, Goodwill and Other [Abstract]  
SCHEDULE OF CARRYING AMOUNT OF GOODWILL

The following table shows the changes in the carrying amount of goodwill for the period:

 

Goodwill as of December 31, 2025 (1)  $70,984 
Acquisition   - 
Impairment   - 
Foreign currency translation adjustment   (1,226)
Goodwill as of March 31, 2026  $69,758 

 

  1) Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.
SCHEDULE OF INTANGIBLE ASSETS

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:

 

   March 31,   December 31, 
   2026   2025 
Trade name (1)  $5,100   $5,100 
Developed technology (1)   40,000    40,000 
Legal and compliance framework (1)   2,400    2,400 
Patents   380    380 
Total   47,880    47,880 
Foreign currency translation adjustment   (456)   371 
Accumulated amortization:          
Trade name   (425)   (303)
Developed technology   (4,162)   (2,975)
Legal and compliance framework   (285)   (204)
Patents   (134)   (130)
Total accumulated amortization   (5,006)   (3,612)
Intangible assets, net  $42,418   $44,639 

 

  1) Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.
SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS

Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:

 

      
Remainder 2026  $4,362 
2027   5,816 
2028   5,816 
2029   5,816 
2030   5,816 
Thereafter   14,792 
Total  $42,418 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.26.1
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended
Mar. 31, 2026
Property, Plant, and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:

 

   March 31,   December 31, 
   2026   2025 
Computer equipment  $531   $531 
Furniture and fixtures   109    109 
Testing/Demo equipment   312    312 
Leasehold improvements   84    84 
Total   1,036    1,036 
Less accumulated depreciation   (1,024)   (1,011)
Property and equipment, net  $12   $25 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.26.1
STREAMEX LTD. (VIE) (Tables)
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:

 

     
Assets    
Other assets held at cost – gold  $15,225 
Cash   60 
Total assets  $15,285 
      
Liabilities     
Accounts payable and accrued expenses  $33 
Total liabilities  $33 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.26.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:

 

   March 31,   December 31, 
   2026   2025 
Accrued accounting and legal  $725   $705 
Accrued consulting   564    406 
Accrued interest   -    200 
Accrued research and development expenses   167    169 
Accrued office and other   41    38 
Accrued insurance premium financing(1)   370    916 
Accrued payroll(2)   1,180    512 
Other accrued expenses   132    6 
Accounts payable and accrued expenses   $3,179   $2,952 

 

  (1) On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.
     
  (2) Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.26.1
CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS (Tables)
3 Months Ended
Mar. 31, 2026
Debt Disclosure [Abstract]  
SCHEDULE OF SETTLEMENT

In connection with the settlement, the Company recognized the following:

 

      
Loss on extinguishment of convertible debentures — prepayment premium  $(3,500)
Gain on derecognition of embedded derivative at settlement   443 
Realized loss on extinguishment of convertible debentures  $(3,057)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Mar. 31, 2026
Fair Value Disclosures [Abstract]  
SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:

 

Description  May 28, 2025 
Trade name  $5,100 
Developed technology  $40,000 
Legal and compliance framework  $2,400 
      
Goodwill  $70,435 
SCHEDULE OF UNOBSERVABLE INPUT

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):

 

SCHEDULE OF UNOBSERVABLE INPUT

   2/6/2026   12/31/2025 
Unobservable / key assumption  Remeasurement   Remeasurement 
Common stock price  $3.28   $3.03 
Indicated conversion price  $4.00   $4.00 
Floor price  $4.00   $4.00 
Prepayment probability   100%   70%
Prepayment premium   10%   10%
Registration probability   0%   0%
SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS

The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:

 

   Amount 
Change in fair value of embedded derivative  $497 
SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:

 SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY

   Amount 
Balance as of December 31, 2025  $1,700 
Change in fair value   (497)
Settlements   (1,203)
Balance as of March 31, 2026  $- 
SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):

 

Description  Level   March 31, 2026   December 31, 2025 
Embedded derivative liabilities – Yorkville Debentures   3   $-   $1,700 
Marketable securities   1   $23,766   $9,706 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.26.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)
3 Months Ended
Mar. 31, 2026
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS

The following table presents information related to stock options as of March 31, 2026:

 

Options Outstanding   Options Exercisable 
Exercise  Number of   Weighted Average Remaining Life  

Exercisable

Number of

 
Price  Options   In Years   Options 
$ Under 9.99   2,900,000    8.6    2,900,000 
$ 10.00-19.99   15,000    7.1    15,000 
$ 20.00-49.99   3,000    3.0    3,000 
$ 50.00-69.99   3,000    3.8    3,000 
    2,921,000    8.6    2,921,000 
SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION

During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026:

 

Assumption  Value 
Weighted average grant date fair value  $3.08 
Expected volatility   124.17%
Risk-free interest rate   4.15%
Expected dividend yield   0.00%
Expected Term (in years)   5.0 
SCHEDULE OF INFORMATION RELATED TO WARRANTS

The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026:

 

Exercise Price     Number of Warrants     Expiration Date
$ 0.3000       11,982     Nov-28
  0.9547       577,916     Sep-28
  3.3640       117,828     Jul-29
  4.0660       25,000     Nov-32
  4.4550       107,483     Jun-28
  4.4660       5,580     Apr-29
  4.6626       49,550     Mar-29
  4.9252       71,593     Mar-29
  4.9290       99,243     Jul-28
  5.1358       83,270     Jul-28
  7.1810       9,846     Jul-28
  7.5020       21,369     Aug-28
  7.9630       21,709     Jun-27
  9.0000       84,390     Jan-29
  9.5960       19,118     Aug-28
  10.0992       51,705     Sep-28
  10.2600       84,296     Sep-28
  10.4678       40,417     Oct-28
  11.3000       96,198     Nov-28
  13.2800       12,500     Jul-26
  48.0000       56,892     Nov-27
  61.6000       11,982     Nov-28
          1,647,885      
SUMMARY OF WARRANT ACTIVITY

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

   Shares  

Weighted-Average

Exercise Price

  

Weighted-Average

Remaining

Contractual Term

  

Aggregate

Intrinsic Value

 
Outstanding at January 1, 2026   1,735,869   $6.94    2.8   $1,414,626 
Issued   -    -    -      
Forfeited/expired   -    -    -    - 
Exercised   (87,984)   0.95    -    - 
Outstanding at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
                     
Vested and expected to vest at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
Exercisable at March 31, 2026   1,647,885   $7.26    2.6   $111,231 
SCHEDULE OF RESTRICTED STOCK UNITS GRANTS

 

Grant Date  Recipient  RSUs Granted   Vesting Terms  GDFV1 
1/1/2026  Third-party consultant   250,000   25,000 immediately; remainder quarterly  $758 
1/8/2026  Interim Executive Chairman   100,000   4 equal quarterly installments over 1 year  $321 
1/8/2026  Chief Executive Officer   1,000,000   100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years  $3,210 
1/27/2026  Third-party consultant   125,000   16 quarterly installments over 4 years  $456 
2/1/2026  Third-party consultant   500,000   300,000 immediately; 200,000 in 4 quarterly installments over 12 months  $1,790 
3/3/2026  Third-party consultant   425,000   212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026  $876 
3/16/2026  Third-party consultant   65,000   5,000 immediately; remainder monthly  $119 
3/16/2026  Chief Financial Officer   500,000   16 quarterly installments over 4 years  $915 
       2,965,000      $8,445 

 

(1)Grant-date fair value (“GDFV”)

 

The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of 5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were 8,868,316, as reflected in the RSU activity table above.

SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE

Assumption  Value 
Grant-date stock price  $3.58 
Stock price milestones   $5.00 – $12.00 
Expected volatility   152.9% 
Risk-free interest rate   3.72% 
Expected dividend yield   0.00% 
Derived service periods (range)   3.437.41 years 
SCHEDULE OF RELATED TO WARRANTS

The following table presents information related to warrants (ViralClear) at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$5.00    473,772    November 2027 
SCHEDULE OF OUTSTANDING TO WARRANTS

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:

 

Exercise   Number   Expiration 
Price   Outstanding   Date 
$1.00    130,500    June-July 2028 

 

 

Warrant [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SUMMARY OF WARRANT ACTIVITY

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

 

           Weighted-Average 
           Remaining 
       Weighted-Average   Contractual 
   Shares   Exercise Price   Term 
Outstanding at January 1, 2026   473,772   $5.00    1.9 
Forfeited/expired   -    -    - 
Outstanding at March 31, 2026   473,772   $5.00    1.6 
Exercisable at March 31, 2026   473,772   $5.00    1.6 
Viral Clear Pharmaceuticals Inc [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF RESTRICTED STOCK ACTIVITY

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

   Number of Shares   Weighted-Average Grant Date Fair Value Per Share 
Restricted shares issued as of January 1, 2026   2,037,500   $5.36 
Granted   8,868,316   $2.91 
Vested and issued   (6,123,941)  $3.01 
Forfeited   (198,500)  $3.21 
Total   4,583,375   $3.86 
Comprised of:          
Vested restricted shares as of March 31, 2026   301,500   $3.21 
Unvested restricted shares as of March 31, 2026   4,281,875   $3.90 
Viral Clear [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF NON VESTED RESTRICTED ACTIVITY

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

 

 

Restricted shares outstanding at January 1, 2026:   678,679 
Forfeited   - 
Total restricted shares outstanding at March 31, 2026:   678,679 
      
Comprised of:     
Vested restricted shares as of March 31, 2026   678,679 
Unvested restricted shares as of March 31, 2026   - 
Total   678,679 
Equity Option [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF STOCK OPTION ACTIVITY

A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows:

 

   Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term   Aggregate Intrinsic Value 
Outstanding at January 1, 2026   2,736,000   $0.78    8.7   $6,744,540 
Issued   250,000   $3.21    9.8      
Forfeited/expired   (65,000)  $5.01           
Outstanding at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 
Exercisable at March 31, 2026   2,921,000   $0.89    8.6   $1,709,540 
Performance Shares [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF NON VESTED RESTRICTED ACTIVITY

The following table summarizes PSU activity for the three months ended March 31, 2026:

 

   PSUs – Stock Price   PSUs - AUM   Total PSUs 
Nonvested as of December 31, 2025   -    -    - 
Granted   500,000    1,000,000    1,500,000 
Vested and issued   -    -    - 
Forfeited   -    -    - 
Nonvested as of March 31, 2026   500,000    1,000,000    1,500,000